Therapeutic indazole compounds and methods of use in the treatment of cancer - Patents.com
Specific TEAD inhibitors, possibly combined with KRAS inhibitors, address the adverse effects of current treatments by effectively targeting the Hippo pathway in cancers, providing a safer therapeutic option.
Patent Information
- Application Number
- JP2024531260
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-05-19
- Filing Date
- 2022-11-21
- Publication Date
- 2024-11-08
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current TEAD inhibitors for treating cancers associated with Hippo pathway dysregulation face adverse events like cardiac arrhythmias due to off-target sodium channel inhibition, necessitating the development of inhibitors with reduced risk.
Development of specific compounds that inhibit TEAD activity, potentially combined with KRAS inhibitors, to treat cancers by modulating the Hippo pathway, thereby reducing adverse effects.
The compounds effectively target TEAD, offering a therapeutic approach for cancers with reduced adverse events, enhancing treatment efficacy while minimizing side effects.
Smart Images

Figure 2024541508001004 
Figure 2024541508001005 
Figure 2024541508001006
Abstract
Description
[Technical Field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to and the benefit of U.S. Provisional Patent Application No. 63 / 283,138, filed November 24, 2021, and U.S. Provisional Patent Application No. 63 / 344,025, filed May 19, 2022, the disclosures of which are incorporated herein by reference in their entireties.
[0002] Electronic sequence listing submission The contents of the electronic sequence listing (file name: 146392054840SeqList.xml, creation date: November 17, 2022, size: 20,029 bytes) are incorporated herein by reference in their entirety.
[0003] Field of Disclosure The present disclosure relates to compounds useful as inhibitors of TEAD, useful for treatment and / or prophylaxis in mammals, particularly useful for treating cancer. [Background technology]
[0004] Short description The Hippo signaling pathway is a signal transduction pathway that regulates cell proliferation and cell death and determines organ size. It is believed to play a role as a tumor suppressor in mammals, and disorders of this pathway are often detected in human cancers. It may be involved in and / or regulate the self-renewal and differentiation of stem and progenitor cells. Additionally, the Hippo signaling pathway may be involved in wound healing and tissue regeneration. Furthermore, the Hippo pathway interacts with other signaling pathways, such as Wnt, Notch, Hedgehog, and MAPK / ERK, which may affect a wide variety of biological events. It is believed that dysfunction of the Hippo pathway could be involved in many human diseases in addition to cancer. For reviews, see, e.g., Halder et al., 2011, Development 138:9-22; Zhao et al., 2011, Nature Cell Biology 13:877-883; Bao et al., 2011, J. Biochem. 149:361-379; Zhao at al., 2010, J. Cell Sci. 123:4001-4006.
[0005] The Hippo signaling pathway is conserved from Drosophila to mammals (Vassilev et al., Genes and Development, 2001, 15, 1229-1241; Zeng and Hong, Cancer Cell, 2008, 13, 188-192). The core of the pathway consists of a cascade of kinases (Hippo-MST1-2 is upstream of Lats1-2 and NDRI-2) that lead to the phosphorylation of two transcriptional coactivators, YAP (Yes-Associated Protein) and TAZ (transcriptional coactivator with a PDZ-binding motif or tafazzin; Zhao et al., Cancer Res., 2009, 69, 1089-1098; Lei et al., Mol. Cell. Biol., 2008, 28, 2426-2436).
[0006] The Hippo signaling pathway is involved in cancer development because it regulates animal development, organ size control, and stem cell regulation (reviewed in Harvey et al., Nat. Rev. Cancer, 2013, 13, 246-257; Zhao et al., Genes Dev., 2010, 24, 862-874). In vitro, overexpression of YAP or TAZ in breast epithelial cells induces cell transformation through the interaction of both proteins with the TEAD family of transcription factors. Increased YAP / TAZ transcriptional activity has also been shown to confer stem cell properties to breast cancer cells by inducing oncogenic properties such as epithelial-mesenchymal transition. In vivo, overexpression of YAP or its upstream regulator MST1-2 in mouse liver leads to the development of hepatocellular carcinoma (HCC). Furthermore, when the tumor suppressor NF2 is inactive in mouse liver, HCC development can be completely blocked by co-inactivation of YAP.
[0007] Deregulation of the Hippo tumor suppressor pathway has been implicated in lung cancer (NSCLC; Zhou et al., Oncogene, 2011, 30, 2181-2186; Wang et al., Cancer Sci., 2010, 101, 1279-1285), breast cancer (Chan et al., Cancer Res., 2008, 68, 2592-2598; Lamar et al., Proc. Natl. Acad. Sci, USA, 2012; 109, E2441-E2250; Wang et al., Eur. J. Cancer, 2012, 48, 1227-1234), and head and neck cancer (Gasparotto et al., Oncotarget., 2011, 2, 1165-1175; Steinmann et al. al.,Oncol.Rep.,2009,22,1519-1526), colon cancer (Angela et al.,Hum. Pathol.,2008,39,1582-1589;Yuen et al.,PLoS One,2013,8,e54211;Avruch et al.,Cell Cycle,2012,11,1090-1096), ovarian cancer (Angela et al.,Hum. Pathol.,2008,39,1582-1589;Chad et al.,Cancer Res.,2010,70,8517-8525;Hall et al.,Cancer Res.,2010,70,8517-8525), liver cancer (Jie et al. al.,Gastroenterol.Res.Pract.,2013,2013,187070;Ahn et al.,Mol.Cancer.Res.,2013,11,748-758;Liu et al.,Expert.Opin.Ther.Targets,2012,16,243-247), brain cancer (Orr et al.,J Neuropathol.Exp.Neurol.2011,70,568-577;Baia et al.,Mol.Cancer Res.,2012,10,904-913;Striedinger et al.,Neoplasia,2008,10,1204-1212) and prostate cancer (Zhao et al.,Genes Dev.,2012,26,54-68;Zhao et al.,Genes Dev.,2007,21,2747-2761), mesothelioma (Fujii et al.,J.Exp.Med.,2012,209,479-494; Mizuno et al.,Oncogene,2012,31,5117-5122; Sekido Y.,Pathol.Int.,2011,61,331-344), sarcoma (Seidel et al.,Mol.Carcinog.,2007,46,865-871), and leukemia (Jimenez-Velasco et al.,Leukemia,2005,19,2347-2350).
[0008] Two core components of the mammalian Hippo pathway are Lats1 and Lats2, nuclear Dbf2-related (NDR) family protein kinases homologous to Drosophila Warts (Wts). Lats1 / 2 proteins are activated by association with the scaffolding protein Mob1A / B (Mps1 binder kinase activator-like 1A and 1B), which is homologous to Drosophila Mats. Lats1 / 2 proteins are also activated by phosphorylation by the STE20 family protein kinases Mst1 and Mst2, which are homologous to Drosophila Hippo. Lats1 / 2 kinases phosphorylate the downstream effectors YAP (Yes-associated protein) and TAZ (transcriptional coactivator with PDZ-binding motifs; WWTR1), which are homologous to Drosophila Yorkie. Phosphorylation of YAP and TAZ by Lats1 / 2 is a key event in the Hippo signaling pathway. Lats1 / 2 phosphorylates YAP at multiple sites, with Ser127 phosphorylation being critical for YAP inhibition. YAP phosphorylation generates a protein-binding motif for 14-3-3 family proteins, and upon binding, 14-3-3 proteins lead to cytoplasmic retention and / or sequestration of YAP. Similarly, Lats1 / 2 phosphorylates TAZ at multiple sites, with Ser89 phosphorylation being critical for TAZ inhibition. TAZ phosphorylation leads to cytoplasmic retention and / or sequestration of TAZ. In addition, phosphorylation of YAP and TAZ is thought to destabilize these proteins by activating phosphorylation-dependent degradation catalyzed by ubiquitination of YAP or TAZ. Therefore, when the Hippo pathway is "on," YAP and / or TAZ are phosphorylated, inactive, and generally trapped in the cytoplasm. In contrast, when the Hippo pathway is "off," YAP and / or TAZ are unphosphorylated, active, and generally found in the nucleus.
[0009] Unphosphorylated, active YAP translocates to the cell nucleus, where its primary target transcription factors are the four proteins in the TEAD domain-containing family (TEAD1-TEAD4, collectively referred to as "TEAD"). YAP, together with other transcription factors such as Smad1, RUNX, ErbB4, and p73, has been shown to induce the expression of various genes, including connective tissue growth factor (CTGF), Gli2, Birc5, Birc2, fibroblast growth factor 1 (FGF1), and amphiregulin (AREG). Similar to YAP, unphosphorylated TAZ translocates to the cell nucleus, where it interacts with multiple DNA-binding transcription factors, including peroxisome proliferator-activated receptor γ (PPARγ), thyroid transcription factor 1 (TTF-1), Pax3, TBX5, RUNX, TEAD1, and Smad2 / 3 / 4. Many of the genes activated by the YAP / TAZ transcription factor complex mediate cell survival and proliferation. Therefore, under some conditions, YAP and / or TAZ act as oncogenes, and the Hippo pathway acts as a tumor suppressor. Therefore, pharmacological targeting of the Hippo cascade via TEAD inhibition would be an important approach for treating cancers with functional alterations of this pathway. Certain TEAD inhibitors have been shown to be associated with an increased risk of adverse events, such as cardiac arrhythmias, due to off-target sodium channel inhibition. Therefore, there is a need for TEAD inhibitors with reduced risk of adverse events.
[0010] Ras is a small GTP-binding protein that functions as a nucleotide-dependent switch in central growth signaling pathways. In response to extracellular signals, Ras undergoes GDP-bound (Ras) exchange, catalyzed by guanine nucleotide exchange factors (GEFs), particularly the SOS1 protein. GDP ) state to GTP-bound (Ras GTP ) state. Active Ras GTPRas mediates its diverse growth-stimulatory functions through direct interaction with effectors, including Raf, PI3K, and the Ral guanine nucleotide dissociation stimulator. The intrinsic GTPase activity of Ras then hydrolyzes GTP to GDP, terminating Ras signaling. Ras GTPase activity can be further accelerated by interaction with GTPase-activating proteins (GAPs), including the neurofibromin 1 tumor suppressor.
[0011] Mutant Ras has reduced GTPase activity, which sustains an activated conformation of Ras, thereby promoting Ras-dependent signaling and cancer cell survival or proliferation. Ras mutations that affect its ability to interact with GAPs or convert GTP back to GDP result in sustained activation of the protein, resulting in sustained signals that promote continued growth and division. Because these signals lead to cell growth and division, overactive RAS signaling can ultimately lead to cancer. Mutations in any one of the three major RAS isoforms (H-Ras, N-Ras, or K-Ras) are common events in human tumorigenesis. Of the three Ras isoforms (K, N, and H), K-Ras is the most frequently mutated.
[0012] The most common K-Ras (or KRAS) mutations are found at residues G12 and G13 in the P loop and at residue Q61. G12C is a frequently observed mutation in the K-Ras gene (glycine-12 to cysteine). G12C is a single point mutation with a glycine-to-cysteine substitution at codon 12. This substitution promotes the activation state of KRAS and amplifies the signaling pathway that leads to tumorigenesis (see, for example, Hallin et al. (Cancer Discov, 2020, 10(1):54-71), Skoulidis et al. (N. Engl. J. Med., 2021, 384(25):2371-2381), and Hong et al. (N. Engl. J. Med., 2020, 383(13):1207-1217)). G12D, G12V, and G13D are other common mutations. Ras mutations in cancer are associated with poor prognosis.
[0013] Inactivation of oncogenic Ras in mice results in tumor regression. Therefore, Ras is widely considered an exceptionally important oncological target. However, treatment with Ras inhibitors (e.g., KRAS) can lead to resistance through bypass of the KRAS / MAPK pathway and activation of the Hippo pathway.
[0014] Thus, there is a need for therapies that improve the ability of inhibitors of Ras (e.g., KRAS) and inhibitors of YAP, TAZ, TEAD and / or YAP:TEAD protein-protein interactions to treat various diseases, disorders and conditions, including cancer. Summary of the Invention
[0015] In some embodiments, the compound of formula (I-AB) below: TIFF2024541508000001.tif34170, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt thereof, wherein: L' is * -N(R 1 )-L-** and TIFF2024541508000002.tif16170; * indicates the point of attachment to Z, ** teeth, This shows the connection point with TIFF2024541508000003.tif33170. R 1 is H or C 1~6 is alkyl, X 1 is N or CR s and R s H, deuterium, -CN, halo, C 1~15 Alkyl, C 1~6 Alkynyl, C 6~20 Aryl, 5-15 membered heteroaryl, C 3~20 Cycloalkyl, 3- to 15-membered heterocyclyl, -OH, -OR f , C 1~15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , and -NR d R e is selected from R d , R e and R f each independently represents H, C 1~6 Alkyl or C 3~20 is cycloalkyl, C 1~6 Alkyl and C 3~20 each cycloalkyl independently may be optionally substituted with one or more halo, oxo, —OH, or —CN; R s C 1~15 Alkyl and C 1~15 Each alkoxy is independently one or more R t1 and R t1 -O-, -OH-, -OR ... f1, -CN, -NR d R e and 3- to 15-membered heterocyclyl optionally substituted with one or more —OH; R f1 is -C(O)CHNR d R e , -C(O)C 1~6 alkyl, -P(O)(OH)2, and R d and R e are each independently H or C 1~6 Rukill and R d or R e C 1~6 The alkyl may be optionally substituted with one or more halo, oxo, —OH, or —CN; R s C 6~20 Aryl, 5-15 membered heteroaryl, C 3~20 Cycloalkyl and 3- to 15-membered heterocyclyl each independently represent one or more R t2 and R t2 represents, at each occurrence, halo, oxo, -OH, -CN, C(O)NH2, -C(O)NR d R e , -NR d R e , C 1~6 Alkoxyl, 3-6 membered heterocyclyl, C 3~6 Cycloalkyl, and C 1~6 alkyl; R t2 C 1~6 Alkyl is a group consisting of one or more -OH, C 1~6 Alkoxyl, halo, oxo, -S(O)2CH3, or -NR d R e and R d and R e are each independently H, -C(O)CH3, or -C(O)C 1~6 Alkyl, or C 1~6 is alkyl, X 2 , X 3 , and X 4 are each independently N, CH, or CD, provided that: 1) X1 , X 2 , X 3 , and X 4 1) Only one of the two is N, or 2) X 1 is N and X 2 is CH and X 3 is CH and X 4 is N or 3) X 1 is CR s and X 2 , X 3 , and X 4 are each independently CH or CD; B is phenyl or 5- to 6-membered heteroaryl, and each phenyl or 5- to 6-membered heteroaryl of B is independently one or more R t and R t At each occurrence, halo, C 1~15 Alkyl, C 1~6 Alkoxy, and S(R y )5 independently selected from y is the halo and R t C 1~15 Alkyl or C 1~6 The alkoxy may be optionally substituted with one or more halo; Z is -C(O)R x and R x is C 1~6 Alkyl, Deuterium, -OH, C 1~6 C optionally substituted with one or more substituents selected from alkoxyl and halo 2~6 alkenyl, or R x C optionally substituted with one or more halo 1~6 alkyl or R x C optionally substituted with -OH 1~6 alkynyl or R x is cyclobutenyl, dihydrofuranyl, bicyclobutanyl or cyclopentenyl, or Z is S(O)2R x1 and R x1 is C 2~6is alkenyl, L is one or more C 1~6 methylene optionally substituted with alkyl; n and m are each 1, or n and m are each 2.
[0016] In some embodiments, the compound of formula (AB): TIFF2024541508000004.tif34170, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein: L' is * -N(R 1 )-L- ** and TIFF2024541508000005.tif16170; * indicates the point of attachment to Z, ** teeth, This shows the connection point with TIFF2024541508000006.tif33170. R 1 is H or C 1~6 is alkyl, X 1 is N or CR s and R s H, deuterium, -CN, halo, C 1~15 Alkyl, C 1~6 Alkynyl, C 6~20 Aryl, 5-15 membered heteroaryl, C 3~20 Cycloalkyl, 3- to 15-membered heterocyclyl, -OH, -OR f , C 1~15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , and -NR d R e is selected from R d , R e and Rf each independently represents H, C 1~6 Alkyl or C 3~20 is cycloalkyl, C 1~6 Alkyl and C 3~20 each cycloalkyl independently may be optionally substituted with one or more halo, oxo, —OH, or —CN; R s C 1~15 Alkyl and C 1~15 Each alkoxy is independently one or more R t1 and R t1 independently, at each occurrence, represents halo, oxo, -OH, -CN, -NR d R e and 3- to 15-membered heterocyclyl optionally substituted with one or more —OH; R d and R e are each independently H or C 1~6 alkyl, and R d or R e C 1~6 The alkyl may be optionally substituted with one or more halo, oxo, —OH, or —CN; R s C 6~20 Aryl, 5-15 membered heteroaryl, C 3~20 Cycloalkyl and 3- to 15-membered heterocyclyl each independently represent one or more R t2 and R t2 independently, at each occurrence, represents halo, oxo, -OH, -CN, C(O)NH, -C(O)NR d R e , -NR d R e , C 1~6 Alkoxy and C 1~6 alkyl, and R t2 C 1~6 Alkyl is one or more -OH or -NR d R e optionally substituted with R d and R e are each independently H, -C(O)CH3, or -C(O)C1~6 Alkyl, or C 1~6 is alkyl, X 2 , X 3 , and X 4 are each independently N, CH, or CD, provided that X 1 , X 2 , X 3 , and X 4 and exactly one of the is N, B is phenyl or 5- to 6-membered heteroaryl, and each phenyl or 5- to 6-membered heteroaryl of B is independently one or more R t and R t At each occurrence, halo, C 1~15 Alkyl, C 1~6 Alkoxy, and S(R y )5, and each R y is the halo and R t C 1~15 Alkyl or C 1~6 The alkoxy may be optionally substituted with one or more halo; Z is -C(O)R x and R x is C 1~6 Alkyl, Deuterium, -OH, C 1~6 C optionally substituted with one or more substituents selected from alkoxyl and halo 2~6 alkenyl, or R x C optionally substituted with one or more halo 1~6 alkyl or R x C optionally substituted with -OH 1~6 alkynyl or R x is cyclobutenyl, L is one or more C 1~6 methylene optionally substituted with alkyl; n and m are each 1, or n and m are each 2.
[0017] In some embodiments, the compound of formula (A) or (B) below: TIFF2024541508000007.tif74170, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein: R 1 is H or C 1~6 is alkyl, X 1 is N or CR s and R s H, -CN, halo, C 1~15 Alkyl, C 6~20 Aryl, 5-15 membered heteroaryl, C 3~20 Cycloalkyl, 3- to 15-membered heterocyclyl, -OH, C 1~15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , and -NR d R e Selected from R d and R e are each independently H or C 1~6 alkyl, and R d or R e C 1~6 The alkyl may be optionally substituted with one or more halo, oxo, —OH, or —CN; R s C 1~15 Alkyl and C 1~15 Each alkoxy is independently one or more R t1 and R t1 independently, at each occurrence, represent halo, oxo, -OH, -CN, and -NR d R e Selected from R d and R e are each independently H or C 1~6 alkyl, and R d or R e C 1~6The alkyl may be optionally substituted with one or more halo, oxo, —OH, or —CN; R s C 6~20 Aryl, 5-15 membered heteroaryl, C 3~20 Cycloalkyl and 3- to 15-membered heterocyclyl each independently represent one or more R t2 and R t2 independently, at each occurrence, represent halo, -OH, -CN, and C 1~6 alkyl, X 2 , X 3 , and X 4 are each independently N or CH, provided that X 1 , X 2 , X 3 , and X 4 and exactly one of the is N, B is phenyl or 5- to 6-membered heteroaryl, and each phenyl or 5- to 6-membered heteroaryl of B is independently one or more R t and R t At each occurrence, halo, C 1~15 Alkyl, C 1~6 Alkoxy, and S(R y )5 independently selected from y is the halo and R t C 1~15 Alkyl or C 1~6 The alkoxy may be optionally substituted with one or more halo; Z is -C(O)R x and R x is C 1~6 C optionally substituted with one or more substituents selected from alkyl and halo 2~6 alkenyl, or R x C optionally substituted with one or more halo 1~6 is alkyl, L is one or more C 1~6 methylene optionally substituted with alkyl; n and m are each independently 1 or 2.
[0018] In some embodiments, the compound of formula (A') or (B') below: TIFF2024541508000008.tif69170, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein: X 1 is N or CR s and R s H, -CN, halo, C 1~15 Alkyl, C 6~20 Aryl, 5-15 membered heteroaryl, C 3~20 Cycloalkyl, 3- to 15-membered heterocyclyl, -OH, C 1~15 Alkoxy, NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , and -NR d R e Selected from R d and R e are each independently H or C 1~6 alkyl, and R d or R e C 1~6 The alkyl may be optionally substituted with one or more halo, oxo, —OH, or —CN; R s C 1~15 Alkyl and C 1~15 Each alkoxy is independently one or more R t1 and R t1 independently, at each occurrence, represent halo, oxo, -OH, -CN, and -NR d R e Selected from R d and R e are each independently H or C 1~6 alkyl, and R d or R e C 1~6The alkyl may be optionally substituted with one or more halo, oxo, —OH, or —CN; R s C 6~20 Aryl, 5-15 membered heteroaryl, C 3~20 Cycloalkyl and 3- to 15-membered heterocyclyl each independently represent one or more R t2 and R t2 independently, at each occurrence, represent halo, -OH, -CN, and C 1~6 alkyl, X 2 , X 3 , and X 4 are each independently N or CH, provided that X 1 , X 2 , X 3 , and X 4 and exactly one of the is N, B is phenyl or 5- to 6-membered heteroaryl, and each phenyl or 5- to 6-membered heteroaryl of B is independently one or more R t and R t At each occurrence, halo, C 1~15 Alkyl, C 1~6 Alkoxy, and S(R y )5 independently selected from y is the halo and R t C 1~15 Alkyl or C 1~6 The alkoxy may be optionally substituted with one or more halo; Z is -C(O)R x and R x is C 1~6 C optionally substituted with one or more substituents selected from alkyl and halo 2~6 alkenyl, or R x C optionally substituted with one or more halo 1~6 is alkyl, L is one or more C 1~6 methylene optionally substituted with alkyl; n and m are each independently 1 or 2.
[0019] In some embodiments, the compound of formula (IA) or (IB) below: TIFF2024541508000009.tif78170, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein: X 1 is N or CR s and R s H, -CN, halo, C 1~15 Alkyl, C 6~20 Aryl, 5-15 membered heteroaryl, C 3~20 Cycloalkyl, 3- to 15-membered heterocyclyl, -OH, C 1~15 Alkoxy, NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , and -NR d R e Selected from R d and R e are each independently H or C 1~6 alkyl, and R d or R e C 1~6 The alkyl may be optionally substituted with one or more halo, oxo, —OH, or —CN; R s C 1~15 Alkyl and C 1~15 Each alkoxy is independently one or more R t1 and R t1 independently, at each occurrence, represent halo, oxo, -OH, -CN, and -NR d R e Selected from R d and R e are each independently H or C 1~6 alkyl, and R d or R e C 1~6The alkyl may be optionally substituted with one or more halo, oxo, —OH, or —CN; R s C 6~20 Aryl, 5-15 membered heteroaryl, C 3~20 Cycloalkyl and 3- to 15-membered heterocyclyl each independently represent one or more R t2 and R t2 independently, at each occurrence, represent halo, -OH, -CN, and C 1~6 alkyl, X 2 , X 3 , and X 4 are each independently N or CH, provided that X 1 , X 2 , X 3 , and X 4 and exactly one of the is N, B is phenyl or 5- to 6-membered heteroaryl, and each phenyl or 5- to 6-membered heteroaryl of B is independently one or more R t and R t At each occurrence, halo, C 1~15 Alkyl, C 1~6 Alkoxy, and S(R y )5 independently selected from y is the halo and R t C 1~15 Alkyl or C 1~6 The alkoxy may be optionally substituted with one or more halo; R a , R b , and R c are each independently H, halo, or C 1~5 is alkyl, L is one or more C 1~6 methylene optionally substituted with alkyl; n and m are each independently 1 or 2.
[0020] In some embodiments, a pharmaceutical composition is provided comprising a compound of Formula (A) or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, diluent, or excipient.
[0021] In some embodiments, a pharmaceutical composition is provided comprising a compound of Formula (B) or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, diluent, or excipient.
[0022] In some embodiments, a pharmaceutical composition is provided comprising a compound of formula (AB) or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, diluent, or excipient.
[0023] In some embodiments, a pharmaceutical composition is provided comprising a compound of formula (I-AB) or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, diluent, or excipient.
[0024] In some embodiments, a pharmaceutical composition is provided comprising a compound of Formula (A') or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, diluent, or excipient.
[0025] In some embodiments, a pharmaceutical composition is provided comprising a compound of Formula (B') or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, diluent, or excipient.
[0026] In some embodiments, a pharmaceutical composition is provided comprising a compound of formula (IA) or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, diluent, or excipient.
[0027] In some embodiments, a pharmaceutical composition is provided comprising a compound of formula (IB) or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, diluent, or excipient.
[0028] In some embodiments, a compound of Formula (A), (B), (A'), (B'), (IA) or (IB) or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof is provided for use in medical therapy.
[0029] In some embodiments, a compound of formula (AB) or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof is provided for use in medical therapy.
[0030] In some embodiments, a compound of formula (I-AB) or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof is provided for use in medical therapy.
[0031] In some embodiments, compounds of Formula (A), (B), (A'), (B'), (IA) or (IB) or stereoisomers, tautomers or pharmaceutically acceptable salts thereof are provided for treating or preventing cancer.
[0032] In some embodiments, a compound of formula (AB) or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof is provided for treating or preventing cancer.
[0033] In some embodiments, a compound of formula (I-AB) or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof is provided for treating or preventing cancer.
[0034] In some embodiments, a compound of Formula (A), (B), (A'), (B'), (IA) or (IB) or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof is provided for preparing a medicament for treating or preventing cancer.
[0035] In some embodiments, a compound of formula (AB) or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof is provided for preparing a medicament for treating or preventing cancer.
[0036] In some embodiments, a compound of formula (I-AB) or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof is provided for preparing a medicament for treating or preventing cancer.
[0037] In some embodiments, provided are methods for treating cancer in a mammal, comprising administering to the mammal a compound of Formula (A), (B), (A'), (B'), (IA) or (IB) or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof.
[0038] In some embodiments, a method for treating cancer in a mammal is provided, comprising administering to the mammal a compound of formula (AB) or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof.
[0039] In some embodiments, a method for treating cancer in a mammal is provided, comprising administering to the mammal a compound of formula (I-AB) or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof.
[0040] In some embodiments, a method for treating cancer in a mammal is provided, comprising administering to the mammal a compound of Formula (A), (B), (A'), (B'), (IA) or (IB) or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof in combination with a second therapeutic agent.
[0041] In some embodiments, a method for treating cancer in a mammal is provided, comprising administering to the mammal a compound of formula (AB) or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof in combination with a second therapeutic agent.
[0042] In some embodiments, a method for treating cancer in a mammal is provided, comprising administering to the mammal a compound of formula (I-AB) or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof in combination with a second therapeutic agent.
[0043] In some embodiments, compounds of Formula (A), (B), (A'), (B'), (IA) or (IB) or stereoisomers, tautomers or pharmaceutically acceptable salts thereof are provided for modulating TEAD activity.
[0044] In some embodiments, a compound of formula (AB) or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof is provided for modulating TEAD activity.
[0045] In some embodiments, a compound of formula (I-AB) or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof is provided for modulating TEAD activity.
[0046] In some embodiments, compounds of Formula (A), (B), (A'), (B'), (IA) or (IB) or stereoisomers, tautomers or pharmaceutically acceptable salts thereof are provided for treating or preventing diseases or conditions mediated by TEAD activity.
[0047] In some embodiments, a compound of formula (AB) or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof is provided for treating or preventing a disease or condition mediated by TEAD activity.
[0048] In some embodiments, a compound of formula (I-AB) or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof is provided for treating or preventing a disease or condition mediated by TEAD activity.
[0049] In some embodiments, a compound of Formula (A), (B), (A'), (B'), (IA) or (IB) or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof is provided for use in the preparation of a medicament for treating or preventing a disease or condition mediated by TEAD activity.
[0050] In some embodiments, a compound of formula (AB) or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof is provided for use in the preparation of a medicament for treating or preventing a disease or condition mediated by TEAD activity.
[0051] In some embodiments, a compound of formula (I-AB) or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof is provided for use in the preparation of a medicament for treating or preventing a disease or condition mediated by TEAD activity.
[0052] In some embodiments, a method of modulating TEAD activity is provided, comprising contacting a TEAD with a therapeutically effective amount of a compound of Formula (A), (B), (A'), (B'), (IA) or (IB) or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof.
[0053] In some embodiments, a method of modulating TEAD activity is provided, comprising contacting a TEAD with a therapeutically effective amount of a compound of formula (AB) or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof.
[0054] In some embodiments, a method of modulating TEAD activity is provided, comprising contacting a TEAD with a therapeutically effective amount of a compound of formula (I-AB) or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof.
[0055] In some embodiments, provided is a method for treating a disease or condition mediated by TEAD activity in a mammal, comprising administering to the mammal a compound of Formula (A), (B), (A'), (B'), (IA) or (IB) or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof.
[0056] In some embodiments, a method is provided for treating a disease or condition mediated by TEAD activity in a mammal, comprising administering to the mammal a compound of formula (AB) or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof.
[0057] In some embodiments, a method is provided for treating a disease or condition mediated by TEAD activity in a mammal, comprising administering to the mammal a compound of formula (I-AB) or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof.
[0058] In one embodiment, the present disclosure relates to a combination comprising (i) one or more YAP / TAZ-TEAD inhibitors and (ii) one or more KRAS inhibitors. In some embodiments, one or more YAP / TAZ-TEAD inhibitors and one or more KRAS inhibitors are co-administered to an individual. In some embodiments, the combination is administered to an individual in the same composition. In some embodiments, the combination is administered to an individual in different compositions. It is therefore understood that one or more YAP / TAZ-TEAD inhibitors and one or more KRAS inhibitors can be administered to an individual simultaneously or sequentially. In some embodiments, provided herein are compositions comprising one or more YAP / TAZ-TEAD inhibitors and one or more KRAS inhibitors. In another embodiment, the present disclosure relates to a method of modulating or inhibiting KRAS activity in a cell, comprising administering to the cell an effective amount of such a combination. In another embodiment, the present disclosure relates to a method of treating cancer in a subject in need thereof, comprising administering to the subject an effective amount of such a combination. In another aspect, the disclosure relates to a method of reducing a subject's resistance to a treatment comprising a KRAS inhibitor, the method comprising administering a therapeutically effective amount of a TEAD inhibitor to the subject.
[0059] In one aspect, the disclosure relates to a method of preparing one or more TEAD inhibitors described herein. [Brief explanation of the drawings]
[0060] The following embodiments are representative of some aspects of the present disclosure.
[0061] [Figure 1] FIG. 1 shows the % inhibition of H2030 cells (KRAS G12C) after administration of a combination comprising Compound T1 (YAP / TAZ-TEAD inhibitor) and Compound K1 (KRAS inhibitor).
[0062] [Figure 2]FIG. 2 shows the % inhibition of H2030 cells (KRAS G12C) after administration of a combination comprising Compound T2 (YAP / TAZ-TEAD inhibitor) and Compound K1 (KRAS inhibitor).
[0063] [Figure 3] FIG. 3 shows the % inhibition of H2030 cells (KRAS G12C) after administration of a combination comprising Compound T3 (YAP / TAZ-TEAD inhibitor) and Compound K1 (KRAS inhibitor).
[0064] [Figure 4] FIG. 4 shows the % inhibition of H2030 cells (KRAS G12C) after administration of a combination comprising Compound T1 (YAP / TAZ-TEAD inhibitor) and Compound K2 (KRAS inhibitor).
[0065] [Figure 5] FIG. 5 shows the % inhibition of H2030 cells (KRAS G12C) after administration of a combination comprising Compound T2 (YAP / TAZ-TEAD inhibitor) and Compound K2 (KRAS inhibitor).
[0066] [Figure 6] FIG. 6 shows the % inhibition of H2030 cells (KRAS G12C) after administration of a combination comprising Compound T3 (YAP / TAZ-TEAD inhibitor) and Compound K2 (KRAS inhibitor).
[0067] [Figure 7] FIG. 7 shows the % inhibition of H2030 cells (KRAS G12C) after administration of a combination comprising Compound T1 (YAP / TAZ-TEAD inhibitor) and Compound K3 (KRAS inhibitor).
[0068] [Figure 8] FIG. 8 shows the % inhibition of H2030 cells (KRAS G12C) after administration of a combination comprising compound T2 (YAP / TAZ-TEAD inhibitor) and compound K3 (KRAS inhibitor).
[0069] [Figure 9] FIG. 9 shows the % inhibition of H2030 cells (KRAS G12C) after administration of a combination comprising Compound T3 (YAP / TAZ-TEAD inhibitor) and Compound K3 (KRAS inhibitor).
[0070] [Figure 10] FIG. 10 shows the % inhibition of H358 parental cells (KRAS G12C) after administration of a combination comprising Compound T1 (YAP / TAZ-TEAD inhibitor) and Compound K1 (KRAS inhibitor).
[0071] [Figure 11] FIG. 11 shows the % inhibition of H358 parental cells (KRAS G12C) after administration of a combination comprising Compound T2 (YAP / TAZ-TEAD inhibitor) and Compound K1 (KRAS inhibitor).
[0072] [Figure 12] FIG. 12 shows the % inhibition of H358 parental cells (KRAS G12C) after administration of a combination comprising Compound T3 (YAP / TAZ-TEAD inhibitor) and Compound K1 (KRAS inhibitor).
[0073] [Figure 13] FIG. 13 shows the % inhibition of H358 parental cells (KRAS G12C) after administration of a combination comprising Compound T1 (YAP / TAZ-TEAD inhibitor) and Compound K2 (KRAS inhibitor).
[0074] [Figure 14] FIG. 14 shows the % inhibition of H358 parental cells (KRAS G12C) after administration of a combination comprising Compound T2 (YAP / TAZ-TEAD inhibitor) and Compound K2 (KRAS inhibitor).
[0075] [Figure 15] FIG. 15 shows the % inhibition of H358 parental cells (KRAS G12C) following administration of a combination comprising Compound T3 (a YAP / TAZ-TEAD inhibitor) and Compound K2 (a KRAS inhibitor).
[0076] [Figure 16] FIG. 16 shows the % inhibition of H358 parental cells (KRAS G12C) after administration of a combination comprising Compound T1 (YAP / TAZ-TEAD inhibitor) and Compound K3 (KRAS inhibitor).
[0077] [Figure 17] FIG. 17 shows the % inhibition of H358 parental cells (KRAS G12C) after administration of a combination comprising compound T2 (YAP / TAZ-TEAD inhibitor) and compound K3 (KRAS inhibitor).
[0078] [Figure 18] FIG. 18 shows the % inhibition of H358 parental cells (KRAS G12C) after administration of a combination comprising Compound T3 (YAP / TAZ-TEAD inhibitor) and Compound K3 (KRAS inhibitor).
[0079] [Figure 19] FIG. 19 shows the % inhibition of H358 resistant cells (KRAS G12C) after administration of a combination comprising Compound T1 (YAP / TAZ-TEAD inhibitor) and Compound K1 (KRAS inhibitor).
[0080] [Figure 20] FIG. 20 shows the % inhibition of H358 resistant cells (KRAS G12C) after administration of a combination comprising Compound T2 (YAP / TAZ-TEAD inhibitor) and Compound K1 (KRAS inhibitor).
[0081] [Figure 21] FIG. 21 shows the % inhibition of H358 resistant cells (KRAS G12C) after administration of a combination comprising Compound T3 (YAP / TAZ-TEAD inhibitor) and Compound K1 (KRAS inhibitor).
[0082] [Figure 22]FIG. 22 shows the % inhibition of H358 resistant cells (KRAS G12C) after administration of a combination comprising Compound T1 (YAP / TAZ-TEAD inhibitor) and Compound K2 (KRAS inhibitor).
[0083] [Figure 23] FIG. 23 shows the % inhibition of H358 resistant cells (KRAS G12C) after administration of a combination comprising Compound T2 (YAP / TAZ-TEAD inhibitor) and Compound K2 (KRAS inhibitor).
[0084] [Figure 24] FIG. 24 shows the % inhibition of H358 resistant cells (KRAS G12C) after administration of a combination comprising Compound T3 (YAP / TAZ-TEAD inhibitor) and Compound K2 (KRAS inhibitor).
[0085] [Figure 25] FIG. 25 shows the % inhibition of H358 resistant cells (KRAS G12C) after administration of a combination comprising Compound T1 (YAP / TAZ-TEAD inhibitor) and Compound K3 (KRAS inhibitor).
[0086] [Figure 26] FIG. 26 shows the % inhibition of H358 resistant cells (KRAS G12C) after administration of a combination comprising compound T2 (YAP / TAZ-TEAD inhibitor) and compound K3 (KRAS inhibitor).
[0087] [Figure 27] FIG. 27 shows the % inhibition of H358 resistant cells (KRAS G12C) after administration of a combination comprising Compound T3 (YAP / TAZ-TEAD inhibitor) and Compound K3 (KRAS inhibitor).
[0088] [Figure 28] FIG. 28 shows the % inhibition of H2030 cells (KRAS G12C) after administration of a combination comprising Compound T1 (YAP / TAZ-TEAD inhibitor) and Compound K4 (KRAS inhibitor).
[0089] [Figure 29] FIG. 29 shows the % inhibition of H2030 cells (KRAS G12C) after administration of a combination comprising compound T2 (YAP / TAZ-TEAD inhibitor) and compound K4 (KRAS inhibitor).
[0090] [Figure 30] FIG. 30 shows the % inhibition of H2030 cells (KRAS G12C) after administration of a combination comprising compound T3 (YAP / TAZ-TEAD inhibitor) and compound K4 (KRAS inhibitor).
[0091] [Figure 31] FIG. 31 shows the % inhibition of H358 parental cells (KRAS G12C) after administration of a combination comprising Compound T1 (YAP / TAZ-TEAD inhibitor) and Compound K4 (KRAS inhibitor).
[0092] [Figure 32] FIG. 32 shows the % inhibition of H358 parental cells (KRAS G12C) after administration of a combination comprising compound T2 (YAP / TAZ-TEAD inhibitor) and compound K4 (KRAS inhibitor).
[0093] [Figure 33] FIG. 33 shows the % inhibition of H358 parental cells (KRAS G12C) following administration of a combination comprising compound T3 (a YAP / TAZ-TEAD inhibitor) and compound K4 (a KRAS inhibitor).
[0094] [Figure 34] FIG. 34 shows the % inhibition of H358 resistant cells (KRAS G12C) after administration of a combination comprising Compound T1 (YAP / TAZ-TEAD inhibitor) and Compound K4 (KRAS inhibitor).
[0095] [Figure 35]FIG. 35 shows the % inhibition of H358 resistant cells (KRAS G12C) after administration of a combination comprising compound T2 (YAP / TAZ-TEAD inhibitor) and compound K4 (KRAS inhibitor).
[0096] [Figure 36] FIG. 36 shows the % inhibition of H358 resistant cells (KRAS G12C) after administration of a combination comprising compound T3 (YAP / TAZ-TEAD inhibitor) and compound K4 (KRAS inhibitor).
[0097] [Figure 37] FIG. 37 shows tumor volume over time in mice inoculated with NCI-H2122 cells; MC 0.5% PO QD×21+MCT PO BID×21.
[0098] [Figure 38] FIG. 38 shows tumor volume over time in mice inoculated with NCI-H2122 cells; Compound K4 25 mg / kg PO QD×21.
[0099] [Figure 39] FIG. 39 shows tumor volume over time in mice inoculated with NCI-H2122 cells; Compound T1 10 mg / kg PO BID×21.
[0100] [Figure 40] FIG. 40 shows tumor volume over time in mice inoculated with NCI-H2122 cells; Compound T1 20 mg / kg PO QD×21.
[0101] [Figure 41] FIG. 41 shows tumor volume over time in mice inoculated with NCI-H2122 cells; Compound K4 25 mg / kg PO QD×21 and Compound T1 10 mg / kg PO BID×21.
[0102] [Figure 42]FIG. 42 shows tumor volume over time in mice inoculated with NCI-H2122 cells; Compound K4 25 mg / kg PO QD×21 and Compound T1 20 mg / kg PO QD×21.
[0103] [Figure 43] FIG. 43 shows the % weight change over time for mice inoculated with NCI-H2122 cells; MC 0.5% PO QD×21+MCT PO BID×21.
[0104] [Figure 44] FIG. 44 shows the % weight change over time in mice inoculated with NCI-H2122 cells; Compound K4 25 mg / kg PO QD×21.
[0105] [Figure 45] Figure 45 shows the % weight change over time for mice inoculated with NCI-H2122 cells; Compound T1 10 mg / kg PO BIDx21.
[0106] [Figure 46] FIG. 46 shows the % weight change over time for mice inoculated with NCI-H2122 cells; Compound T1 20 mg / kg PO QD×21.
[0107] [Figure 47] FIG. 47 shows the % weight change over time for mice inoculated with NCI-H2122 cells; Compound K4 25 mg / kg PO QD×21 and Compound T1 10 mg / kg PO BID×21.
[0108] [Figure 48] FIG. 48 shows the % weight change over time for mice inoculated with NCI-H2122 cells; Compound K4 25 mg / kg PO QD×21 and Compound T1 20 mg / kg PO QD×21. DETAILED DESCRIPTION OF THE INVENTION
[0109] Detailed Description definition Unless otherwise indicated, the following specific terms used in the specification and claims are defined as follows:
[0110] The term "moiety" refers to an atom or chemically bonded atom or group that is attached to another atom or molecule by one or more chemical bonds, thereby forming part of the molecule.
[0111] The term "substituted" refers to the replacement of at least one of a compound or moiety's hydrogen atoms with another substituent or moiety.
[0112] The term "alkyl" refers to an aliphatic straight- or branched-chain saturated hydrocarbon moiety having 1 to 20 carbon atoms, e.g., 1 to 12 carbon atoms or 1 to 6 carbon atoms. An alkyl group can be optionally substituted. In some embodiments, an alkyl is unsubstituted.
[0113] In some embodiments, "alkoxy" is --O-alkyl.
[0114] The term "cycloalkyl" refers to monocyclic or bicyclic (including bridged bicyclic) rings and saturated or partially unsaturated carbocyclic moieties having 3 to 10 carbon atoms in the ring. In other specific embodiments, cycloalkyl contains 3 to 8 carbon atoms (i.e., (C3-C8)cycloalkyl). In other specific embodiments, cycloalkyl contains 3 to 6 carbon atoms (i.e., (C3-C6)cycloalkyl). Examples of cycloalkyl moieties include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and their partially unsaturated (cycloalkenyl) derivatives (e.g., cyclopentenyl, cyclohexenyl, and cycloheptenyl). The cycloalkyl moieties may be attached in a spirocyclic fashion, such as spirocyclopropyl: TIFF2024541508000010.tif12170
[0115] The term "haloalkyl" refers to an alkyl group in which one or more of the alkyl group's hydrogen atoms have been replaced by the same or different halogen atoms, such as fluorine atoms. Examples of haloalkyl include monofluoro-, difluoro-, or trifluoro-methyl, -ethyl, or -propyl, such as 3,3,3-trifluoropropyl, 2-fluoroethyl, 2,2,2-trifluoroethyl, fluoroethyl, or trifluoromethyl. Haloalkyl groups can be optionally substituted. In some embodiments, haloalkyl is unsubstituted.
[0116] The term "alkenyl" refers to a straight or branched chain alkyl or substituted alkyl group, as defined elsewhere herein, having at least one carbon-carbon double bond. Alkenyl groups can be optionally substituted. In some embodiments, alkenyl is unsubstituted.
[0117] The term "alkynyl" refers to a straight or branched chain alkyl or substituted alkyl group, as defined elsewhere herein, having at least one carbon-carbon triple bond. Alkynyl groups can be optionally substituted. In some embodiments, alkynyl is unsubstituted.
[0118] The terms "heterocyclyl" and "heterocycle" refer to 4-, 5-, 6-, and 7-membered monocyclic heterocyclic moieties, or 7-, 8-, 9-, and 10-membered bicyclic (including bridged bicyclic) heterocyclic moieties, which are saturated or partially unsaturated and have one or more (e.g., 1, 2, 3, or 4) heteroatoms selected from oxygen, nitrogen, and sulfur in the ring, with the remaining ring atoms being carbon. When used in reference to a ring atom of a heterocycle, nitrogen or sulfur may also be in oxidized form, and the nitrogen may be substituted. A heterocycle can be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure, and any of the ring atoms can be optionally substituted. Examples of such saturated or partially unsaturated heterocyclic rings include, but are not limited to, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydrothienyl, pyrrolidinyl, pyrrolidonyl, piperidinyl, pyrrolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, diazepinyl, oxazepinyl, thiazolyl, thiazepinyl, morpholinyl, and quinuclidinyl. Heterocyclic rings also include groups in which a heterocyclic ring is fused to one or more aryl rings, heteroaryl rings, or cycloalkyl rings, such as benzothiazolyl, benzofuranyl, furopyridinyl, indolinyl, 3H-indolyl, chromanyl, 2-azabicyclo[2.2.1]heptanyl, octahydroindolyl, or tetrahydroquinolinyl. Heterocyclyl groups can be optionally substituted. In some embodiments, the heterocyclyl is unsubstituted.
[0119] The term "aryl" refers to a cyclic aromatic hydrocarbon moiety having a monocyclic, bicyclic, or tricyclic aromatic ring of 5 to 20 carbon ring atoms. Examples of aryl moieties include, but are not limited to, phenyl, naphthyl, benzyl, and the like. The term "aryl" also includes partially hydrogenated derivatives of cyclic aromatic hydrocarbon moieties, provided that at least one ring of the cyclic aromatic hydrocarbon moiety is aromatic, each of which may be optionally substituted. In some embodiments, a monocyclic aryl ring may have 5 or 6 carbon ring atoms. An aryl group may be optionally substituted. In some embodiments, an aryl is unsubstituted.
[0120] The term "heteroaryl" refers to an aromatic heterocyclic monocyclic or bicyclic ring system of 1 to 20 ring atoms containing 1, 2, 3, or 4 heteroatoms selected from N, O, and S, with the remaining ring atoms being carbon. Examples of heteroaryl include pyrrolyl, furanyl, thienyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyridinyl, pyrazinyl, pyrazolyl, pyridazinyl, pyrimidinyl, triazinyl, isoxazolyl, benzofuranyl, isothiazolyl, benzothienyl, indolyl, isoindolyl, isobenzofuranyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzoxadiazolyl, benzothiadiazolyl, benzotriazolyl, purinyl, quinolinyl, isoquinolinyl, quinazolinyl, or quinoxalinyl. Heteroaryl groups can be optionally substituted, hi some embodiments, heteroaryl is unsubstituted.
[0121] The terms "halo" and "halogen" refer to fluoro, chloro, bromo, and iodo. In some embodiments, halo is fluoro or chloro.
[0122] The term "oxo" refers to a =O moiety.
[0123] The term "cyano" refers to a -C≡N moiety.
[0124] The terms "spirocycle" and "spirocyclyl" refer to a carbocyclic bicyclic ring system containing 5 to 13 carbon atoms, with both rings connected through a single atom. The rings may vary in size and nature or may be the same in size and nature. Examples include spiropentane, spirohexane, spiroheptane, spirooctane, spirodecane, or spirodecane. One or more of the carbon atoms in the spirocycle may be replaced with a heteroatom (e.g., O, N, S, or P). The spirocycle group may be optionally substituted.
[0125] In some embodiments, the spiro ring is unsubstituted.
[0126] The term "pharmaceutically acceptable salt" refers to a salt that retains the biological effectiveness and properties of the free base or free acid, without being biologically or otherwise undesirable. Salts are formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, and phosphoric acid, preferably hydrochloric acid, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, salicylic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, N-acetylcysteine, and the like. In addition, salts can be prepared by adding an inorganic or organic base to the free acid. Salts derived from inorganic bases include, but are not limited to, sodium, potassium, lithium, ammonium, calcium, and magnesium salts, and the like. Salts derived from organic bases include, but are not limited to, primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins such as isopropylamine resin, trimethylamine resin, diethylamine resin, triethylamine resin, tripropylamine resin, ethanolamine resin, lysine resin, arginine resin, N-ethylpiperidine resin, piperidine resin, polyamine resin, and the like.
[0127] The term "prodrug" refers to a compound that readily undergoes chemical changes under physiological conditions to provide a compound of the present disclosure. Additionally, prodrugs can be converted to a compound of the present disclosure by chemical or biochemical methods in an ex vivo environment. For example, prodrugs can be slowly converted to a compound of the present disclosure when placed in a transdermal patch reservoir with a suitable enzyme or chemical reagent.
[0128] In some prodrug embodiments, the prodrug comprises an amino acid residue, or a polypeptide chain of two or more (e.g., 2, 3, or 4) amino acid residues, covalently linked via amide or ester bonds to a free amino, hydroxy, or carboxylic acid group of a compound of the present disclosure. Amino acid residues include, but are not limited to, the 20 naturally occurring amino acids commonly represented by their three-letter symbols, including phosphoserine, phosphothreonine, phosphotyrosine, 4-hydroxyproline, hydroxylysine, demosin, isodemosin, gamma-carboxyglutamate, hippuric acid, octahydroindole-2-carboxylic acid, statin, 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, penicillamine, ornithine, 3-methylhistidine, norvaline, beta-alanine, gamma-aminobutyric acid, citrulline, homocysteine, homoserine, methyl-alanine, para-benzoylphenylalanine, phenylglycine, propargylglycine, sarcosine, methionine sulfone, and tert-butylglycine.
[0129] In some other prodrug embodiments, free carboxyl groups of the compounds of the present disclosure can be derivatized as amides or alkyl esters. In yet other prodrug embodiments, prodrugs containing free hydroxy groups can be derivatized as prodrugs by converting the hydroxy group to groups such as, but not limited to, phosphate esters, hemisuccinates, dimethylaminoacetates, or phosphoryloxymethyloxycarbonyl groups, as outlined in Fleisher, D. et al. (1996) Improved oral drug delivery: solubility limitations overcome by the use of prodrugs (Advanced Drug Delivery Reviews, 19:115). Carbamate prodrugs of hydroxy and amino groups are also included, as are carbamate prodrugs, sulfonate esters, and sulfate esters of hydroxy groups. The acyl group may be an alkyl ester optionally substituted with groups including, but not limited to, ether, amine, and carboxylic acid functional groups, or when the acyl group is an amino acid ester as described above, derivatization of the hydroxy group as (acyloxy)methyl and (acyloxy)ethyl ethers is also encompassed. This type of prodrug is described in J. Med. Chem., (1996), 39:10. More specific examples include those in which the hydrogen atom of the alcohol group is substituted with (C 1-6 ) alkanoyloxymethyl, 1-((C 1~6 )alkanoyloxy)ethyl, 1-methyl-1-((C 1~6 )alkanoyloxy)ethyl, (C 1-6 )alkoxycarbonyloxymethyl, N-(C 1~6 ) alkoxycarbonylaminomethyl, succinoyl, (C 1~6 ) alkanoyl, alpha-amino (C 1~4 ) alkanoyl, arylacyl and alpha-aminoacyl, or alpha-aminoacyl-alpha-aminoacyl (each alpha-aminoacyl group is a natural L-amino acid, P(O)(OH)2, -P(O)(O(C1~6 ) alkyl) 2 or glycosyl (independently selected from radicals generated by removing the hydroxyl group of the hemiacetal form of a carbohydrate).
[0130] For further examples of prodrug derivatives, see, for example, a) Design of Prodrugs, edited by H. Bundgaard, (Elsevier, 1985) and Methods in Enzymology, Vol. 42, pp. 309-396, edited by K. Widder, et al. (Academic Press, 1985); b) A Textbook of Drug Design and Development, edited by Krogsgaard-Larsen and H. Bundgaard, Chapter 5 "Design and Application of Prodrugs," by H. Bundgaard, pp. 113-191 (1991); c) H. Bundgaard, Advanced Drug Delivery Reviews, 8:1-38 (1992); d) H. Bundgaard, et al., Journal of Pharmaceutical Sciences, 77:285 (1988); and e) N. Kakeya, et al. al., Chem. Pharm. Bull., 32:692 (1984), each of which is specifically incorporated herein by reference.
[0131] In addition, the present disclosure provides metabolic products of the compounds of the present disclosure. As used herein, "metabolite" refers to a product produced through metabolism in the body of a particular compound or its salt. Such products may result from, for example, oxidation, reduction, hydrolysis, amidation, deamidation, esterification, deesterification, enzymatic cleavage, etc., of the administered compound.
[0132] The metabolites are typically radiolabeled (e.g., 14 C or 3H) isotopes are prepared and identified by parenteral administration of the isotope at a detectable dose (e.g., greater than about 0.5 mg / kg) to animals such as rats, mice, guinea pigs, monkeys, or humans, allowing sufficient time for metabolism (typically about 30 seconds to 30 hours), and isolating the conversion products from urine, blood, or other physiological samples. These products are easily isolated because they are labeled (others are isolated by the use of antibodies capable of binding epitopes surviving in the metabolites). The structures of the metabolites are determined by conventional methods, such as MS, LC / MS, or NMR analysis. Metabolite analysis is generally performed in the same manner as conventional drug metabolism studies well known to those skilled in the art. Metabolites are useful in diagnostic assays for therapeutic dosing of the disclosed compounds, unless otherwise found in vivo.
[0133] Certain compounds of the present disclosure can exist in non-solvated form and solvated form, including hydrated form.In general, the solvated form is equivalent to the non-solvated form and is intended to be included in the scope of the present disclosure.Certain compounds of the present disclosure can exist in multiple crystalline forms or amorphous forms.In general, all physical forms are equivalent for the use contemplated by the present disclosure and are intended to be within the scope of the present disclosure.
[0134] Compounds that have the same molecular formula but differ in the nature or sequence of bonding of their atoms or in the arrangement of their atoms in space are called "isomers." Isomers that differ in the arrangement of their atoms in space are called "stereoisomers." Diastereomers are stereoisomers with opposite configurations at one or more chiral centers that are not mirror isomers. Stereoisomers with one or more asymmetric centers that are non-superimposable mirror images of each other are called "enantiomers." When a compound has an asymmetric center, for example, when a carbon atom is bonded to four different groups, a pair of enantiomers is possible. Enantiomers can be characterized by the absolute configuration of their asymmetric center(s) and are described by the Cahn-Ingold-Prelog R- and S-sequencing rules or by the way the molecule rotates the plane of polarized light and are designated as dextrorotatory or levorotatory (i.e., (+) or (-) isomers, respectively). Chiral compounds can exist as either individual enantiomers or as a mixture thereof. A mixture containing equal proportions of enantiomers is called a "racemic mixture." In certain embodiments, the compound is enriched with a single diastereomer or enantiomer to at least about 90% by weight. In other embodiments, the compound is enriched with a single diastereomer or enantiomer to at least about 95%, 98%, or 99% by weight.
[0135] Certain compounds of the present disclosure possess asymmetric carbon atoms (optical centers) or double bonds; the racemates, diastereomers, geometric isomers, positional isomers and individual isomers (e.g., separate enantiomers) are all intended to be encompassed within the scope of the present disclosure.
[0136] The compounds of the present disclosure may also exist in various tautomeric forms, and all such forms are included within the scope of the present disclosure. The term "tautomer" or "tautomeric form" refers to structural isomers with different energies that are interconvertible via a low energy barrier. For example, proton tautomers (also known as prototropic tautomers) include interconversions via migration of a proton, such as keto-enol and imine-enamine isomerizations. Valence tautomers include interconversions via reorganization of some of the bonding electrons.
[0137] Unless otherwise indicated, the term "a compound of the formula" or "a compound of formula" or "compounds of the formula" or "compounds of formula" refers to any compound selected from the genus of compounds defined by the formula. In some embodiments or aspects, the term also includes pharmaceutically acceptable salts or esters of any such compound, stereoisomers or tautomers of such compounds.
[0138] The term "therapeutically effective amount" of a compound refers to an amount of compound effective to prevent, alleviate, or ameliorate symptoms of disease, or to prolong the survival of a subject being treated. Determining a therapeutically effective amount is within the skill of those in the art. The therapeutically effective amount or therapeutically effective dose of a compound according to the present disclosure can vary within wide limits and can be determined in a manner known in the art. Such doses will be adjusted to the individual requirements in each particular case, including the specific compound(s) being administered, the route of administration, the condition being treated, and the patient being treated. Generally, for oral or parenteral administration to an adult weighing approximately 70 kg, a daily dose of about 0.1 mg to about 5,000 mg, 1 mg to about 1,000 mg, or 1 mg to 100 mg may be appropriate, although the lower and upper limits may be exceeded when indicated. The daily dose can be administered as a single dose, in divided doses, or, for parenteral administration, as a continuous infusion.
[0139] In some embodiments, the term "therapeutically effective amount" of a compound refers to an amount of compound effective to alleviate or ameliorate symptoms of disease or to prolong the survival of a subject being treated. Determining a therapeutically effective amount is within the skill of those in the art. Therapeutically effective amounts or therapeutically effective dosages of compounds according to the present disclosure can vary within wide limits and can be determined in a manner known in the art. Such dosages will be tailored to the individual requirements in each particular case, including the specific compound(s) being administered, the route of administration, the condition being treated, and the patient being treated. Generally, for oral or parenteral administration to an adult weighing approximately 70 kg, a daily dosage of about 0.1 mg to about 5,000 mg, 1 mg to about 1,000 mg, or 1 mg to 100 mg may be appropriate, although the lower and upper limits may be exceeded when indicated. The daily dosage can be administered as a single dose or in divided doses, or, for parenteral administration, may be given as a continuous infusion.
[0140] In embodiments herein, a therapeutically effective amount of a compound can be an amount of compound effective to alleviate or ameliorate the condition or disease, or a symptom thereof, or prolong the survival of the subject being treated.
[0141] The term "pharmaceutically acceptable carrier" is intended to include any and all materials compatible with pharmaceutical administration, including solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and other materials and compounds compatible with pharmaceutical administration. Except insofar as any conventional media or agent is incompatible with the compounds of the present disclosure, its use in the compositions of the present disclosure is contemplated. Supplementary active compounds can also be incorporated into the compositions.
[0142] compound In some embodiments, the compound of formula (I-AB) below: TIFF2024541508000011.tif34170, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt thereof, wherein: L' is * -N(R 1 )-L- ** and TIFF2024541508000012.tif16170; * indicates the point of attachment to Z, ** teeth, This shows the connection point with TIFF2024541508000013.tif33170. R 1 is H or C 1~6 is alkyl, X 1 is N or CR s and R s H, deuterium, -CN, halo, C 1~15 Alkyl, C 1~6 Alkynyl, C 6~20 Aryl, 5-15 membered heteroaryl, C 3~20 Cycloalkyl, 3- to 15-membered heterocyclyl, -OH, -OR f , C 1~15Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , and -NR d R e is selected from R d , R e and R f each independently represents H, C 1~6 Alkyl or C 3~20 is cycloalkyl, C 1~6 Alkyl and C 3~20 each cycloalkyl independently may be optionally substituted with one or more halo, oxo, —OH, or —CN; R s C 1~15 Alkyl and C 1~15 Each alkoxy is independently one or more R t1 and R t1 -O-, -OH-, -OR ... f1 , -CN, -NR d R e and 3- to 15-membered heterocyclyl optionally substituted with one or more —OH; R f1 is -C(O)CHNR d R e , -C(O)C 1~6 alkyl, -P(O)(OH)2, and R d and R e are each independently H or C 1~6 Rukill and R d or R e C 1~6 The alkyl may be optionally substituted with one or more halo, oxo, —OH, or —CN; R s C 6~20 Aryl, 5-15 membered heteroaryl, C 3~20Cycloalkyl and 3- to 15-membered heterocyclyl each independently represent one or more R t2 and R t2 represents, at each occurrence, halo, oxo, -OH, -CN, C(O)NH2, -C(O)NR d R e , -NR d R e , C 1~6 Alkoxyl, 3-6 membered heterocyclyl, C 3~6 Cycloalkyl, and C 1~6 alkyl; R t2 C 1~6 Alkyl is a group consisting of one or more -OH, C 1~6 Alkoxyl, halo, oxo, -S(O)2CH3, or -NR d R e and R d and R e are each independently H, -C(O)CH3, or -C(O)C 1~6 Alkyl, or C 1~6 is alkyl, X 2 , X 3 , and X 4 are each independently N, CH, or CD, provided that: 1) X 1 , X 2 , X 3 , and X 4 1) Only one of the two is N, or 2) X 1 is N and X 2 is CH and X 3 is CH and X 4 is N or 3) X 1 is CR s and X 2 , X 3 , and X 4 are each independently CH or CD; B is phenyl or 5- to 6-membered heteroaryl, and each phenyl or 5- to 6-membered heteroaryl of B is independently one or more R t and R t At each occurrence, halo, C1~15 Alkyl, C 1~6 Alkoxy, and S(R y )5 independently selected from y is the halo and R t C 1~15 Alkyl or C 1~6 The alkoxy may be optionally substituted with one or more halo; Z is -C(O)R x and R x is C 1~6 Alkyl, Deuterium, -OH, C 1~6 C optionally substituted with one or more substituents selected from alkoxyl and halo 2~6 alkenyl, or R x C optionally substituted with one or more halo 1~6 alkyl or R x C optionally substituted with -OH 1~6 alkynyl or R x is cyclobutenyl, dihydrofuranyl, bicyclobutanyl or cyclopentenyl, or Z is S(O)2R x1 and R x1 is C 2~6 is alkenyl, L is one or more C 1~6 methylene optionally substituted with alkyl; n and m are each 1, or n and m are each 2.
[0143] Any embodiment, aspect, or variation described herein with respect to one formula may, where applicable, be applied to any other formula listed herein. For example, any embodiment, aspect, or variation described herein with respect to any one or more of formulas (AB), (A), (B), (A'), (B'), (IA), and (IB) applies to formula (I-AB) and is the same as if each embodiment, aspect, and variation were specifically and individually listed with respect to formula (I-AB). It is understood that such embodiments apply to the structural features of the compounds and methods of making and using such compounds. For example, methods of using any one or more of formulas (AB), (A), (B), (A'), (B'), (IA), and (IB), where applicable, apply to methods of using compounds of formula (I-AB), and is the same as if each and every embodiment, aspect, and variation were specifically and individually listed with respect to formula (I-AB).
[0144] In some embodiments, in conjunction with the above or below embodiments, L' in formula (I-AB) is * -N(R 1 )-L- ** In some embodiments, in conjunction with the above or below embodiments, L' in formula (I-AB) is The file is TIFF2024541508000014.tif16170.
[0145] In some embodiments, the compound of formula (AB): TIFF2024541508000015.tif34170, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein: L' is * -N(R 1 )-L- ** and TIFF2024541508000016.tif16170; * indicates the point of attachment to Z, ** teeth, This shows the connection point with TIFF2024541508000017.tif33170. R 1 is H or C 1~6 is alkyl, X 1 is N or CR s and R s H, deuterium, -CN, halo, C 1~15 Alkyl, C 1~6 Alkynyl, C 6~20 Aryl, 5-15 membered heteroaryl, C 3~20 Cycloalkyl, 3- to 15-membered heterocyclyl, -OH, -OR f , C 1~15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , and -NR d R e is selected from R d , R e and R f each independently represents H, C 1~6 Alkyl or C 3~20 is cycloalkyl, C 1~6 Alkyl and C 3~20 each cycloalkyl independently may be optionally substituted with one or more halo, oxo, —OH, or —CN; R s C 1~15 Alkyl and C 1~15 Each alkoxy is independently one or more R t1 and R t1 independently, at each occurrence, represents halo, oxo, -OH, -CN, -NR d R e and 3- to 15-membered heterocyclyl optionally substituted with one or more —OH; R d and R e are each independently H or C1~6 alkyl, and R d or R e C 1~6 The alkyl may be optionally substituted with one or more halo, oxo, —OH, or —CN; R s C 6~20 Aryl, 5-15 membered heteroaryl, C 3~20 Cycloalkyl and 3- to 15-membered heterocyclyl each independently represent one or more R t2 and R t2 independently, at each occurrence, represents halo, oxo, -OH, -CN, C(O)NH, -C(O)NR d R e , -NR d R e , C 1~6 Alkoxy and C 1~6 alkyl, and R t2 C 1~6 Alkyl is one or more -OH or -NR d R e optionally substituted with R d and R e are each independently -C(O)CH3, H, -C(O)C 1~6 Alkyl, or C 1~6 is alkyl, X 2 , X 3 , and X 4 are each independently N, CH, or CD, provided that X 1 , X 2 , X 3 , and X 4 and exactly one of the is N, B is phenyl or 5- to 6-membered heteroaryl, and each phenyl or 5- to 6-membered heteroaryl of B is independently one or more R t and R t At each occurrence, halo, C 1~15 Alkyl, C 1~6 Alkoxy, and S(R y )5, and each R y is the halo and R t C1~15 Alkyl or C 1~6 The alkoxy may be optionally substituted with one or more halo; Z is -C(O)R x and R x is C 1~6 Alkyl, Deuterium, -OH, C 1~6 C optionally substituted with one or more substituents selected from alkoxyl and halo 2~6 alkenyl, or R x C optionally substituted with one or more halo 1~6 alkyl or R x C optionally substituted with -OH 1~6 alkynyl or R x is cyclobutenyl, L is one or more C 1~6 methylene optionally substituted with alkyl; n and m are each 1, or n and m are each 2.
[0146] In some embodiments, the compound of formula (A) or (B) below: TIFF2024541508000018.tif74170, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein: R 1 is H or C 1~6 is alkyl, X 1 is N or CR s and R s H, -CN, halo, C 1~15 Alkyl, C 6~20 Aryl, 5-15 membered heteroaryl, C 3~20 Cycloalkyl, 3- to 15-membered heterocyclyl, -OH, C 1~15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NRd SO2R e , and -NR d R e Selected from R d and R e are each independently H or C 1~6 alkyl, and R d or R e C 1~6 The alkyl may be optionally substituted with one or more halo, oxo, —OH, or —CN; R s C 1~15 Alkyl and C 1~15 Each alkoxy is independently one or more R t1 and R t1 independently, at each occurrence, represent halo, oxo, -OH, -CN, and -NR d R e Selected from R d and R e are each independently H or C 1~6 alkyl, and R d or R e C 1~6 The alkyl may be optionally substituted with one or more halo, oxo, —OH, or —CN; R s C 6~20 Aryl, 5-15 membered heteroaryl, C 3~20 Cycloalkyl and 3- to 15-membered heterocyclyl each independently represent one or more R t2 and R t2 independently, at each occurrence, represent halo, -OH, -CN, and C 1~6 alkyl, X 2 , X 3 , and X 4 are each independently N or CH, provided that X 1 , X 2 , X 3 , and X 4 and exactly one of the is N, B is phenyl or 5- to 6-membered heteroaryl, and each phenyl or 5- to 6-membered heteroaryl of B is independently one or more R t and R t At each occurrence, halo, C 1~15 Alkyl, C 1~6 Alkoxy, and S(R y )5 independently selected from y is the halo and R t C 1~15 Alkyl or C 1~6 The alkoxy may be optionally substituted with one or more halo; Z is -C(O)R x and R x is C 1~6 C optionally substituted with one or more substituents selected from alkyl and halo 2~6 alkenyl, or R x C optionally substituted with one or more halo 1~6 is alkyl, L is one or more C 1~6 methylene optionally substituted with alkyl; n and m are each independently 1 or 2.
[0147] In some embodiments, the compound of formula (A) or (B) below: TIFF2024541508000019.tif74170, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein: R 1 is H or C 1~6 is alkyl, X 1 is N or CR s and R s H, deuterium, -CN, halo, C 1~15 Alkyl, C 1~6 Alkynyl, C 6~20 Aryl, 5-15 membered heteroaryl, C 3~20 Cycloalkyl, 3- to 15-membered heterocyclyl, -OH, -OR f , C 1~15Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , and -NR d R e is selected from R d , R e and R f each independently represents H, C 1~6 Alkyl or C 3~20 is cycloalkyl, C 1~6 Alkyl and C 3~20 each cycloalkyl independently may be optionally substituted with one or more halo, oxo, —OH, or —CN; R s C 1~15 Alkyl and C 1~15 Each alkoxy is independently one or more R t1 and R t1 independently, at each occurrence, represents halo, oxo, -OH, -CN, -NR d R e and 3- to 15-membered heterocyclyl optionally substituted with one or more —OH; R d and R e are each independently H or C 1~6 alkyl, and R d or R e C 1~6 The alkyl may be optionally substituted with one or more halo, oxo, —OH, or —CN; R s C 6~20 Aryl, 5-15 membered heteroaryl, C 3~20 Cycloalkyl and 3- to 15-membered heterocyclyl each independently represent one or more R t2 and R t2 independently, at each occurrence, represents halo, oxo, -OH, -CN, C(O)NH, -C(O)NR dR e , -NR d R e , C 1~6 Alkoxy and C 1~6 alkyl, and R t2 C 1~6 Alkyl is one or more -OH or -NR d R e optionally substituted with R d and R e are each independently H, -C(O)CH3, or -C(O)C 1~6 Alkyl, or C 1~6 is alkyl, X 2 , X 3 , and X 4 are each independently N, CH, or CD, provided that X 1 , X 2 , X 3 , and X 4 and exactly one of the is N, B is phenyl or 5- to 6-membered heteroaryl, and each phenyl or 5- to 6-membered heteroaryl of B is independently one or more R t and R t At each occurrence, halo, C 1~15 Alkyl, C 1~6 Alkoxy, and S(R y )5, and each R y is the halo and R t C 1~15 Alkyl or C 1~6 The alkoxy may be optionally substituted with one or more halo; Z is -C(O)R x and R x is C 1~6 Alkyl, Deuterium, -OH, C 1~6 C optionally substituted with one or more substituents selected from alkoxyl and halo 2~6 alkenyl, or R x C optionally substituted with one or more halo 1~6 alkyl or R xC optionally substituted with -OH 1~6 alkynyl or R x is cyclobutenyl, L is one or more C 1~6 methylene optionally substituted with alkyl; n and m are each 1, or n and m are each 2.
[0148] In some embodiments, the compound is a compound of Formula (A): In some embodiments, the compound is a compound of Formula (B):
[0149] In some embodiments, the compound of formula (A') or (B') below: TIFF2024541508000020.tif69170, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein: X 1 is N or CR s and R s H, -CN, halo, C 1~15 Alkyl, C 6~20 Aryl, 5-15 membered heteroaryl, C 3~20 Cycloalkyl, 3- to 15-membered heterocyclyl, -OH, C 1~15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , and -NR d R e Selected from R d and R e are each independently H or C 1~6 alkyl, and R d or R e C 1~6 The alkyl may be optionally substituted with one or more halo, oxo, —OH, or —CN; R s C1~15 Alkyl and C 1~15 Each alkoxy is independently one or more R t1 and R t1 independently, at each occurrence, represent halo, oxo, -OH, -CN, and -NR d R e Selected from R d and R e are each independently H or C 1~6 alkyl, and R d or R e C 1~6 The alkyl may be optionally substituted with one or more halo, oxo, —OH, or —CN; R s C 6~20 Aryl, 5-15 membered heteroaryl, C 3~20 Cycloalkyl and 3- to 15-membered heterocyclyl each independently represent one or more R t2 and R t2 independently, at each occurrence, represent halo, -OH, -CN, and C 1~6 alkyl, X 2 , X 3 , and X 4 are each independently N or CH, provided that X 1 , X 2 , X 3 , and X 4 and exactly one of the is N, B is phenyl or 5- to 6-membered heteroaryl, and each phenyl or 5- to 6-membered heteroaryl of B is independently one or more R t and R t At each occurrence, halo, C 1~15 Alkyl, C 1~6 Alkoxy, and S(R y )5 independently selected from y is the halo and R t C 1~15 Alkyl or C 1~6 The alkoxy may be optionally substituted with one or more halo; Z is -C(O)R x and R x is C 1~6 C optionally substituted with one or more substituents selected from alkyl and halo 2~6 alkenyl, or R x C optionally substituted with one or more halo 1~6 is alkyl, L is one or more C 1~6 methylene optionally substituted with alkyl; n and m are each independently 1 or 2.
[0150] In some embodiments, provided herein are compounds of formula (AB), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein L' is * -N(R 1 )-L- ** where: * represents the point of attachment to Z, ** teeth, Represents the junction point with TIFF2024541508000021.tif33170.
[0151] In some embodiments, provided herein are compounds of formula (AB), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein L' is TIFF2024541508000022.tif16170, wherein: * represents the point of attachment to Z, ** teeth, Represents the junction point with TIFF2024541508000023.tif33170.
[0152] In some embodiments, provided herein are compounds of Formula (A) or (A′), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein R 1 is H. In some embodiments, R 1 is C 1~6 In some embodiments, R 1is methyl.
[0153] In some embodiments, provided herein are compounds of Formula (A) or (A') or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is N. In some embodiments, X 1 is C-CR s In some embodiments, X 1 is C-CR s and R s are independently H, halo, and C 1-15 Alkyl, C 6~20 Aryl, 5-15 membered heteroaryl, C 3~20 Cycloalkyl, 3- to 15-membered heterocyclyl, -OH, -CN, C 1~15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , or -NR d R e In another embodiment, R s is H. In other embodiments, each R s is halo. In other embodiments, R s is C 1~15 In other embodiments, R s is C 6~20 In other embodiments, R s is a 5- to 15-membered heteroaryl. s is C 3~20 In another embodiment, R s is 3-15 membered heterocyclyl. s is —OH. In other embodiments, R s is -CN. In other embodiments, R s is C 1~15In another embodiment, R s is -NR d COR e In another embodiment, R s -CONR d R e In another embodiment, R s is -SO2R d In another embodiment, R s is -SO2NR d R e In another embodiment, R s is -NR d SO2R e In another embodiment, R s is -NR d R e is.
[0154] In some embodiments, provided herein are compounds of Formula (A) or (A'), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is C-CR s and R s is C 1~15 Alkyl or C 1~15 is alkoxy, and R s C 1~15 Alkyl and C 1~15 Each alkoxy is independently one or more R t1 and R t1 is independently, at each occurrence, halo, oxo, -OH, -CN or -NR d R e In some embodiments, R s is one or more R t1 C replaced with 1~15 alkyl, and R t1 is halo. In some embodiments, R s is one or more R t1 C replaced with 1~15 alkyl, and R t1 is oxo. In some embodiments, R s is one or more Rt1 C replaced with 1~15 alkyl, and R t1 is —OH. In some embodiments, R s is one or more R t1 C replaced with 1~15 alkyl, and R t1 In some embodiments, R s is one or more R t1 C replaced with 1~15 alkyl, and R t1 is -NR d R e In some embodiments, R s is one or more R t1 C replaced with 1~15 is alkoxy, and R t1 is halo. In some embodiments, R s is one or more R t1 C replaced with 1~15 is alkoxy, and R t1 is oxo. In some embodiments, R s is one or more R t1 C replaced with 1~15 is alkoxy, and R t1 is —OH. In some embodiments, R s is one or more R t1 C replaced with 1~15 is alkoxy, and R t1 In some embodiments, R s is one or more R t1 C replaced with 1~15 is alkoxy, and R t1 is -NR d R e is.
[0155] In some embodiments, provided herein are compounds of Formula (A) or (A'), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is C-CR s and R s is C 1~15Alkyl or C 1~15 is alkoxy, and R s C 1~15 Alkyl and C 1~15 Each alkoxy is independently one or more R t1 and R t1 independently, at each occurrence, represents halo, oxo, -OH, -CN, -NR d R e or 3-15 membered heterocyclyl optionally substituted with —OH. In some embodiments, R s is one or more R t1 C replaced with 1~15 alkyl, and R t1 is halo. In some embodiments, R s is one or more R t1 C replaced with 1~15 alkyl, and R t1 is oxo. In some embodiments, R s is one or more R t1 C replaced with 1~15 alkyl, and R t1 is —OH. In some embodiments, R s is one or more R t1 C replaced with 1~15 alkyl, and R t1 In some embodiments, R s is one or more R t1 C replaced with 1~15 alkyl, and R t1 is -NR d R e In some embodiments, R s is one or more R t1 C replaced with 1~15 is alkoxy, and R t1 is halo. In some embodiments, R s is one or more R t1 C replaced with 1~15 is alkoxy, and R t1 is oxo. In some embodiments, R sis one or more R t1 C replaced with 1~15 is alkoxy, and R t1 is —OH. In some embodiments, R s is one or more R t1 C replaced with 1~15 is alkoxy, and R t1 In some embodiments, R s is one or more R t1 C replaced with 1~15 is alkoxy, and R t1 is -NR d R e In some embodiments, R s is one or more R t1 C replaced with 1~15 is alkoxy, and R t1 is a 3- to 15-membered heterocyclyl optionally substituted with —OH.
[0156] In some embodiments, provided herein are compounds of Formula (A) or (A'), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is C-CR s and R s is C 6~20 Aryl, 5-15 membered heteroaryl, C 3~20 cycloalkyl, or 3- to 15-membered heterocyclyl, and R s C 6~20 Aryl, 5-15 membered heteroaryl, C 3~20 Each cycloalkyl or 3- to 15-membered heterocyclyl independently has one or more R t2 and R t2 independently, at each occurrence, is halo, oxo, -OH, -CN, or -NR d R e In some embodiments, R s is one or more R t2 C replaced with 6~20 aryl, and R t2 is halo. In some embodiments, R sis one or more R t2 C replaced with 6~20 aryl, and R t2 is halo. In some embodiments, R s is one or more R t2 C replaced with 6~20 aryl, and R t2 is —OH. In some embodiments, R s is one or more R t2 C replaced with 6~20 aryl, and R t2 In some embodiments, R s is one or more R t2 C replaced with 6~20 aryl, and R t2 is -NR d R e In some embodiments, R s is one or more R t2 and R is a 5- to 15-membered heteroaryl substituted with t2 is halo. In some embodiments, R s is one or more R t2 and R is a 5- to 15-membered heteroaryl substituted with t2 is oxo. In some embodiments, R s is a 5- to 15-membered heteroaryl, and R t2 is —OH. In some embodiments, R s is one or more R t2 and R is a 5- to 15-membered heteroaryl substituted with t2 In some embodiments, R s is one or more R t2 and R is a 5- to 15-membered heteroaryl substituted with t2 Ha-NR d R e In some embodiments, R s is one or more R t2 C replaced with 3~20 is cycloalkyl, and R t2 is halo. In some embodiments, R sis one or more R t2 C replaced with 3~20 is cycloalkyl, and R t2 is oxo. In some embodiments, R s is one or more R t2 C replaced with 3~20 is cycloalkyl, and R t2 is —OH. In some embodiments, R s is one or more R t2 C replaced with 3~20 is cycloalkyl, and R t2 In some embodiments, R s is one or more R t2 C replaced with 3~20 is cycloalkyl, and R t2 is -NR d R e In some embodiments, R s is one or more R t2 3- to 15-membered heterocyclyl substituted with R t2 is halo. In some embodiments, R s is one or more R t2 3- to 15-membered heterocyclyl substituted with R t2 is oxo. In some embodiments, R s is one or more R t2 3- to 15-membered heterocyclyl substituted with R t2 is —OH. In some embodiments, R s is one or more R t2 3- to 15-membered heterocyclyl substituted with R t2 In some embodiments, R s is one or more R t1 3- to 15-membered heterocyclyl substituted with R t1 is -NR d R e is.
[0157] In some embodiments, provided herein are compounds of Formula (A) or (A'), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is C-CR s and each R s are independently t1 is further substituted by R t1 Ha-NR d R e and R d and R e are each independently H or C 1~6 alkyl, and R d or R e C 1~6 The alkyl may be optionally substituted with one or more halo, oxo, -OH, or -CN. In some embodiments, R d is H. In some embodiments, R d is C 1~6 In some embodiments, R e is H. In some embodiments, R e is C 1~6 R is alkyl. d C 1~6 In some embodiments, R is alkyl. d C 1~6 The alkyl may be optionally substituted with one or more halo, oxo, -OH, or -CN. In some embodiments, R d C 1~6 The alkyl is substituted with one or more halo. In some embodiments, R d C 1~6 The alkyl is substituted with one or more oxo. In some embodiments, R d C 1~6 The alkyl is substituted with one or more -OH. In some embodiments, R d C 1~6 The alkyl is substituted with one or more -CN. e C 1~6 In some embodiments, R is alkyl. e C 1~6The alkyl may be optionally substituted with one or more halo, oxo, -OH, or -CN. In some embodiments, R e C 1~6 The alkyl is substituted with one or more halo. In some embodiments, R e C 1~6 The alkyl is substituted with one or more oxo. In some embodiments, R e C 1~6 The alkyl is substituted with one or more -OH. In some embodiments, R e C 1~6 The alkyl is substituted with one or more -CN groups.
[0158] In some embodiments, provided herein are compounds of Formula (A) or (A'), or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein B is phenyl or 5-6 membered heteroaryl. In some embodiments, B is phenyl. In some embodiments, B is 5-6 membered heteroaryl. In some embodiments, the phenyl or 5-6 membered heteroaryl of B each independently is selected from one or more R t and R t independently at each occurrence, halo, C 1~15 Alkyl, or C 1~6 is alkoxy, and R t C 1~15 Alkyl or C 1~6 The alkoxy may be optionally substituted with one or more halo. In some embodiments, B is selected from the group consisting of one or more R t is phenyl substituted with R t independently at each occurrence, halo, C 1~15 Alkyl, or C 1~6 is alkoxy, and R t C 1~15 Alkyl or C 1~6 The alkoxy may be optionally substituted with one or more halo. In some embodiments, B is selected from the group consisting of one or more R t is phenyl substituted with R tIn some embodiments, B is selected from the group consisting of one or more R t is phenyl substituted with R t is C 1~15 In some embodiments, B is one or more R t is phenyl substituted with R t is C 1~6 In some embodiments, B is one or more R t is phenyl substituted with R t is S(R y )5, and each R y In some embodiments, B is selected from the group consisting of one or more R t and R is a 5- to 6-membered heteroaryl substituted with t independently at each occurrence, halo, C 1~15 Alkyl, or C 1~6 is alkoxy, and R t C 1~15 Alkyl or C 1~6 The alkoxy may be optionally substituted with one or more halo. In some embodiments, B is selected from the group consisting of one or more R t and R is a 5- to 6-membered heteroaryl substituted with t In some embodiments, B is selected from the group consisting of one or more R t and R is a 5- to 6-membered heteroaryl substituted with t is C 1~15 In some embodiments, B is one or more R t and R is a 5- to 6-membered heteroaryl substituted with t is C 1~6 B is phenyl or one or more R t and R is a 5- to 6-membered heteroaryl substituted with t C 1~15 Alkyl or C 1~6 In some embodiments, R is alkoxy. t C 1~15 Alkyl or C 1~6 The alkoxy may be optionally substituted with one or more halo. In some embodiments, Rt C 1~15 The alkyl is substituted with one or more fluoro. In some embodiments, R t C 1~15 In some embodiments, B is substituted with one or more R t and R is a 5- to 6-membered heteroaryl substituted with t is S(R y )5, and each R y is a halo.
[0159] In some embodiments, provided herein are compounds of Formula (A) or (A'), or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein B is phenyl. In some embodiments, B is a 5-6 membered heteroaryl. In other embodiments, B is unsubstituted phenyl. In other embodiments, B is substituted phenyl. In other embodiments, B is selected from the group consisting of one or more R t In another embodiment, R t is C 1~6 In another embodiment, R t is C substituted with one or more halo 1~6 In another embodiment, R t is a C substituted with one or more fluoro groups 1~6 In another embodiment, B is The file is TIFF2024541508000024.tif17170.
[0160] In some embodiments, provided herein are compounds of Formula (A) or (A') or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is N or C-CR s In some embodiments, X 1 is N. In some embodiments, X 1 is C-CR s is.
[0161] In some embodiments, provided herein are compounds of formula (A) or (A') or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is CR s and X 2 is CH and X 3 is CH and X 4 is N and R s is the unsubstituted C 1~15 In another embodiment, X is alkyl. 1 is CR s and X 2 is CH and X 3 is CH and X 4 is N and R s is one or more R t1 C replaced with 1~15 In another embodiment, X is alkyl. 1 is CR s and X 2 is CH and X 3 is CH and X 4 is N and R s is one or more R t1 C replaced with 1~15 alkyl, and R t1 is —OH. In another embodiment, X 1 is CR s and X 2 is CH and X 3 is CH and X 4 is N and R s teeth The file is TIFF2024541508000025.tif12170.
[0162] In some embodiments, provided herein are compounds of Formula (A) or (A′), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein L is one or more C 1~6 In some embodiments, L is methylene, optionally substituted with alkyl. In some embodiments, L is unsubstituted methylene. In some embodiments, L is one or more C 1~6 It is methylene substituted with alkyl.
[0163] In some embodiments, provided herein are compounds of Formula (A), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein Z is —C(O)R x and R x is C 1~6 optionally substituted with one or more substituents selected from alkyl and halo, or C 2~6 alkenyl, and R x C optionally substituted with one or more halo 1~6 In some embodiments, R x is C 1~6 C optionally substituted with one or more substituents selected from alkyl and halo 2~6 In some embodiments, R is alkenyl. x is the unsubstituted C 2~6 In some embodiments, R x is one or more C 1~6 Alkyl-substituted C 2~6 In some embodiments, R is alkenyl. x is C substituted with one or more halo 2~6 In some embodiments, R is alkenyl. x C optionally substituted with one or more halo 1~6 In some embodiments, R x is the unsubstituted C 1~6 In some embodiments, R x is C substituted with one or more halo 1~6 It is alkyl.
[0164] In some embodiments, provided herein are compounds of Formula (A) or (A'), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein Z is -C(O)R x and R x is C 1~6 optionally substituted with one or more substituents selected from alkyl and halo, or C2~6 alkenyl, and R x C optionally substituted with one or more halo 1~6 In some embodiments, R x is C 1~6 C optionally substituted with one or more substituents selected from alkyl and halo 2~6 In some embodiments, R is alkenyl. x is the unsubstituted C 2~6 In some embodiments, R x is one or more C 1~6 Alkyl-substituted C 2~6 In some embodiments, R is alkenyl. x is C substituted with one or more halo 2~6 In some embodiments, R is alkenyl. x C optionally substituted with one or more halo 1~6 In some embodiments, R x is the unsubstituted C 1~6 In some embodiments, R x is C substituted with one or more halo 1~6 It is alkyl.
[0165] In some embodiments, provided herein are compounds of Formula (A) or (A'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt thereof, wherein X 1 is N or CR s and R s is H, -CN and one or more R t1 C may be optionally substituted 1~15 alkyl, and R t1 is -OH at each occurrence, and X 2 and X 3 are CH and X 4 is N or CH, and B is one or more R t phenyl optionally substituted with R tindependently at each occurrence, C optionally substituted with one or more halo 1~6 Alkoxy, and S(R y )5, and each R y is halo, L is methylene, and Z is -C(O)R x and R x is C 2~6 alkenyl, or R x is halo-substituted C 1~6 It is alkyl.
[0166] In some embodiments, X 1 is N and X 2 and X 3 and X 4 are each CH. In an embodiment, X 1 is CR s and X 2 , X 3 and X 4 are each CH. In some embodiments, X 1 is CR s and R s is H and X 2 and X 3 are CH and X 4 is N. In some embodiments, X 1 is CR s and R s is one R t1 is methyl substituted with R t1 is —OH. In some embodiments, X 1 is CR s and R s is two R t1 is ethyl substituted with R t1 In some embodiments, B is -OH at each occurrence. t is phenyl substituted with R t is S(R y )5, and each R y In some embodiments, B is fluoro. t is phenyl substituted with R tIn some embodiments, Z is -C(O)R x and R x In some embodiments, Z is -C(O)R x and R x is ethyl substituted with chloro.
[0167] In some embodiments, provided herein are compounds of Formula (B) or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is N. In some embodiments, X 1 is C-CR s In some embodiments, X 1 is C-CR s and C-CR s and R s are independently H, halo, and C 1~15 Alkyl, C 6~20 Aryl, 5-15 membered heteroaryl, C 3~20 Cycloalkyl, 3- to 15-membered heterocyclyl, -OH, -CN, C 1~15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , or -NR d R e In another embodiment, R s is H. In other embodiments, each R s is halo. In other embodiments, R s is C 1~15 In other embodiments, R s is C 6~20 In other embodiments, R s is a 5- to 15-membered heteroaryl. s is C 3~20 In another embodiment, Rs is 3-15 membered heterocyclyl. s is —OH. In other embodiments, R s is -CN. In other embodiments, R s is C 1~15 In another embodiment, R s is -NR d COR e In another embodiment, R s -CONR d R e In another embodiment, R s is -SO2R d In another embodiment, R s is -SO2NR d R e In another embodiment, R s is -NR d SO2R e In another embodiment, R s is -NR d R e is.
[0168] In some embodiments, provided herein are compounds of Formula (B), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is C-CR s and R s is C 1~15 Alkyl or C 1~15 is alkoxy, and R s C 1~15 Alkyl and C 1~15 Each alkoxy is independently one or more R t1 and R t1 is independently, at each occurrence, halo, oxo, -OH, -CN or -NR d R e In some embodiments, R s is one or more R t1 C replaced with 1~15 alkyl, and R t1is halo. In some embodiments, R s is one or more R t1 C replaced with 1~15 alkyl, and R t1 is oxo. In some embodiments, R s is one or more R t1 C replaced with 1~15 alkyl, and R t1 is —OH. In some embodiments, R s is one or more R t1 C replaced with 1~15 alkyl, and R t1 In some embodiments, R s is one or more R t1 C replaced with 1~15 alkyl, and R t1 is -NR d R e In some embodiments, R s is one or more R t1 C replaced with 1~15 is alkoxy, and R t1 is halo. In some embodiments, R s is one or more R t1 C replaced with 1~15 is alkoxy, and R t1 is oxo. In some embodiments, R s is one or more R t1 C replaced with 1~15 is alkoxy, and R t1 is —OH. In some embodiments, R s is one or more R t1 C replaced with 1~15 is alkoxy, and R t1 In some embodiments, R s is one or more R t1 C replaced with 1~15 is alkoxy, and R t1 is -NR d R e is.
[0169] In some embodiments, provided herein are compounds of Formula (B), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is C-CR s and R s is C 6~20 Aryl, 5-15 membered heteroaryl, C 3~20 cycloalkyl, or 3- to 15-membered heterocyclyl, and R s C 6~20 Aryl, 5-15 membered heteroaryl, C 3~20 Each cycloalkyl or 3- to 15-membered heterocyclyl independently has one or more R t2 and R t2 independently, at each occurrence, is halo, oxo, -OH, -CN, or -NR d R e In some embodiments, R s is one or more R t2 C replaced with 6~20 aryl, and R t2 is halo. In some embodiments, R s is one or more R t2 C replaced with 6~20 aryl, and R t2 is halo. In some embodiments, R s is one or more R t2 C replaced with 6~20 aryl, and R t2 is —OH. In some embodiments, R s is one or more R t2 C replaced with 6~20 aryl, and R t2 In some embodiments, R s is one or more R t2 C replaced with 6~20 aryl, and R t2 is -NR d R e In some embodiments, R s is one or more R t2and R is a 5- to 15-membered heteroaryl substituted with t2 is halo. In some embodiments, R s is one or more R t2 and R is a 5- to 15-membered heteroaryl substituted with t2 is oxo. In some embodiments, R s is a 5- to 15-membered heteroaryl, and R t2 is —OH. In some embodiments, R s is one or more R t2 and R is a 5- to 15-membered heteroaryl substituted with t2 In some embodiments, R s is one or more R t2 and R is a 5- to 15-membered heteroaryl substituted with t2 Ha-NR d R e In some embodiments, R s is one or more R t2 C replaced with 3~20 is cycloalkyl, and R t2 is halo. In some embodiments, R s is one or more R t2 C replaced with 3~20 is cycloalkyl, and R t2 is oxo. In some embodiments, R s is one or more R t2 C replaced with 3~20 is cycloalkyl, and R t2 is —OH. In some embodiments, R s is one or more R t2 C replaced with 3~20 is cycloalkyl, and R t2 In some embodiments, R s is one or more R t2 C replaced with 3~20 is cycloalkyl, and R t2 is -NR d R e In some embodiments, R s is one or more Rt2 3- to 15-membered heterocyclyl substituted with R t2 is halo. In some embodiments, R s is one or more R t2 3- to 15-membered heterocyclyl substituted with R t2 is oxo. In some embodiments, R s is one or more R t2 3- to 15-membered heterocyclyl substituted with R t2 is —OH. In some embodiments, R s is one or more R t2 3- to 15-membered heterocyclyl substituted with R t2 In some embodiments, R s is one or more R t2 3- to 15-membered heterocyclyl substituted with R t2 is -NR d R e is.
[0170] In some embodiments, provided herein are compounds of Formula (B), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is C-CR s and each R s are independently t2 is further substituted by R t2 Ha-NR d R e and R d and R e are each independently H or C 1~6 alkyl, and R d or R e C 1~6 The alkyl may be optionally substituted with one or more halo, oxo, -OH, or -CN. In some embodiments, R d is H. In some embodiments, R d is C 1~6 In some embodiments, R e is H. In some embodiments, R eis C 1~6 R is alkyl. d C 1~6 In some embodiments, R is alkyl. d C 1~6 The alkyl may be optionally substituted with one or more halo, oxo, -OH, or -CN. In some embodiments, R d C 1~6 The alkyl is substituted with one or more halo. In some embodiments, R d C 1~6 The alkyl is substituted with one or more oxo. In some embodiments, R d C 1~6 The alkyl is substituted with one or more -OH. In some embodiments, R d C 1~6 The alkyl is substituted with one or more -CN. e C 1~6 In some embodiments, R is alkyl. e C 1~6 The alkyl may be optionally substituted with one or more halo, oxo, -OH, or -CN. In some embodiments, R e C 1~6 The alkyl is substituted with one or more halo. In some embodiments, R e C 1~6 The alkyl is substituted with one or more oxo. In some embodiments, R e C 1~6 The alkyl is substituted with one or more -OH. In some embodiments, R e C 1~6 The alkyl is substituted with one or more -CN groups.
[0171] In some embodiments, provided herein are compounds of Formula (B) or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein B is phenyl or 5-6 membered heteroaryl. In some embodiments, B is phenyl. In some embodiments, B is 5-6 membered heteroaryl. In some embodiments, the phenyl or 5-6 membered heteroaryl of B each independently is selected from one or more R t and R t independently at each occurrence, halo, C 1~15 Alkyl, or C 1~6 is alkoxy, and R t C 1~15 Alkyl or C 1~6 The alkoxy may be optionally substituted with one or more halo. In some embodiments, B is selected from the group consisting of one or more R t is phenyl substituted with R t independently at each occurrence, halo, C 1~15 Alkyl, or C 1~6 is alkoxy, and R t C 1~15 Alkyl or C 1~6 The alkoxy may be optionally substituted with one or more halo. In some embodiments, B is selected from the group consisting of one or more R t is phenyl substituted with R t In some embodiments, B is selected from the group consisting of one or more R t is phenyl substituted with R t is C 1~15 In some embodiments, B is one or more R t is phenyl substituted with R t is C 1~6 In some embodiments, B is one or more R t is phenyl substituted with R t is S(R y )5, and each R y In some embodiments, B is selected from the group consisting of one or more R tand R is a 5- to 6-membered heteroaryl substituted with t independently at each occurrence, halo, C 1~15 Alkyl, or C 1~6 is alkoxy, and R t C 1~15 Alkyl or C 1~6 The alkoxy may be optionally substituted with one or more halo. In some embodiments, B is selected from the group consisting of one or more R t and R is a 5- to 6-membered heteroaryl substituted with t In some embodiments, B is selected from the group consisting of one or more R t and R is a 5- to 6-membered heteroaryl substituted with t is C 1~15 In some embodiments, B is one or more R t and R is a 5- to 6-membered heteroaryl substituted with t is C 1~6 B is phenyl or one or more R t and R is a 5- to 6-membered heteroaryl substituted with t C 1~15 Alkyl or C 1~6 In some embodiments, R is alkoxy. t C 1~15 Alkyl or C 1~6 The alkoxy may be optionally substituted with one or more halo. In some embodiments, R t C 1~15 The alkyl is substituted with one or more fluoro. In some embodiments, R t C 1~15 In some embodiments, B is substituted with one or more R t and R is a 5- to 6-membered heteroaryl substituted with t is S(R y )5, and each R y is a halo.
[0172] In some embodiments, provided herein are compounds of Formula (B) or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein B is phenyl. In some embodiments, B is a 5-6 membered heteroaryl. In other embodiments, B is unsubstituted phenyl. In other embodiments, B is substituted phenyl. In other embodiments, B is selected from the group consisting of one or more R t In another embodiment, R t is C 1~6 In another embodiment, R t is C substituted with one or more halo 1~6 In another embodiment, R t is a C substituted with one or more fluoro groups 1~6 In another embodiment, B is The file is TIFF2024541508000026.tif17170.
[0173] In some embodiments, provided herein are compounds of Formula (B) or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein n and m are each independently 1 or 2. In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, m is 1. In some embodiments, m is 2. In some embodiments, n is 1 and m is 1. In some embodiments, n is 1 and m is 2. In some embodiments, n is 2 and m is 1. In some embodiments, n is 2 and m is 2.
[0174] In some embodiments, provided herein are compounds of Formula (B) or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is N or C-CR s In some embodiments, X 1 is N. In some embodiments, X 1 is C-CR s is.
[0175] In some embodiments, provided herein are compounds of Formula (B) or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is CR s and X 2 is CH and X 3 is CH and X 4 is N and R s is the unsubstituted C 1~15 In another embodiment, X is alkyl. 1 is CR s and X 2 is CH and X 3 is CH and X 4 is N and R s is one or more R t1 C replaced with 1~15 In another embodiment, X is alkyl. 1 is CR s and X 2 is CH and X 3 is CH and X 4 is N and R s is one or more R t1 C replaced with 1~15 alkyl, and R t1 is —OH. In another embodiment, X 1 is CR s and X 2 is CH and X 3 is CH and X 4 is N and R s teeth The file is TIFF2024541508000027.tif12170.
[0176] In some embodiments, in conjunction with the above or below embodiments, provided herein are compounds of Formula (B) or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is CR s and X 2 is CH and X 3 is CH and X 4is N and R s teeth The file is TIFF2024541508000028.tif11170.
[0177] In some embodiments, provided herein are compounds of Formula (B), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein Z is —C(O)R x and R x is C 1~6 optionally substituted with one or more substituents selected from alkyl and halo, or C 2~6 alkenyl, and R x C optionally substituted with one or more halo 1~6 In some embodiments, R x is C 1~6 C optionally substituted with one or more substituents selected from alkyl and halo 2~6 In some embodiments, R is alkenyl. x is the unsubstituted C 2~6 In some embodiments, R x is one or more C 1~6 Alkyl-substituted C 2~6 In some embodiments, R is alkenyl. x is C substituted with one or more halo 2~6 In some embodiments, R is alkenyl. x C optionally substituted with one or more halo 1~6 In some embodiments, R x is the unsubstituted C 1~6 In some embodiments, R x is C substituted with one or more halo 1~6 It is alkyl.
[0178] In some embodiments, the compound of formula (IA) or (IB) below: TIFF2024541508000029.tif78170, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein: X 1 is N or CR s and R s H, -CN, halo, C 1~15 Alkyl, C 6~20 Aryl, 5-15 membered heteroaryl, C 3~20 Cycloalkyl, 3- to 15-membered heterocyclyl, -OH, C 1~15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , and -NR d R e Selected from R d and R e are each independently H or C 1~6 alkyl, and R d or R e C 1~6 The alkyl may be optionally substituted with one or more halo, oxo, —OH, or —CN; R s C 1~15 Alkyl and C 1~15 Each alkoxy is independently one or more R t1 and R t1 independently, at each occurrence, represent halo, oxo, -OH, -CN, and -NR d R e Selected from R d and R e are each independently H or C 1~6 alkyl, and R d or R e C 1~6 The alkyl may be optionally substituted with one or more halo, oxo, —OH, or —CN; R s C 6~20Aryl, 5-15 membered heteroaryl, C 3~20 Cycloalkyl and 3- to 15-membered heterocyclyl each independently represent one or more R t2 and R t2 independently, at each occurrence, represent halo, -OH, -CN, and C 1~6 alkyl, X 2 , X 3 , and X 4 are each independently N or CH, provided that X 1 , X 2 , X 3 , and X 4 and exactly one of the is N, B is phenyl or 5- to 6-membered heteroaryl, and each phenyl or 5- to 6-membered heteroaryl of B is independently one or more R t and R t At each occurrence, halo, C 1~15 Alkyl, C 1~6 Alkoxy, and S(R y )5 independently selected from y is the halo and R t C 1~15 Alkyl or C 1~6 The alkoxy may be optionally substituted with one or more halo; R a , R b , and R c are each independently H, halo, or C 1~5 is alkyl, L is one or more C 1~6 methylene optionally substituted with alkyl; n and m are each independently 1 or 2.
[0179] In some embodiments, provided herein are compounds of formula (IA) or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is N. In some embodiments, X 1 is C-CR sIn some embodiments, X 1 is C-CR s and R s are independently H, halo, and C 1~15 Alkyl, C 6~20 Aryl, 5-15 membered heteroaryl, C 3~20 Cycloalkyl, 3- to 15-membered heterocyclyl, -OH, -CN, C 1~15 Alkoxy, or -NR d R e In another embodiment, R s is H. In other embodiments, each R s is halo. In other embodiments, R s is C 1~15 In other embodiments, R s is C 6~20 In other embodiments, R s is a 5- to 15-membered heteroaryl. s is C 3~20 In another embodiment, R s is 3-15 membered heterocyclyl. s is —OH. In other embodiments, R s is -CN. In other embodiments, R s is C 1~15 In another embodiment, R s is -NR d R e is.
[0180] In some embodiments, provided herein are compounds of formula (IA), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is C-CR s and R s is C 1~15 Alkyl or C 1~15 is alkoxy, and R s C 1~15 Alkyl and C 1~15 Each alkoxy is independently one or more R t1and R t1 is independently, at each occurrence, halo, oxo, -OH, -CN or -NR d R e In some embodiments, R s is one or more R t1 C replaced with 1~15 alkyl, and R t1 is halo. In some embodiments, R s is one or more R t1 C replaced with 1~15 alkyl, and R t1 is oxo. In some embodiments, R s is one or more R t1 C replaced with 1~15 alkyl, and R t1 is —OH. In some embodiments, R s is one or more R t1 C replaced with 1~15 alkyl, and R t1 In some embodiments, R s is one or more R t1 C replaced with 1~15 alkyl, and R t1 is -NR d R e In some embodiments, R s is one or more R t1 C replaced with 1~15 is alkoxy, and R t1 is halo. In some embodiments, R s is one or more R t1 C replaced with 1~15 is alkoxy, and R t1 is oxo. In some embodiments, R s is one or more R t1 C replaced with 1~15 is alkoxy, and R t1 is —OH. In some embodiments, R s is one or more R t1 C replaced with 1~15 is alkoxy, and Rt1 In some embodiments, R s is one or more R t1 C replaced with 1~15 is alkoxy, and R t1 is -NR d R e is.
[0181] In some embodiments, provided herein are compounds of formula (IA), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is C-CR s and R s is C 6~20 Aryl, 5-15 membered heteroaryl, C 3~20 cycloalkyl, or 3- to 15-membered heterocyclyl, and R s C 6~20 Aryl, 5-15 membered heteroaryl, C 3~20 Each cycloalkyl or 3- to 15-membered heterocyclyl independently has one or more R t2 and R t2 independently, at each occurrence, is halo, oxo, -OH, -CN, or -NR d R e In some embodiments, R s is one or more R t2 C replaced with 6~20 aryl, and R t2 is halo. In some embodiments, R s is one or more R t2 C replaced with 6~20 aryl, and R t2 is halo. In some embodiments, R s is one or more R t2 C replaced with 6~20 aryl, and R t2 is —OH. In some embodiments, R s is one or more R t2 C replaced with 6~20 aryl, and R t2 In some embodiments, Rs is one or more R t2 C replaced with 6~20 aryl, and R t2 is -NR d R e In some embodiments, R s is one or more R t2 and R is a 5- to 15-membered heteroaryl substituted with t2 is halo. In some embodiments, R s is one or more R t2 and R is a 5- to 15-membered heteroaryl substituted with t2 is oxo. In some embodiments, R s is a 5- to 15-membered heteroaryl, and R t2 is —OH. In some embodiments, R s is one or more R t2 and R is a 5- to 15-membered heteroaryl substituted with t2 In some embodiments, R s is one or more R t2 and R is a 5- to 15-membered heteroaryl substituted with t2 Ha-NR d R e In some embodiments, R s is one or more R t2 C replaced with 3~20 is cycloalkyl, and R t2 is halo. In some embodiments, R s is one or more R t2 C replaced with 3~20 is cycloalkyl, and R t2 is oxo. In some embodiments, R s is one or more R t2 C replaced with 3~20 is cycloalkyl, and R t2 is —OH. In some embodiments, R s is one or more R t2 C replaced with 3~20 is cycloalkyl, and R t2In some embodiments, R s is one or more R t2 C replaced with 3~20 is cycloalkyl, and R t2 is -NR d R e In some embodiments, R s is one or more R t2 3- to 15-membered heterocyclyl substituted with R t2 is halo. In some embodiments, R s is one or more R t2 3- to 15-membered heterocyclyl substituted with R t2 is oxo. In some embodiments, R s is one or more R t2 3- to 15-membered heterocyclyl substituted with R t2 is —OH. In some embodiments, R s is one or more R t2 3- to 15-membered heterocyclyl substituted with R t2 In some embodiments, R s is one or more R t2 3- to 15-membered heterocyclyl substituted with R t2 is -NR d R e is.
[0182] In some embodiments, provided herein are compounds of formula (IA), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is C-CR s and each R s are independently t1 is further substituted by R t1 Ha-NR d R e and R d and R e are each independently H or C 1~6 alkyl, and R d or R e C 1~6The alkyl may be optionally substituted with one or more halo, oxo, -OH, or -CN. In some embodiments, R d is H. In some embodiments, R d is C 1~6 In some embodiments, R e is H. In some embodiments, R e is C 1~6 R is alkyl. d C 1~6 In some embodiments, R is alkyl. d C 1~6 The alkyl may be optionally substituted with one or more halo, oxo, -OH, or -CN. In some embodiments, R d C 1~6 The alkyl is substituted with one or more halo. In some embodiments, R d C 1~6 The alkyl is substituted with one or more oxo. In some embodiments, R d C 1~6 The alkyl is substituted with one or more -OH. In some embodiments, R d C 1~6 The alkyl is substituted with one or more -CN. e C 1~6 In some embodiments, R is alkyl. e C 1~6 The alkyl may be optionally substituted with one or more halo, oxo, -OH, or -CN. In some embodiments, R e C 1~6 The alkyl is substituted with one or more halo. In some embodiments, R e C 1~6 The alkyl is substituted with one or more oxo. In some embodiments, R e C 1~6 The alkyl is substituted with one or more -OH. In some embodiments, R e C 1~6 The alkyl is substituted with one or more -CN groups.
[0183] In some embodiments, provided herein are compounds of Formula (IA) or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein B is phenyl or 5-6 membered heteroaryl. In some embodiments, B is phenyl. In some embodiments, B is 5-6 membered heteroaryl. In some embodiments, the phenyl or 5-6 membered heteroaryl of B each independently is selected from one or more R t and R t independently at each occurrence, halo, C 1~15 Alkyl, or C 1~6 is alkoxy, and R t C 1~15 Alkyl or C 1~6 The alkoxy may be optionally substituted with one or more halo. In some embodiments, B is selected from the group consisting of one or more R t is phenyl substituted with R t independently at each occurrence, halo, C 1~15 Alkyl, or C 1~6 is alkoxy, and R t C 1~15 Alkyl or C 1~6 The alkoxy may be optionally substituted with one or more halo. In some embodiments, B is selected from the group consisting of one or more R t is phenyl substituted with R t In some embodiments, B is selected from the group consisting of one or more R t is phenyl substituted with R t is C 1~15 In some embodiments, B is one or more R t is phenyl substituted with R t is C 1~6 In some embodiments, B is one or more R t is phenyl substituted with R t is S(R y )5, and each R y In some embodiments, B is selected from the group consisting of one or more Rt and R is a 5- to 6-membered heteroaryl substituted with t independently at each occurrence, halo, C 1~15 Alkyl, or C 1~6 is alkoxy, and R t C 1~15 Alkyl or C 1~6 The alkoxy may be optionally substituted with one or more halo. In some embodiments, B is selected from the group consisting of one or more R t and R is a 5- to 6-membered heteroaryl substituted with t In some embodiments, B is selected from the group consisting of one or more R t and R is a 5- to 6-membered heteroaryl substituted with t is C 1~15 In some embodiments, B is one or more R t and R is a 5- to 6-membered heteroaryl substituted with t is C 1~6 B is phenyl or one or more R t and R is a 5- to 6-membered heteroaryl substituted with t C 1~15 Alkyl or C 1~6 In some embodiments, R is alkoxy. t C 1~15 Alkyl or C 1~6 The alkoxy may be optionally substituted with one or more halo. In some embodiments, R t C 1~15 The alkyl is substituted with one or more fluoro. In some embodiments, R t C 1~15 In some embodiments, B is substituted with one or more R t and R is a 5- to 6-membered heteroaryl substituted with t is S(R y )5, and each R y is a halo.
[0184] In some embodiments, provided herein are compounds of Formula (IA) or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein B is phenyl. In some embodiments, B is 5-6 membered heteroaryl. In other embodiments, B is unsubstituted phenyl. In other embodiments, B is substituted phenyl. In other embodiments, B is substituted with one or more R t In another embodiment, R t is C 1~6 In another embodiment, R t is C substituted with one or more halo 1~6 In another embodiment, R t is a C substituted with one or more fluoro groups 1~6 In another embodiment, B is The file is TIFF2024541508000030.tif17170.
[0185] In some embodiments, provided herein are compounds of formula (IA), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein R a , R b , and R c are each independently H, halo, or C 1~5 In some embodiments, R a is H. In some embodiments, R a is halo. In some embodiments, R a is C 1~5 In some embodiments, R b is H. In some embodiments, R b is halo. In some embodiments, R b is C 1~5 In some embodiments, R c is H. In some embodiments, R c is halo. In some embodiments, R c is C 1~5In some embodiments, provided herein are compounds of formula (IA) or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein R a , R b , and R c is H.
[0186] In some embodiments, provided herein are compounds of formula (IA) or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is N or C-CR s In some embodiments, X 1 is N. In some embodiments, X 1 is C-CR s is.
[0187] In some embodiments, provided herein are compounds of formula (IA) or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is CR s and X 2 is CH and X 3 is CH and X 4 is N and R s is the unsubstituted C 1~15 In another embodiment, X is alkyl. 1 is CR s and X 2 is CH and X 3 is CH and X 4 is N and R s is one or more R t1 C replaced with 1~15 In another embodiment, X is alkyl. 1 is CR s and X 2 is CH and X 3 is CH and X 4 is N and R s is one or more R t1 C replaced with 1~15 alkyl, and R t1 is —OH. In another embodiment, X 1is CR s and X 2 is CH and X 3 is CH and X 4 is N and R s teeth The file is TIFF2024541508000031.tif12170.
[0188] In some embodiments, provided herein are compounds of formula (IA), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein L is one or more C 1~6 In some embodiments, L is methylene, optionally substituted with alkyl. In some embodiments, L is unsubstituted methylene. In some embodiments, L is one or more C 1~6 It is methylene substituted with alkyl.
[0189] In some embodiments, provided herein are compounds of Formula (B) or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is N. In some embodiments, X 1 is C-CR s In some embodiments, X 1 is C-CR s and C-CR s and R s are independently H, halo, and C 1~15 Alkyl, C 6~20 Aryl, 5-15 membered heteroaryl, C 3~20 Cycloalkyl, 3- to 15-membered heterocyclyl, -OH, -CN, C 1~15 Alkoxy, or -NR d R e In another embodiment, R s is H. In other embodiments, each R s is halo. In other embodiments, R s is C 1~15 In other embodiments, R s is C 6~20 In other embodiments, R sis a 5- to 15-membered heteroaryl. s is C 3~20 In another embodiment, R s is 3-15 membered heterocyclyl. s is —OH. In other embodiments, R s is -CN. In other embodiments, R s is C 1~15 In another embodiment, R s is -NR d R e is.
[0190] In some embodiments, provided herein are compounds of formula (IB), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is C-CR s and R s is C 1~15 Alkyl or C 1~15 is alkoxy, and R s C 1~15 Alkyl and C 1~15 Each alkoxy is independently one or more R t1 and R t1 is independently, at each occurrence, halo, oxo, -OH, -CN or -NR d R e In some embodiments, R s is one or more R t1 C replaced with 1~15 alkyl, and R t1 is halo. In some embodiments, R s is one or more R t1 C replaced with 1~15 alkyl, and R t1 is oxo. In some embodiments, R s is one or more R t1 C replaced with 1~15 alkyl, and R t1 is —OH. In some embodiments, R sis one or more R t1 C replaced with 1~15 alkyl, and R t1 In some embodiments, R s is one or more R t1 C replaced with 1~15 alkyl, and R t1 is -NR d R e In some embodiments, R s is one or more R t1 C replaced with 1~15 is alkoxy, and R t1 is halo. In some embodiments, R s is one or more R t1 C replaced with 1~15 is alkoxy, and R t1 is oxo. In some embodiments, R s is one or more R t1 C replaced with 1~15 is alkoxy, and R t1 is —OH. In some embodiments, R s is one or more R t1 C replaced with 1~15 is alkoxy, and R t1 In some embodiments, R s is one or more R t1 C replaced with 1~15 is alkoxy, and R t1 is -NR d R e is.
[0191] In some embodiments, provided herein are compounds of formula (IB), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is C-CR s and R s is C 6~20 Aryl, 5-15 membered heteroaryl, C 3~20 cycloalkyl, or 3- to 15-membered heterocyclyl, and R s C 6~20Aryl, 5-15 membered heteroaryl, C 3~20 Each cycloalkyl or 3- to 15-membered heterocyclyl independently has one or more R t2 and R t2 independently, at each occurrence, is halo, oxo, -OH, -CN, or -NR d R e In some embodiments, R s is one or more R t2 C replaced with 6~20 aryl, and R t2 is halo. In some embodiments, R s is one or more R t2 C replaced with 6~20 aryl, and R t2 is halo. In some embodiments, R s is one or more R t2 C replaced with 6~20 aryl, and R t2 is —OH. In some embodiments, R s is one or more R t2 C replaced with 6~20 aryl, and R t2 In some embodiments, R s is one or more R t2 C replaced with 6~20 aryl, and R t2 is -NR d R e In some embodiments, R s is one or more R t2 and R is a 5- to 15-membered heteroaryl substituted with t2 is halo. In some embodiments, R s is one or more R t2 and R is a 5- to 15-membered heteroaryl substituted with t2 is oxo. In some embodiments, R s is a 5- to 15-membered heteroaryl, and R t2 is —OH. In some embodiments, R s is one or more Rt2 and R is a 5- to 15-membered heteroaryl substituted with t2 In some embodiments, R s is one or more R t2 and R is a 5- to 15-membered heteroaryl substituted with t2 Ha-NR d R e In some embodiments, R s is one or more R t2 C replaced with 3~20 is cycloalkyl, and R t2 is halo. In some embodiments, R s is one or more R t2 C replaced with 3~20 is cycloalkyl, and R t2 is oxo. In some embodiments, R s is one or more R t2 C replaced with 3~20 is cycloalkyl, and R t2 is —OH. In some embodiments, R s is one or more R t2 C replaced with 3~20 is cycloalkyl, and R t2 In some embodiments, R s is one or more R t2 C replaced with 3~20 is cycloalkyl, and R t2 is -NR d R e In some embodiments, R s is one or more R t2 3- to 15-membered heterocyclyl substituted with R t2 is halo. In some embodiments, R s is one or more R t2 3- to 15-membered heterocyclyl substituted with R t2 is oxo. In some embodiments, R s is one or more R t2 3- to 15-membered heterocyclyl substituted with R t2is —OH. In some embodiments, R s is one or more R t2 3- to 15-membered heterocyclyl substituted with R t2 In some embodiments, R s is one or more R t2 3- to 15-membered heterocyclyl substituted with R t2 is -NR d R e is.
[0192] In some embodiments, provided herein are compounds of formula (IB), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is C-CR s and each R s are independently t1 is further substituted by R t1 Ha-NR d R e and R d and R e are each independently H or C 1~6 alkyl, and R d or R e C 1~6 The alkyl may be optionally substituted with one or more halo, oxo, -OH, or -CN. In some embodiments, R d is H. In some embodiments, R d is C 1~6 In some embodiments, R e is H. In some embodiments, R e is C 1~6 R is alkyl. d C 1~6 In some embodiments, R is alkyl. d C 1~6 The alkyl may be optionally substituted with one or more halo, oxo, -OH, or -CN. In some embodiments, R d C 1~6 The alkyl is substituted with one or more halo. In some embodiments, Rd C 1~6 The alkyl is substituted with one or more oxo. In some embodiments, R d C 1~6 The alkyl is substituted with one or more -OH. In some embodiments, R d C 1~6 The alkyl is substituted with one or more -CN. e C 1~6 In some embodiments, R is alkyl. e C 1~6 The alkyl may be optionally substituted with one or more halo, oxo, -OH, or -CN. In some embodiments, R e C 1~6 The alkyl is substituted with one or more halo. In some embodiments, R e C 1~6 The alkyl is substituted with one or more oxo. In some embodiments, R e C 1~6 The alkyl is substituted with one or more -OH. In some embodiments, R e C 1~6 The alkyl is substituted with one or more -CN groups.
[0193] In some embodiments, provided herein are compounds of Formula (IB) or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein B is phenyl or 5-6 membered heteroaryl. In some embodiments, B is phenyl. In some embodiments, B is 5-6 membered heteroaryl. In some embodiments, the phenyl or 5-6 membered heteroaryl of B each independently is selected from one or more R t and R t independently at each occurrence, halo, C 1~15 Alkyl, or C 1~6 is alkoxy, and R t C 1~15 Alkyl or C 1~6The alkoxy may be optionally substituted with one or more halo. In some embodiments, B is selected from the group consisting of one or more R t is phenyl substituted with R t independently at each occurrence, halo, C 1~15 Alkyl, or C 1~6 is alkoxy, and R t C 1~15 Alkyl or C 1~6 The alkoxy may be optionally substituted with one or more halo. In some embodiments, B is selected from the group consisting of one or more R t is phenyl substituted with R t In some embodiments, B is selected from the group consisting of one or more R t is phenyl substituted with R t is C 1~15 In some embodiments, B is one or more R t is phenyl substituted with R t is C 1~6 In some embodiments, B is one or more R t is phenyl substituted with R t is S(R y )5, and each R y In some embodiments, B is selected from the group consisting of one or more R t and R is a 5- to 6-membered heteroaryl substituted with t independently at each occurrence, halo, C 1~15 Alkyl, or C 1~6 is alkoxy, and R t C 1~15 Alkyl or C 1~6 The alkoxy may be optionally substituted with one or more halo. In some embodiments, B is selected from the group consisting of one or more R t and R is a 5- to 6-membered heteroaryl substituted with t In some embodiments, B is selected from the group consisting of one or more R t and R is a 5- to 6-membered heteroaryl substituted with t is C 1~15 In some embodiments, B is one or more Rt and R is a 5- to 6-membered heteroaryl substituted with t is C 1~6 B is phenyl or one or more R t and R is a 5- to 6-membered heteroaryl substituted with t C 1~15 Alkyl or C 1~6 In some embodiments, R is alkoxy. t C 1~15 Alkyl or C 1~6 The alkoxy may be optionally substituted with one or more halo. In some embodiments, R t C 1~15 The alkyl is substituted with one or more fluoro. In some embodiments, R t C 1~15 In some embodiments, B is substituted with one or more R t and R is a 5- to 6-membered heteroaryl substituted with t is S(R y )5, and each R y is a halo.
[0194] In some embodiments, provided herein are compounds of Formula (IB) or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein B is phenyl. In some embodiments, B is a 5-6 membered heteroaryl. In other embodiments, B is unsubstituted phenyl. In other embodiments, B is substituted phenyl. In other embodiments, B is selected from the group consisting of one or more R t In another embodiment, R t is C 1~6 In another embodiment, R t is C substituted with one or more halo 1~6 In another embodiment, R t is a C substituted with one or more fluoro groups 1~6 In another embodiment, B is The file is TIFF2024541508000032.tif17170.
[0195] In some embodiments, provided herein are compounds of formula (IB), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein R a , R b , and R c are each independently H, halo, or C 1~5 In some embodiments, R a is H. In some embodiments, R a is halo. In some embodiments, R a is C 1~5 In some embodiments, R b is H. In some embodiments, R b is halo. In some embodiments, R b is C 1~5 In some embodiments, R c is H. In some embodiments, R c is halo. In some embodiments, R c is C 1~5 In some embodiments, provided herein are compounds of formula (IA) or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein R a , R b , and R c is H.
[0196] In some embodiments, in conjunction with the above or below embodiments, provided herein are compounds of formula (IB), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein R b and R c are H and R, respectively. a is a halo.
[0197] In some embodiments, provided herein is a compound of Formula (IB) or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein n and m are each independently 1 or 2. In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, m is 1. In some embodiments, m is 2. In some embodiments, n is 1 and m is 1. In some embodiments, n is 1 and m is 2. In some embodiments, n is 2 and m is 1. In some embodiments, n is 2 and m is 2.
[0198] In some embodiments, provided herein are compounds of formula (IB) or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is N or C-CR s In some embodiments, X 1 is N. In some embodiments, X 1 is C-CR s is.
[0199] In some embodiments, provided herein are compounds of formula (IB) or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is CR s and X 2 is CH and X 3 is CH and X 4 is N and R s is the unsubstituted C 1~15 In another embodiment, X is alkyl. 1 is CR s and X 2 is CH and X 3 is CH and X 4 is N and R s is one or more R t1 C replaced with 1~15 In another embodiment, X is alkyl. 1 is CR s and X 2is CH and X 3 is CH and X 4 is N and R s is one or more R t1 C replaced with 1~15 alkyl, and R t1 is —OH. In another embodiment, X 1 is CR s and X 2 is CH and X 3 is CH and X 4 is N and R s teeth The file is TIFF2024541508000033.tif12170.
[0200] In some embodiments, in conjunction with the above or below embodiments, provided herein are compounds of formula (IB) or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is CR s and X 2 is CH and X 3 is CH and X 4 is N and R s teeth The file is TIFF2024541508000034.tif11170.
[0201] In some embodiments, the compound of formula (A') or (B') below: TIFF2024541508000035.tif69170, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein: X 1 is N or CR s and R s H, deuterium, -CN, halo, C 1~15 Alkyl, C 1~6 Alkynyl, C 6~20 Aryl, 5-15 membered heteroaryl, C 3~20 Cycloalkyl, 3- to 15-membered heterocyclyl, -OH, -OR f , C 1~15 Alkoxy, -NR d CORe , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , and -NR d R e is selected from R d , R e and R f each independently represents H, C 1~6 Alkyl or C 3~20 is cycloalkyl, C 1~6 Alkyl and C 3~20 each cycloalkyl independently may be optionally substituted with one or more halo, oxo, —OH, or —CN; R s C 1~15 Alkyl and C 1~15 Each alkoxy is independently one or more R t1 and R t1 independently, at each occurrence, represents halo, oxo, -OH, -CN, -NR d R e and 3- to 15-membered heterocyclyl optionally substituted with one or more —OH; R d and R e are each independently H or C 1~6 alkyl, and R d or R e C 1~6 The alkyl may be optionally substituted with one or more halo, oxo, —OH, or —CN; R s C 6~20 Aryl, 5-15 membered heteroaryl, C 3~20 Cycloalkyl and 3- to 15-membered heterocyclyl each independently represent one or more R t2 and R t2 independently, at each occurrence, represents halo, oxo, -OH, -CN, C(O)NH, -C(O)NR d R e , -NRd R e , C 1~6 Alkoxy and C 1~6 alkyl, and R t2 C 1~6 Alkyl is one or more -OH or -NR d R e optionally substituted with R d and R e are each independently H, -C(O)CH3, or -C(O)C 1~6 Alkyl, or C 1~6 is alkyl, X 2 , X 3 , and X 4 are each independently N, CH, or CD, provided that X 1 , X 2 , X 3 , and X 4 and exactly one of the is N, B is phenyl or 5- to 6-membered heteroaryl, and each phenyl or 5- to 6-membered heteroaryl of B is independently one or more R t and R t At each occurrence, halo, C 1~15 Alkyl, C 1~6 Alkoxy, and S(R y )5, and each R y is the halo and R t C 1~15 Alkyl or C 1~6 The alkoxy may be optionally substituted with one or more halo; Z is -C(O)R x and R x is C 1~6 Alkyl, Deuterium, -OH, C 1~6 C optionally substituted with one or more substituents selected from alkoxyl and halo 2~6 alkenyl, or R x C optionally substituted with one or more halo 1~6 alkyl or R x C optionally substituted with -OH 1~6alkynyl or R x is cyclobutenyl, L is one or more C 1~6 methylene optionally substituted with alkyl; n and m are each 1, or n and m are each 2.
[0202] In some embodiments, the compound of formula (IA) or (IB) below: TIFF2024541508000036.tif78170, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein: X 1 is N or CR s and R s H, deuterium, -CN, halo, C 1~15 Alkyl, C 1~6 Alkynyl, C 6~20 Aryl, 5-15 membered heteroaryl, C 3~20 Cycloalkyl, 3- to 15-membered heterocyclyl, -OH, -OR f , C 1~15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , and -NR d R e is selected from R d , R e and R f each independently represents H, C 1~6 Alkyl or C 3~20 is cycloalkyl, C 1~6 Alkyl and C 3~20 each cycloalkyl independently may be optionally substituted with one or more halo, oxo, —OH, or —CN; R s C 1~15 Alkyl and C 1~15Each alkoxy is independently one or more R t1 and R t1 independently, at each occurrence, represents halo, oxo, -OH, -CN, -NR d R e and 3- to 15-membered heterocyclyl optionally substituted with one or more —OH; R d and R e are each independently H or C 1~6 alkyl, and R d or R e C 1~6 The alkyl may be optionally substituted with one or more halo, oxo, —OH, or —CN; R s C 6~20 Aryl, 5-15 membered heteroaryl, C 3~20 Cycloalkyl and 3- to 15-membered heterocyclyl each independently represent one or more R t2 and R t2 independently, at each occurrence, represents halo, oxo, -OH, -CN, C(O)NH, -C(O)NR d R e , -NR d R e , C 1~6 Alkoxy and C 1~6 alkyl, and R t2 C 1~6 Alkyl is one or more -OH or -NR d R e optionally substituted with R d and R e are each independently H, -C(O)CH3, or -C(O)C 1~6 Alkyl, or C 1~6 is alkyl, X 2 , X 3 , and X 4 are each independently N, CH, or CD, provided that X 1 , X 2 , X 3 , and X 4 and exactly one of the is N, B is phenyl or 5- to 6-membered heteroaryl, and each phenyl or 5- to 6-membered heteroaryl of B is independently one or more R t and R t At each occurrence, halo, C 1~15 Alkyl, C 1~6 Alkoxy, and S(R y )5 independently selected from y is the halo and R t C 1~15 Alkyl or C 1~6 The alkoxy may be optionally substituted with one or more halo; R a , R b , and R c are each independently H, halo, or C 1~5 is alkyl, L is one or more C 1~6 methylene optionally substituted with alkyl; n and m are each 1, or n and m are each 2.
[0203] In some embodiments, provided herein are compounds of formula (AB), (A), (A'), (IA), (B), (B') or (IB), or any applicable subformula thereof, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein X 1 is N. In some embodiments, X 1 is CR s In some embodiments, X 1 is CR s and R s are independently H, deuterium, -CN, halo, and C 1~15 Alkyl, C 1~6 Alkynyl, C 6~20 Aryl, 5-15 membered heteroaryl, C 3~20 Cycloalkyl, 3- to 15-membered heterocyclyl, -OH, -OR f , C 1~15 Alkoxy, -NR d COR e , -CONR dR e , -SO2R d , -SO2NR d R e , -NR d SO2R e , and -NR d R e In other embodiments, each R s is H. In other embodiments, each R s is D. In other embodiments, each R s is -CN. In other embodiments, each R s is halo. In other embodiments, each R s is C 1~15 In other embodiments, each R s is C 1~6 In other embodiments, each R s is C 6~20 In other embodiments, each R s is a 5- to 15-membered heteroaryl. s is C 3~20 In other embodiments, each R s is 3- to 15-membered heterocyclyl. s is —OH. In other embodiments, each R s -OR f In other embodiments, each R s is C 1~15 In other embodiments, each R s is -NR d COR e In other embodiments, each R s -CONR d R e In other embodiments, each R s is -SO2R d In other embodiments, each R s is -SO2NR d R e In other embodiments, each R s is -NR d SO2Re In other embodiments, each R s is -NR d R e is.
[0204] In some embodiments, provided herein are compounds of formula (AB), (A), (A'), (IA), (B), (B') or (IB), or any applicable subformula thereof, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein X 1 is CR s and R s is C 1~15 Alkyl or C 1~15 is alkoxy, and R s C 1~15 Alkyl and C 1~15 Each alkoxy is independently one or more R t1 and R t1 independently at each occurrence, represents halo, oxo, -OH, -CN, -NR d R e and 3- to 15-membered heterocyclyl optionally substituted with one or more —OH; R d and R e are each independently H or C 1~6 alkyl, and R d or R e C 1~6 The alkyl may be optionally substituted with one or more halo, oxo, -OH, or -CN. In some embodiments, R s is one or more R t1 C replaced with 1~15 alkyl, and R t1 is halo. In some embodiments, R s is one or more R t1 C replaced with 1~15 alkyl, and R t1 is oxo. In some embodiments, R s is one or more R t1 C replaced with 1~15 alkyl, and R t1is —OH. In some embodiments, R s is one or more R t1 C replaced with 1~15 alkyl, and R t1 In some embodiments, R s is one or more R t1 C replaced with 1~15 alkyl, and R t1 is -NR d R e In some embodiments, R s is one or more R t1 C replaced with 1~15 alkyl, and R t1 is a 3- to 15-membered heterocyclyl optionally substituted with one or more —OH. In some embodiments, R s is one or more R t1 C replaced with 1~15 is alkoxy, and R t1 is halo. In some embodiments, R s is one or more R t1 C replaced with 1~15 is alkoxy, and R t1 is oxo. In some embodiments, R s is one or more R t1 C replaced with 1~15 is alkoxy, and R t1 is —OH. In some embodiments, R s is one or more R t1 C replaced with 1~15 is alkoxy, and R t1 In some embodiments, R s is one or more R t1 C replaced with 1~15 is alkoxy, and R t1 is -NR d R e In some embodiments, R s is one or more R t1 C replaced with 1~15 is alkoxy, and R t1is a 3- to 15-membered heterocyclyl optionally substituted with one or more -OH.
[0205] In some embodiments, provided herein are compounds of formula (AB), (A), (A'), (IA), (B), (B') or (IB), or any applicable subformula thereof, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein X 1 is CR s and R s is C 6~20 Aryl, 5-15 membered heteroaryl, C 3~20 cycloalkyl, or 3- to 15-membered heterocyclyl, and R s C 6~20 Aryl, 5-15 membered heteroaryl, C 3~20 Cycloalkyl and 3- to 15-membered heterocyclyl each independently represent one or more R t2 and R t2 represents, at each occurrence, halo, oxo, -OH, -CN, C(O)NH2, -C(O)NR d R e , -NR d R e , C 1~6 Alkoxy and C 1~6 alkyl, and R t2 C 1~6 Alkyl is one or more -OH or -NR d R e and R d and R e are each independently H, -C(O)CH3, or -C(O)C 1~6 Alkyl, or C 1~6 It is alkyl.
[0206] In some embodiments, R s is one or more R t2 C replaced with 6~20 aryl, and R t2 is halo. In some embodiments, R s is one or more R t2 C replaced with6~20 aryl, and R t2 is halo. In some embodiments, R s is one or more R t2 C replaced with 6~20 aryl, and R t2 is —OH. In some embodiments, R s is one or more R t2 C replaced with 6~20 aryl, and R t2 In some embodiments, R s is one or more R t2 C replaced with 6~20 aryl, and R t2 is C(O)NH. In some embodiments, R s is one or more R t2 C replaced with 6~20 aryl, and R t2 is -C(O)NR d R e In some embodiments, R s is one or more R t2 C replaced with 6~20 aryl, and R t2 is -NR d R e In some embodiments, R s is one or more R t2 C replaced with 6~20 aryl, and R t2 is C 1~6 In some embodiments, R s is one or more R t2 C replaced with 6~20 aryl, and R t2 is C 1=6 It is alkyl.
[0207] In some embodiments, R s is one or more R t2 and R is a 5- to 15-membered heteroaryl substituted with t2 is halo. In some embodiments, R sis one or more R t2 and R is a 5- to 15-membered heteroaryl substituted with t2 is oxo. In some embodiments, R s is one or more R t2 and R is a 5- to 15-membered heteroaryl substituted with t2 is —OH. In some embodiments, R s is one or more R t2 and R is a 5- to 15-membered heteroaryl substituted with t2 In some embodiments, R s is one or more R t2 and R is a 5- to 15-membered heteroaryl substituted with t2 is C(O)NH. In some embodiments, R s is one or more R t2 and R is a 5- to 15-membered heteroaryl substituted with t2 is -C(O)NR d R e In some embodiments, R s is one or more R t2 and R is a 5- to 15-membered heteroaryl substituted with t2 is -NR d R e In some embodiments, R s is one or more R t2 and R is a 5- to 15-membered heteroaryl substituted with t2 is C 1~6 In some embodiments, R s is one or more R t2 and R is a 5- to 15-membered heteroaryl substituted with t2 is C 1~6 It is alkyl.
[0208] In some embodiments, R s is one or more R t2 C replaced with 3~20 is cycloalkyl, and R t2 is halo. In some embodiments, R s is one or more Rt2 C replaced with 3~20 is cycloalkyl, and R t2 is oxo. In some embodiments, R s is one or more R t2 C replaced with 3~20 is cycloalkyl, and R t2 is —OH. In some embodiments, R s is one or more R t2 C replaced with 3~20 is cycloalkyl, and R t2 In some embodiments, R s is one or more R t2 C replaced with 3~20 is cycloalkyl, and R t2 is C(O)NH. In some embodiments, R s is one or more R t2 C replaced with 3~20 is cycloalkyl, and R t2 is -C(O)NR d R e In some embodiments, R s is one or more R t2 C replaced with 3~20 is cycloalkyl, and R t2 is -NR d R e In some embodiments, R s is one or more R t2 C replaced with 3~20 is cycloalkyl, and R t2 is C 1~6 In some embodiments, R s is one or more R t2 C replaced with 3~20 is cycloalkyl, and R t2 is C 1~6 It is alkyl.
[0209] In some embodiments, R s is one or more R t2 3- to 15-membered heterocyclyl substituted with R t2is halo. In some embodiments, R s is one or more R t2 3- to 15-membered heterocyclyl substituted with R t2 is oxo. In some embodiments, R s is one or more R t2 3- to 15-membered heterocyclyl substituted with R t2 is —OH. In some embodiments, R s is one or more R t2 3- to 15-membered heterocyclyl substituted with R t2 In some embodiments, R s is one or more R t2 3- to 15-membered heterocyclyl substituted with R t2 is C(O)NH. In some embodiments, R s is one or more R t2 3- to 15-membered heterocyclyl substituted with R t2 is -C(O)NR d R e In some embodiments, R s is one or more R t2 3- to 15-membered heterocyclyl substituted with R t2 is -NR d R e In some embodiments, R s is one or more R t2 3- to 15-membered heterocyclyl substituted with R t2 is C 1~6 In some embodiments, R s is one or more R t2 3- to 15-membered heterocyclyl substituted with R t2 is C 1~6 It is alkyl.
[0210] In some embodiments, provided herein are compounds of formula (AB), (A), (A'), (IA), (B), (B') or (IB), or any applicable subformula thereof, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein X 1 is CR s and each R s is R t1 and R t1 Ha-NR d R e and R d and R e are each independently H or C 1~6 alkyl, and R d or R e C 1-~6 The alkyl may be optionally substituted with one or more halo, oxo, -OH, or -CN. In some embodiments, R d is H. In some embodiments, R d is C 1~6 In some embodiments, R e is H. In some embodiments, R e is C 1~6 R is alkyl. d C 1~6 In some embodiments, R is alkyl. d C 1~6 The alkyl may be optionally substituted with one or more halo, oxo, -OH, or -CN. In some embodiments, R d C 1~6 The alkyl is substituted with one or more halo. In some embodiments, R d C 1~6 The alkyl is substituted with one or more oxo. In some embodiments, R d C 1~6 The alkyl is substituted with one or more -OH. In some embodiments, R d C 1~6 The alkyl is substituted with one or more -CN. e C 1~6In some embodiments, R is alkyl. e C 1~6 The alkyl may be optionally substituted with one or more halo, oxo, -OH, or -CN. In some embodiments, R e C 1~6 The alkyl is substituted with one or more halo. In some embodiments, R e C 1~6 The alkyl is substituted with one or more oxo. In some embodiments, R e C 1~6 The alkyl is substituted with one or more -OH. In some embodiments, R e C 1~6 The alkyl is substituted with one or more -CN groups.
[0211] In some embodiments, provided herein are compounds of Formula (AB), (A), (A'), (IA), (B), (B'), or (IB), or any applicable subformula thereof, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein B is phenyl or 5-6 membered heteroaryl. In some embodiments, B is phenyl. In some embodiments, B is 5-6 membered heteroaryl. In some embodiments, the phenyl or 5-6 membered heteroaryl of B is each independently selected from one or more R t and R t independently at each occurrence, halo, C 1~15 Alkyl, or C 1~6 is alkoxy, and R t C 1~15 Alkyl or C 1~6 The alkoxy may be optionally substituted with one or more halo. In some embodiments, B is selected from the group consisting of one or more R t is phenyl substituted with R t independently at each occurrence, halo, C 1~15 Alkyl, or C 1~6 is alkoxy, and R t C 1~15 Alkyl or C1~6 The alkoxy may be optionally substituted with one or more halo. In some embodiments, B is selected from the group consisting of one or more R t is phenyl substituted with R t In some embodiments, B is selected from the group consisting of one or more R t is phenyl substituted with R t is C 1~15 In some embodiments, B is one or more R t is phenyl substituted with R t is C 1~6 In some embodiments, B is one or more R t is phenyl substituted with R t is S(R y )5, and each R y In some embodiments, B is selected from the group consisting of one or more R t and R is a 5- to 6-membered heteroaryl substituted with t independently at each occurrence, halo, C 1~15 Alkyl, or C 1~6 is alkoxy, and R t C 1~15 Alkyl or C 1~6 The alkoxy may be optionally substituted with one or more halo. In some embodiments, B is selected from the group consisting of one or more R t and R is a 5- to 6-membered heteroaryl substituted with t In some embodiments, B is selected from the group consisting of one or more R t and R is a 5- to 6-membered heteroaryl substituted with t is C 1~15 In some embodiments, B is one or more R t and R is a 5- to 6-membered heteroaryl substituted with t is C 1~6 B is phenyl or one or more R t and R is a 5- to 6-membered heteroaryl substituted with t C 1~15 Alkyl or C 1~6In some embodiments, R is alkoxy. t C 1~15 Alkyl or C 1~6 The alkoxy may be optionally substituted with one or more halo. In some embodiments, R t C 1~15 The alkyl is substituted with one or more fluoro. In some embodiments, R t C 1~15 In some embodiments, B is substituted with one or more R t and R is a 5- to 6-membered heteroaryl substituted with t is S(R y )5, and each R y is a halo.
[0212] In some embodiments, provided herein are compounds of Formula (AB), (A), (A'), (IA), (B), (B'), or (IB), or any applicable subformula thereof, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein B is phenyl. In some embodiments, B is a 5-6 membered heteroaryl. In other embodiments, B is unsubstituted phenyl. In other embodiments, B is substituted phenyl. In other embodiments, B is a ... t In another embodiment, R t is C 1~6 In another embodiment, R t is C substituted with one or more halo 1~6 In another embodiment, R t is a C substituted with one or more fluoro groups 1~6 In another embodiment, B is The file is TIFF2024541508000037.tif17170.
[0213] In some embodiments, provided herein are compounds of formula (AB), (A), (A'), (IA), (B), (B') or (IB), or any applicable subformula thereof, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein X 1 is N or CR s In some embodiments, X 1 is N. In some embodiments, X 1 is CR s is.
[0214] In some embodiments, provided herein are compounds of formula (AB), (A), (A'), (IA), (B), (B') or (IB), or any applicable subformula thereof, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein X 1 is CR s and X 2 is CH and X 3 is CH and X 4 is N and R s is the unsubstituted C 1~15 In another embodiment, X is alkyl. 1 is CR s and X 2 is CH and X 3 is CH and X 4 is N and R s is one or more R t1 C replaced with 1~15 In another embodiment, X is alkyl. 1 is CR s and X 2 is CH and X 3 is CH and X 4 is N and R s is one or more R t1 C replaced with 1~15 alkyl, and R t1 is —OH. In another embodiment, X 1 is CR s and X 2 is CH and X 3 is CH and X4 is N and R s teeth TIFF2024541508000038.tif12170. In another embodiment, X 1 is CR s and X 2 is CH and X 3 is CH and X 4 is N and R s teeth TIFF2024541508000039.tif11170. In another embodiment, X 1 is CR s and X 2 is CH and X 3 is CH and X 4 is N and R s teeth TIFF2024541508000040.tif12170. In another embodiment, X 1 is CR s and X 2 is CH and X 3 is CH and X 4 is N and R s teeth TIFF2024541508000041.tif10170. In another embodiment, X 1 is CR s and X 2 is CH and X 3 is CH and X 4 is N and R s teeth TIFF2024541508000042.tif18170. In another embodiment, X 1 is CR s and X 2 is CH and X 3 is CH and X 4 is N and R s teeth TIFF2024541508000043.tif12170. In another embodiment, X 1 is CR s and X 2is CH and X 3 is CH and X 4 is N and R s teeth TIFF2024541508000044.tif9170. In another embodiment, X 1 is CR s and X 2 is CH and X 3 is CH and X 4 is N and R s teeth TIFF2024541508000045.tif13170. In another embodiment, X 1 is CR s and X 2 is CH and X 3 is CH and X 4 is N and R s teeth TIFF2024541508000046.tif8170. In another embodiment, X 1 is CR s and X 2 is CH and X 3 is CH and X 4 is N and R s teeth TIFF2024541508000047.tif13170. In another embodiment, X 1 is CR s and X 2 is CH and X 3 is CH and X 4 is N and R s teeth TIFF2024541508000048.tif9170. In another embodiment, X 1 is CR s and X 2 is CH and X 3 is CH and X 4 is N and R s teeth TIFF2024541508000049.tif14170. In another embodiment, X 1 is CRs and X 2 is CH and X 3 is CH and X 4 is N and R s teeth TIFF2024541508000050.tif19170. In another embodiment, X 1 is CR s and X 2 is CH and X 3 is CH and X 4 is N and R s teeth TIFF2024541508000051.tif17170. In another embodiment, X 1 is CR s and X 2 is CH and X 3 is CH and X 4 is N and R s teeth TIFF2024541508000052.tif12170. In another embodiment, X 1 is CR s and X 2 is CH and X 3 is CH and X 4 is N and R s teeth TIFF2024541508000053.tif23170. In another embodiment, X 1 is CR s and X 2 is CH and X 3 is CH and X 4 is N and R s teeth TIFF2024541508000054.tif15170. In another embodiment, X 1 is CR s and X 2 is CH and X 3 is CH and X 4 is N and R s teeth TIFF2024541508000055.tif12170. In another embodiment, X 1 is CR s and X 2 is CH and X 3 is CH and X 4 is N and R s teeth TIFF2024541508000056.tif12170. In another embodiment, X 1 is CR s and X 2 is CH and X 3 is CH and X 4 is N and R s teeth TIFF2024541508000057.tif9170. In another embodiment, X 1 is CR s and X 2 is CH and X 3 is CH and X 4 is N and R s teeth TIFF2024541508000058.tif17170. In another embodiment, X 1 is CR s and X 2 is CH and X 3 is CH and X 4 is N and R s teeth TIFF2024541508000059.tif13170. In another embodiment, X 1 is CR s and X 2 is CH and X 3 is CH and X 4 is N and R s teeth TIFF2024541508000060.tif8170. In another embodiment, X 1 is CR s and X 2 is CH and X 3 is CH and X 4 is N and Rs teeth TIFF2024541508000061.tif12170. In another embodiment, X 1 is CR s and X 2 is CH and X 3 is CH and X 4 is N and R s teeth TIFF2024541508000062.tif11170. In another embodiment, X 1 is CR s and X 2 is CH and X 3 is CH and X 4 is N and R s teeth TIFF2024541508000063.tif17170. In another embodiment, X 1 is CR s and X 2 is CH and X 3 is CH and X 4 is N and R s teeth TIFF2024541508000064.tif20170. In another embodiment, X 1 is CR s and X 2 is CH and X 3 is CH and X 4 is N and R s teeth TIFF2024541508000065.tif13170. In another embodiment, X 1 is CR s and X 2 is CH and X 3 is CH and X 4 is N and R s teeth TIFF2024541508000066.tif14170. In another embodiment, X 1 is CR s and X 2 is CH and X 3is CH and X 4 is N and R s teeth TIFF2024541508000067.tif12170. In another embodiment, X 1 is CR s and X 2 is CH and X 3 is CH and X 4 is N and R s teeth TIFF2024541508000068.tif9170. In another embodiment, X 1 is CR s and X 2 is CH and X 3 is CH and X 4 is N and R s teeth TIFF2024541508000069.tif17170. In another embodiment, X 1 is CR s and X 2 is CH and X 3 is CH and X 4 is N and R s teeth TIFF2024541508000070.tif9170. In another embodiment, X 1 is CR s and X 2 is CH and X 3 is CH and X 4 is N and R s is methyl. In another embodiment, X 1 is CR s and X 2 is CH and X 3 is CH and X 4 is N and R s teeth TIFF2024541508000071.tif13170. In another embodiment, X 1 is CR s and X 2 is CH and X 3 is CH and X4 is N and R s teeth TIFF2024541508000072.tif7170. In another embodiment, X 1 is CR s and X 2 is CH and X 3 is CH and X 4 is N and R s teeth TIFF2024541508000073.tif16170. In another embodiment, X 1 is CR s and X 2 is CH and X 3 is CH and X 4 is N and R s teeth TIFF2024541508000074.tif12170. In another embodiment, X 1 is CR s and X 2 is CH and X 3 is CH and X 4 is N and R s teeth TIFF2024541508000075.tif12170. In another embodiment, X 1 is CR s and X 2 is CH and X 3 is CH and X 4 is N and R s teeth TIFF2024541508000076.tif9170. In another embodiment, X 1 is CR s and X 2 is CH and X 3 is CH and X 4 is N and R s teeth TIFF2024541508000077.tif12170. In another embodiment, X 1 is CR s and X 2 is CH and X3 is CH and X 4 is N and R s teeth TIFF2024541508000078.tif12170. In another embodiment, X 1 is CR s and X 2 is CH and X 3 is CH and X 4 is N and R s teeth TIFF2024541508000079.tif17170. In another embodiment, X 1 is CR s and X 2 is CH and X 3 is CH and X 4 is N and R s teeth TIFF2024541508000080.tif13170. In another embodiment, X 1 is CR s and X 2 is CH and X 3 is CH and X 4 is N and R s is Cl. In another embodiment, X 1 is CR s and X 2 is CH and X 3 is CH and X 4 is N and R s teeth TIFF2024541508000081.tif13170. In another embodiment, X 1 is CR s and X 2 is CH and X 3 is CH and X 4 is N and R s teeth TIFF2024541508000082.tif9170. In another embodiment, X 1 is CR s and X 2 is CH and X 3is CH and X 4 is N and R s teeth TIFF2024541508000083.tif17170. In another embodiment, X 1 is CR s and X 2 is CH and X 3 is CH and X 4 is N and R s teeth In some embodiments, provided herein are compounds of Formula (A) or (A'), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein L is selected from the group consisting of one or more C 1~6 In some embodiments, L is methylene, optionally substituted with alkyl. In some embodiments, L is unsubstituted methylene. In some embodiments, L is one or more C 1~6 It is methylene substituted with alkyl.
[0215] In some embodiments, provided herein are compounds of Formula (AB), (A), (A'), (B) or (B'), or any applicable subformula thereof, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein Z is -C(O)R x and R x is C 1~6 Alkyl, Deuterium, -OH, C 1~6 C optionally substituted with one or more substituents selected from alkoxyl and halo 2~6 alkenyl, or R x C optionally substituted with one or more halo 1~6 alkyl or R x C optionally substituted with -OH 1~6 alkynyl, or R x is cyclobutenyl. In some embodiments, R x is C 1~6 Alkyl, Deuterium, -OH, C 1~6C optionally substituted with one or more substituents selected from alkoxyl and halo 2~6 In some embodiments, R is alkenyl. x is the unsubstituted C 2~6 In some embodiments, R x is one or more C 1~6 Alkyl-substituted C 2~6 In some embodiments, R is alkenyl. x is a C substituted with one or more deuterium atoms. 2~6 In some embodiments, R is alkenyl. x is a C substituted with one or more -OH 2~6 In some embodiments, R is alkenyl. x is one or more C 1~6 Alkoxy-substituted C 2~6 In some embodiments, R is alkenyl. x is C substituted with one or more halo 2~6 In some embodiments, R is alkenyl. x C optionally substituted with one or more halo 1~6 In some embodiments, R x is the unsubstituted C 1~6 In some embodiments, R x is C substituted with one or more halo 1~6 In some embodiments, R x C optionally substituted with -OH 1~6 In some embodiments, R is alkynyl. x is the unsubstituted C 1~6 In some embodiments, R is alkynyl. x is a C substituted with one or more -OH 1~6 In some embodiments, R is alkynyl. x is cyclobutenyl.
[0216] In some embodiments, provided herein are compounds of formula (I-AB), or any applicable subformula thereof, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is N. In some embodiments, X 1 is CR s In some embodiments, X 1 is CR s and CR s and R s are independently H, deuterium, -CN, halo, C 1~15 Alkyl, C 1~6 Alkynyl, C 6~20 Aryl, 5-15 membered heteroaryl, C 3~20 Cycloalkyl, 3- to 15-membered heterocyclyl, -OH, -OR f ,C 1-15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , and -NR d R e In other embodiments, each R s is H. In other embodiments, each R s is D. In other embodiments, each R s is -CN. In other embodiments, each R s is halo. In other embodiments, each R s is C 1~15 In other embodiments, each R s is C 1~6 In other embodiments, each R s is C 6~20 In other embodiments, each R s is a 5- to 15-membered heteroaryl. s is C 3~20 In other embodiments, each Rs is 3- to 15-membered heterocyclyl. s is —OH. In other embodiments, each R s -OR f In other embodiments, each R s is C 1~15 In other embodiments, each R s is -NR d COR e In other embodiments, each R s -CONR d R e In other embodiments, each R s is -SO2R d In other embodiments, each R s is -SO2NR d R e In other embodiments, each R s is -NR d SO2R e In other embodiments, each R s is -NR d R e is.
[0217] In some embodiments, provided herein are compounds of formula (I-AB), or any applicable subformula thereof, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is CR s and R s is C 1~15 Alkyl or C 1-15 is alkoxy, and R s C 1-15 Alkyl and C 1-15 Each alkoxy is independently one or more R t1 and R t1 independently at each occurrence, halo, oxo, -OH, -OR f1 , -CN, -NR d R e and 3- to 15-membered heterocyclyl optionally substituted with one or more —OH; R f1is -C(O)CHNR d R e , -C(O)C 1~6 alkyl, -P(O)(OH)2, and R d and R e are each independently H or C 1~6 alkyl, and R d or R e C 1~6 The alkyl may be optionally substituted with one or more halo, oxo, -OH, or -CN. In some embodiments, R s is one or more R t1 C replaced with 1~15 alkyl, and R t1 is halo. In some embodiments, R s is one or more R t1 C replaced with 1~15 alkyl, and R t1 is oxo. In some embodiments, R s is one or more R t1 C replaced with 1~15 alkyl, and R t1 is —OH. In some embodiments, R s is one or more R t1 C replaced with 1~15 alkyl, and R t1 -OR f1 and R f1 is -C(O)CHNR d R e , -C(O)C 1~6 alkyl, -P(O)(OH). In some embodiments, R s is one or more R t1 C replaced with 1~15 alkyl, and R t1 In some embodiments, R s is one or more R t1 C replaced with 1~15 alkyl, and R t1 is -NR d R e In some embodiments, R s is one or more Rt1 C replaced with 1~15 alkyl, and R t1 is a 3- to 15-membered heterocyclyl optionally substituted with one or more —OH. In some embodiments, R s is one or more R t1 C replaced with 1~15 is alkoxy, and R t1 is halo. In some embodiments, R s is one or more R t1 C replaced with 1~15 is alkoxy, and R t1 is oxo. In some embodiments, R s is one or more R t1 C replaced with 1~15 is alkoxy, and R t1 is —OH. In some embodiments, R s is one or more R t1 C replaced with 1~15 is alkoxy, and R t1 is OR f1 and R f1 is -C(O)CHNR d R e , -C(O)C 1~6 alkyl, -P(O)(OH). In some embodiments, R s is one or more R t1 C replaced with 1~15 is alkoxy, and R t1 In some embodiments, R s is one or more R t1 C replaced with 1~15 is alkoxy, and R t1 is -NR d R e In some embodiments, R s is one or more R t1 C replaced with 1~15 is alkoxy, and R t1 is a 3- to 15-membered heterocyclyl optionally substituted with one or more -OH.
[0218] In some embodiments, provided herein are compounds of formula (I-AB), or any applicable subformula thereof, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is CR s and R s is C 6~20 Aryl, 5-15 membered heteroaryl, C 3~20 cycloalkyl, or 3- to 15-membered heterocyclyl, and R s C 6~20 Aryl, 5-15 membered heteroaryl, C 3~20 Cycloalkyl and 3- to 15-membered heterocyclyl each independently represent one or more R t2 and R t2 independently at each occurrence, represents halo, oxo, -OH, -CN, C(O)NH2, -C(O)NR d R e , -NR d R e , C 1~6 Alkoxyl, 3-6 membered heterocyclyl, C 3~6 Cycloalkyl, and C 1~6 alkyl, and R t2 C 1~6 Alkyl is a group consisting of one or more -OH, C 1~6 Alkoxyl, halo, oxo, -S(O)2CH3, or -NR d R e and R d and R e are each independently H, -C(O)CH3, or -C(O)C 1~6 Alkyl, or C 1~6 It is alkyl.
[0219] In some embodiments, R s is one or more R t2 C replaced with 6~20 aryl, and R t2 is halo. In some embodiments, R s is one or more R t2 C replaced with 6~20 aryl, and R t2is halo. In some embodiments, R s is one or more R t2 C replaced with 6~20 aryl, and R t2 is —OH. In some embodiments, R s is one or more R t2 C replaced with 6~20 aryl, and R t2 In some embodiments, R s is one or more R t2 C replaced with 6~20 aryl, and R t2 is C(O)NH. In some embodiments, R s is one or more R t2 C replaced with 6~20 aryl, and R t2 is -C(O)NR d R e In some embodiments, R s is one or more R t2 C replaced with 6~20 aryl, and R t2 is -NR d R e In some embodiments, R s is one or more R t2 C replaced with 6~20 aryl, and R t2 is C 1~6 In some embodiments, R s is one or more R t2 C replaced with 6~20 aryl, and R t2 is a 3- to 6-membered heterocyclyl. s is one or more R t2 C replaced with 6~20 aryl, and R t2 is C 3~6 In some embodiments, R s is one or more R t2 C replaced with 6~20 aryl, and Rt2 is C 1~6 alkyl, and R t2 C 1~6 Alkyl is a group consisting of one or more -OH, C 1~6 Alkoxyl, halo, oxo, -S(O)2CH3, or -NR d R e may be optionally substituted with
[0220] In some embodiments, R s is one or more R t2 and R is a 5- to 15-membered heteroaryl substituted with t2 is halo. In some embodiments, R s is one or more R t2 and R is a 5- to 15-membered heteroaryl substituted with t2 is oxo. In some embodiments, R s is one or more R t2 and R is a 5- to 15-membered heteroaryl substituted with t2 is —OH. In some embodiments, R s is one or more R t2 and R is a 5- to 15-membered heteroaryl substituted with t2 In some embodiments, R s is one or more R t2 and R is a 5- to 15-membered heteroaryl substituted with t2 is C(O)NH. In some embodiments, R s is one or more R t2 and R is a 5- to 15-membered heteroaryl substituted with t2 is -C(O)NR d R e In some embodiments, R s is one or more R t2 and R is a 5- to 15-membered heteroaryl substituted with t2 is -NR d R e In some embodiments, R s is one or more R t2 and R is a 5- to 15-membered heteroaryl substituted witht2 is C 1~6 In some embodiments, R s is one or more R t2 and R is a 5- to 15-membered heteroaryl substituted with t2 is C 1~6 In some embodiments, R s is one or more R t2 C replaced with 3~20 is cycloalkyl, and R t2 is halo. In some embodiments, R s is one or more R t2 C replaced with 3~20 is cycloalkyl, and R t2 is oxo. In some embodiments, R s is one or more R t2 C replaced with 3~20 is cycloalkyl, and R t2 is —OH. In some embodiments, R s is one or more R t2 C replaced with 3~20 is cycloalkyl, and R t2 In some embodiments, R s is one or more R t2 C replaced with 3~20 is cycloalkyl, and R t2 is C(O)NH. In some embodiments, R s is one or more R t2 C replaced with 3~20 is cycloalkyl, and R t2 is -C(O)NR d R e In some embodiments, R s is one or more R t2 C replaced with 3~20 is cycloalkyl, and R t2 is -NR d R e In some embodiments, R s is one or more R t2 C replaced with 3~20is cycloalkyl, and R t2 is C 1~6 In some embodiments, R s is one or more R t2 C replaced with 3~20 is cycloalkyl, and R t2 is C 1~6 In some embodiments, R s is one or more R t2 3- to 15-membered heterocyclyl substituted with R t2 is halo. In some embodiments, R s is one or more R t2 3- to 15-membered heterocyclyl substituted with R t2 is oxo. In some embodiments, R s is one or more R t2 3- to 15-membered heterocyclyl substituted with R t2 is —OH. In some embodiments, R s is one or more R t2 3- to 15-membered heterocyclyl substituted with R t2 In some embodiments, R s is one or more R t2 3- to 15-membered heterocyclyl substituted with R t2 is C(O)NH. In some embodiments, R s is one or more R t2 3- to 15-membered heterocyclyl substituted with R t2 is -C(O)NR d R e In some embodiments, R s is one or more R t2 3- to 15-membered heterocyclyl substituted with R t2 is -NR d R e In some embodiments, R s is one or more R t2 3- to 15-membered heterocyclyl substituted with R t2 is C 1~6In some embodiments, R s is one or more R t2 3- to 15-membered heterocyclyl substituted with R t2 is C 1~6 It is alkyl.
[0221] In some embodiments, provided herein are compounds of formula (I-AB), or any applicable subformula thereof, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is CR s and each R s is R t1 and R t1 Ha-NR d R e and R d and R e are each independently H or C 1~6 alkyl, and R d or R e C 1~6 The alkyl may be optionally substituted with one or more halo, oxo, -OH, or -CN. In some embodiments, R d is H. In some embodiments, R d is C 1~6 In some embodiments, R e is H. In some embodiments, R e is C 1~6 R is alkyl. d C 1~6 In some embodiments, R is alkyl. d C 1~6 The alkyl may be optionally substituted with one or more halo, oxo, -OH, or -CN. In some embodiments, R d C 1~6 The alkyl is substituted with one or more halo. In some embodiments, R d C 1~6 The alkyl is substituted with one or more oxo. In some embodiments, R d C 1~6The alkyl is substituted with one or more -OH. In some embodiments, R d C 1~6 The alkyl is substituted with one or more -CN. e C 1~6 In some embodiments, R is alkyl. e C 1~6 The alkyl may be optionally substituted with one or more halo, oxo, -OH, or -CN. In some embodiments, R e C 1~6 The alkyl is substituted with one or more halo. In some embodiments, R e C 1~6 The alkyl is substituted with one or more oxo. In some embodiments, R e C 1~6 The alkyl is substituted with one or more -OH. In some embodiments, R e C 1~6 The alkyl is substituted with one or more -CN groups.
[0222] In some embodiments, provided herein are compounds of Formula (I-AB), or any applicable subformula thereof, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein B is phenyl or 5-6 membered heteroaryl. In some embodiments, B is phenyl. In some embodiments, B is 5-6 membered heteroaryl. In some embodiments, the phenyl or 5-6 membered heteroaryl of B each independently is selected from one or more R t and R t independently at each occurrence, halo, C 1~15 Alkyl, or C 1~6 is alkoxy, and R t C 1~15 Alkyl or C 1~6 The alkoxy may be optionally substituted with one or more halo. In some embodiments, B is selected from the group consisting of one or more R t is phenyl substituted with R t independently at each occurrence, halo, C1~15 Alkyl, or C 1~6 is alkoxy, and R t C 1~15 Alkyl or C 1~6 The alkoxy may be optionally substituted with one or more halo. In some embodiments, B is selected from the group consisting of one or more R t is phenyl substituted with R t In some embodiments, B is selected from the group consisting of one or more R t is phenyl substituted with R t is C 1~15 In some embodiments, B is one or more R t is phenyl substituted with R t is C 1~6 In some embodiments, B is one or more R t is phenyl substituted with R t is S(R y )5, and each R y In some embodiments, B is selected from the group consisting of one or more R t and R is a 5- to 6-membered heteroaryl substituted with t independently at each occurrence, halo, C 1~15 Alkyl, or C 1~6 is alkoxy, and R t C 1~15 Alkyl or C 1~6 The alkoxy may be optionally substituted with one or more halo. In some embodiments, B is selected from the group consisting of one or more R t and R is a 5- to 6-membered heteroaryl substituted with t In some embodiments, B is selected from the group consisting of one or more R t and R is a 5- to 6-membered heteroaryl substituted with t is C 1~15 In some embodiments, B is one or more R t and R is a 5- to 6-membered heteroaryl substituted with t is C 1~6 B is phenyl or one or more R tand R is a 5- to 6-membered heteroaryl substituted with t C 1~15 Alkyl or C 1~6 In some embodiments, R is alkoxy. t C 1~15 Alkyl or C 1~6 The alkoxy may be optionally substituted with one or more halo. In some embodiments, R t C 1~15 The alkyl is substituted with one or more fluoro. In some embodiments, R t C 1~15 In some embodiments, B is substituted with one or more R t and R is a 5- to 6-membered heteroaryl substituted with t is S(R y )5, and each R y is a halo.
[0223] In some embodiments, provided herein are compounds of Formula (I-AB), or any applicable subformula thereof, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein B is phenyl. In some embodiments, B is a 5-6 membered heteroaryl. In other embodiments, B is unsubstituted phenyl. In other embodiments, B is substituted phenyl. In other embodiments, B is substituted with one or more R t In another embodiment, R t is C 1~6 In another embodiment, R t is C substituted with one or more halo 1~6 In another embodiment, R t is a C substituted with one or more fluoro groups 1~6 In another embodiment, B is The file is TIFF2024541508000085.tif17170.
[0224] In some embodiments, provided herein are compounds of formula (I-AB), or any applicable subformula thereof, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is N or CR s and X 2 , X 3 , and X 4 are each independently N, CH, or CD, provided that: 1) X 1 , X 2 , X 3 , and X 4 1) Only one of the two is N, or 2) X 1 is N and X 2 is CH and X 3 is CH and X 4 is N or 3) X 1 is CR s and X 2 , X 3 , and X 4 are each independently CH or CD.
[0225] In some embodiments, X 1 is N and X 2 , X 3 , and X 4 are each independently CH or CD. 1 is N and X 2 and X 3 are each independently CH or CD, and X 4 is N. In some embodiments, X 1 is CR s In some embodiments, X 1 is CR s and X 2 is N. In some embodiments, X 1 is CR s and X 3 is N. In some embodiments, X 1 is CR s and X 4 is N.
[0226] In some embodiments, provided herein are compounds of formula (I-AB), or any applicable subformula thereof, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is CR s and X 2 is CH and X 3 is CH and X 4 is N and R s is the unsubstituted C 1~15 In another embodiment, X is alkyl. 1 is CR s and X 2 is CH and X 3 is CH and X 4 is N and R s is one or more R t1 C replaced with 1~15 In another embodiment, X is alkyl. 1 is CR s and X 2 is CH and X 3 is CH and X 4 is N and R s is one or more R t1 C replaced with 1~15 alkyl, and R t1 is —OH. In another embodiment, X 1 is CR s and X 2 is CH and X 3 is CH and X 4 is N and R s teeth TIFF2024541508000086.tif12170. In another embodiment, X 1 is CR s and X 2 is CH and X 3 is CH and X 4 is N and R s teeth TIFF2024541508000087.tif11170. In some embodiments, in conjunction with the above or below embodiments, Rs is methyl, cyano, halo, chloro, -H, -CCH, TIFF2024541508000088.tif248170TIFF2024541508000089.tif93170.
[0227] In some embodiments, provided herein are compounds of formula (I-AB) or any applicable subformula thereof, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein L is methylene and one or more C 1~6 In some embodiments, L is an unsubstituted methylene. In some embodiments, L is an alkyl group optionally substituted with one or more C 1~6 It is methylene substituted with alkyl.
[0228] In some embodiments, provided herein are compounds of formula (I-AB), or any applicable subformula thereof, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein Z is —C(O)R x and R x is C 1~6 Alkyl, Deuterium, -OH, C 1~6 C optionally substituted with one or more substituents selected from alkoxyl and halo 2~6 alkenyl, or R x C optionally substituted with one or more halo 1~6 alkyl or R x C optionally substituted with -OH 1~6 alkynyl, or R x is cyclobutenyl, dihydrofuranyl, bicyclobutanyl, or cyclopentenyl. x is C 1~6 Alkyl, Deuterium, -OH, C 1~6 C optionally substituted with one or more substituents selected from alkoxyl and halo 2~6 In some embodiments, R is alkenyl. xis the unsubstituted C 2~6 In some embodiments, R x is one or more C 1~6 Alkyl-substituted C 2~6 In some embodiments, R is alkenyl. x is a C substituted with one or more deuterium atoms. 2~6 In some embodiments, R is alkenyl. x is a C substituted with one or more -OH 2~6 In some embodiments, R is alkenyl. x is one or more C 1~6 Alkoxy-substituted C 2~6 In some embodiments, R is alkenyl. x is C substituted with one or more halo 2~6 In some embodiments, R is alkenyl. x C optionally substituted with one or more halo 1~6 In some embodiments, R x is the unsubstituted C 1~6 In some embodiments, R x is C substituted with one or more halo 1~6 In some embodiments, R x C optionally substituted with -OH 1~6 In some embodiments, R is alkynyl. x is the unsubstituted C 1~6 In some embodiments, R is alkynyl. x is a C substituted with one or more -OH 1~6 In some embodiments, R is alkynyl. x is cyclobutenyl. In some embodiments, R x is dihydrofuranyl. In some embodiments, R x is bicyclobutanyl. In some embodiments, R x is cyclopentenyl. In some embodiments, Z is S(O)R x1 and R x1is C 2~6 It is alkenyl.
[0229] In some embodiments, the compound of formula (AB') is TIFF2024541508000090.tif48170 or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 2 , X 3 , X 4 , R s B, L' and Z are as defined in formula (AB). X described for formula (AB) 2 , X 3 , X 4 , R s It is understood that the embodiments of B, L', and Z may be applied to formula (AB') in some embodiments, where applicable. s is not H or deuterium. In some embodiments, R s is methyl, cyano, halo, chloro, -H, -CCH, TIFF2024541508000091.tif248170 TIFF2024541508000092.tif93170. In some embodiments, R s is a C substituted with one or more -OH 1~6 In some embodiments, R s is a C substituted with one or more -OH 1~3 In some embodiments, R s teeth, TIFF2024541508000093.tif12170, or a stereoisomer thereof. s teeth, The file is TIFF2024541508000094.tif11170.
[0230] In some embodiments, a compound of any one of the formulae described herein may include one or more of the following structural features: i) L' is * -NH-CH2-** or ii) L' is TIFF2024541508000095.tif17170, and / or iii) B is halo C 1~6 phenyl substituted with alkoxy; and / or iv) R s is a C substituted with one or more -OH 1~6 and / or v) X is alkyl; 2 is CH, and / or vi) X 3 is CH, and / or vii) X 4 is N, and / or viii) Z is -C(O)R x and R x is the unsubstituted C 2~6 alkenyl, and / or ix) Z is —C(O)R x and R x C optionally substituted with one or more halo 2~6It is alkenyl. In some embodiments, a compound of any one of the formulae described herein may include two of the above structural features, such as i) and iii), i) and iv), i) and v), i) and vi), i) and vii), i) and viii), i) and viii), i) and (ix), ii) and iii), ii) and iv), ii) and v), ii) and vi), ii) and vii), ii) and viii), ii) and (ix), iii) and iv), iii) and v), iii) and vi), iii) and vii), iii) and viii), iii) and ix), iv) and v), iv) and vi), iv) and vii), iv) and viii), iv) and ix), v) and vi), v) and vii), v) and viii), v) and ix), vi) and vii), vi) and viii), vi) and ix), vii) and viii), and vii), ... In some embodiments, a compound of any one of formulae described herein is selected from the group consisting of i) and (iii) and iv), i) and (iii) and v), i) and iii) and vi), i) and (iii) and vii), i) and iii) and viii), i) and iii) and (ix), ii) and iii) and iv), ii) and iii) and v), ii) and iii) and vi), ii) and iii) and vii), ii) and iii) and viii), ii) and iii) and (ix), ii It may include three of the above structural features, such as i), iv), and v), iii), iv), and vi), iii), iv), and vii), iii), iv), and viiii), iii), iv), and ix), iv), v), and vi), iv), v), and vii), iv), v), and viiii), iv), v), and ix), v), vi), and vii), v), vi), and viiii), v), vi), and ix), vi), vii), and viiii), and vii), and ix), vi), vii), and viii), and vii), and ix).In some embodiments, a compound of any one of formulae described herein is selected from the group consisting of i), iii), iv), and v), i), iii), iv), and vi), i), (iii), iv), and vii), i), iii), iv), and viii), i), iii), iv), and (ix), ii), iii), iv), and v), ii), iii), iv), and vi), ii), iii), iv), and vii), ii), iii), iv), and viii). , ii) and iii) and iv) and (ix), iii) and iv) and v) and vi), iii) and iv) and v) and vii), iii) and iv) and v) and viii), iii) and iv) and v) and ix), iv) and v) and vi) and vii), iv) and v) and vi) and viii), iv) and v) and vi) and viii), iv) and v) and vi) and ix), v) and vi) and vii) and viii), and v) and vi) and vii) and ix). In some embodiments, a compound of any one of the formulae described herein may include five of the above structural features, such as i), iii), iv), v), and vi), i), iii), iv), v), and vii), i), iii), iv), v), and viii), i), iii), iv), v), and ix), ii), iii), iv), v), and vii), ii), iii), iv), v), and viiii), ii), iii), iv), v), and ix), iii), iv), v), and vii), iii), iv), v), and viii), iii), iv), v), and ix), iv), v), vii), and viii), and ix), iv), v), vii), and viii), and ix), iv), v), vii), and viii), and ix), iv), v), vii), and viii), and ix). In some embodiments, a compound of any one of the formulas described herein may include six of the above structural features, such as i), iii), iv), v), vi), and vii), i), iii), iv), v), vi), and viiii), i), iii), iv), v), vi), and ix), ii), iii), iv), v), vi), and vii), ii), iii), iv), v), vi), and viiii), ii), iii), iv), v), vi), and vii), and viiii), ii), iii), iv), v), vi), vii), and viiii), and iii), iv), v), vi), vii), and ix).In some embodiments, a compound of any one of the formulas described herein may include seven of the above structural features, such as i), iii), iv), v), vi), vii), and viii); i), iii), iv), v), vi), vii), and viii); ii), iii), iv), v), vi), vii), and viii); and ii), iii), iv), v), vi), vii), and ix).
[0231] In some embodiments, in conjunction with the above or below embodiments, references to "one or more / one or more" may be 1-5, 1-4, 1-3, 1-2, 5, 4, 3, 2, or 1.
[0232] In some embodiments, in conjunction with the above or below embodiments, "one or more substituents" such as "C 1~6 Reference to "one or more substituents of an alkyl" can be 1 to 3 substituents, 1 to 2 substituents, 2 substituents, or 1 substituent.
[0233] In some embodiments, in conjunction with the above or below embodiments, B is one or more R t R t C optionally substituted with 1 to 3 halo 1~15 In some embodiments, in conjunction with the above or below embodiments, R t is C substituted with 1 to 3 halo groups 1~15 In some embodiments, in conjunction with the above or below embodiments, R t Yes, it is OCF3.
[0234] In some embodiments, in conjunction with the above or below embodiments, X 1 is CR s If R s teeth, TIFF2024541508000096.tif12170 or a stereoisomer thereof. In some embodiments, R s teeth, The file is TIFF2024541508000097.tif11170.
[0235] In some embodiments, in conjunction with the above or below embodiments, n and m are each 1.
[0236] In some embodiments, the following formula (A-1): TIFF2024541508000098.tif43170(A-1), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In one embodiment, X in formula (A-1) 1 , X 2 , X 3 , X 4 , R t , L, and Z are as defined in formula (I-AB). In one embodiment, X in formula (A-1) 1 , X 2 , X 3 , X 4 , R t , L, and Z are as defined in formula (AB). In one embodiment, X in formula (A-1) 1 , X 2 , X 3 , X 4 , R t , L, and Z are as defined in formula (A). In one embodiment, X in formula (A-1) 1 , X 2 , X 3 , X 4 , R t , L, and Z are as defined in formula (A'). X described for formula (I-AB), (AB), (A), or (A') 1 , X 2 , X 3 , X 4 , R t It is understood that the embodiments of, L, and Z may be applied to formula (A-1) in some embodiments, where applicable.
[0237] In some embodiments, the following formula (B-1): TIFF2024541508000099.tif47170(B-1), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In one embodiment, X in formula (B-1) 1 , X 2 , X 3 , X 4 , R t and Z are as defined in formula (I-AB). In one embodiment, X in formula (B-1) 1 , X 2 , X 3 , X 4 , R t and Z are as defined in formula (AB). In one embodiment, X in formula (B-1) 1 , X 2 , X 3 , X 4 , R t and Z are as defined in formula (B). In one embodiment, X in formula (B-1) 1 , X 2 , X 3 , X 4 , R t and Z are as defined in formula (B'). X as described for formula (I-AB), (AB), (B), or (B') 1 , X 2 , X 3 , X 4 , R t It is understood that the embodiments of and Z may be applied to formula (B-1) in some embodiments, where applicable.
[0238] In some embodiments, the compound of formula (IA-1) below: TIFF2024541508000100.tif43170 (IA-1), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In one embodiment, X in formula (IA-1) 1 , X 2 , X 3 , X 4 , R t , R a , R b , Rc , L, and R t is as defined in formula (I-AB). In one embodiment, X in formula (IA-1) 1 , X 2 , X 3 , X 4 , R t , R a , R b , R c , L, and R t is as defined in formula (AB). In one embodiment, X in formula (IA-1) 1 , X 2 , X 3 , X 4 , R t , R a , R b , R c , L, and R t is as defined in formula (A). In one embodiment, X in formula (IA-1) 1 , X 2 , X 3 , X 4 , R t , R a , R b , R c , L, and R t is as defined in formula (A'). X described for formula (I-AB), (AB), (A) or (A') 1 , X 2 , X 3 , X 4 , R t , R a , R b , R c , L, and R t It is understood that the embodiments of may be applied to formula (IA-1) in some embodiments, where applicable.
[0239] In some embodiments, the compound of formula (IA-2) below: TIFF2024541508000101.tif47170 (IA-2), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In one embodiment, X in formula (IA-2) 1, X 2 , X 3 , X 4 , R t , R a , R b , L, and R c is as defined in formula (I-AB). In one embodiment, X in formula (IA-2) 1 , X 2 , X 3 , X 4 , R t , R a , R b , L, and R c is as defined in formula (AB). In one embodiment, X in formula (IA-2) 1 , X 2 , X 3 , X 4 , R t , R a , R b , L, and R c is as defined in formula (A). In one embodiment, X in formula (IA-2) 1 , X 2 , X 3 , X 4 , R t , R a , R b , L, and R c is as defined in formula (A'). X described for formula (I-AB), (AB), (A) or (A') 1 , X 2 , X 3 , X 4 , R t , R a , R b , L, and R c It is understood that the embodiments of may be applied to formula (IA-2) in some embodiments, where applicable.
[0240] In some embodiments, the compound of formula (IA-3) below: TIFF2024541508000102.tif33170 (IA-3), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In one embodiment, X in formula (IA-3) 1 , X 2 , X 3 , X 4 and B are as defined in formula (I-AB). In one embodiment, X in formula (IA-3) 1 , X 2 , X 3 , X 4 and B is as defined in formula (AB). In one embodiment, X in formula (IA-3) 1 , X 2 , X 3 , X 4 and B are as defined in formula (A). In one embodiment, X in formula (IA-3) 1 , X 2 , X 3 , X 4 and B are as defined in formula (A'). X described for formula (I-AB), (AB), (A) or (A') 1 , X 2 , X 3 , X 4 It is understood that the embodiments of and B may be applied to formula (IA-3) in some embodiments, where applicable.
[0241] In some embodiments, the compound of formula (IA-4) below: TIFF2024541508000103.tif43170 (IA-4), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In one embodiment, X in formula (IA-4) 1 , X 2 , X 3 , X 4 , L and R t is as defined in formula (I-AB). In one embodiment, X in formula (IA-4) 1 , X 2 , X 3 , X 4 , L and R t is as defined in formula (AB). In one embodiment, X in formula (IA-4) 1 , X 2 , X3 , X 4 , L, and R t is as defined in formula (A). In one embodiment, X in formula (IA-4) 1 , X 2 , X 3 , X 4 , L, and R t is as defined in formula (A'). X described for formula (I-AB), (AB), (A), or (A') 1 , X 2 , X 3 , X 4 , L, and R t It is understood that the embodiments of may be applied to formula (IA-4) in some embodiments, where applicable.
[0242] In some embodiments, the compound of formula (A-1a) below: TIFF2024541508000104.tif44170(A-1a), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In one embodiment, X in formula (A-1a) 1 , X 2 , X 3 , X 4 , L, and R t is as defined in formula (I-AB). In one embodiment, X in formula (A-1a) 1 , X 2 , X 3 , X 4 , L, and R t is as defined in formula (AB). In one embodiment, X in formula (A-1a) 1 , X 2 , X 3 , X 4 , L, and R t is as defined in formula (A). In one embodiment, X in formula (A-1a) 1 , X 2 , X 3 , X 4 , L, and R tis as defined in formula (A'). X described for formula (I-AB), (AB), (A), or (A') 1 , X 2 , X 3 , X 4 , L, and R t It is understood that the above embodiments may be applied to formula (A-1a) in some embodiments, where applicable.
[0243] In some embodiments, the compound of formula (B-1a) below: TIFF2024541508000105.tif43170(B-1a), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In one embodiment, X in formula (B-1a) 1 , X 2 , X 3 , X 4 , R t , n, m, and Z are as defined in formula (I-AB). 1 , X 2 , X 3 , X 4 , R t , n, m, and Z are as defined in formula (AB). In one embodiment, X in formula (B-1a) 1 , X 2 , X 3 , X 4 , R t , n, m, and Z are as defined in formula (B). In one embodiment, X in formula (B-1a) 1 , X 2 , X 3 , X 4 , R t , n, m, and Z are as defined in formula (B'). X described for formula (I-AB), (AB), (B), or (B') 1 , X 2 , X 3 , X 4 , R t It is understood that the embodiments of n, m, and Z may be applied to formula (B-1a) in some embodiments, where applicable.
[0244] In some embodiments, the compound of formula (IA-1a) below: TIFF2024541508000106.tif43170 (IA-1a), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In one embodiment, X in formula (IA-1a) 1 , X 2 , X 3 , X 4 , R t , R a , R b , R c , L, and R t is as defined in formula (I-AB). In one embodiment, X in formula (IA-1a) 1 , X 2 , X 3 , X 4 , R t , R a , R b , R c , L, and R t is as defined in formula (AB). In one embodiment, X in formula (IA-1a) 1 , X 2 , X 3 , X 4 , R t , R a , R b , R c , L, and R t is as defined in formula (A). In one embodiment, X in formula (IA-1a) 1 , X 2 , X 3 , X 4 , R t , R a , R b , R c , L, and R t is as defined in formula (A'). X described for formula (I-AB), (AB), (A) or (A') 1 , X 2 , X 3 , X 4 , R t , R a , Rb , R c , L, and R t It is understood that the embodiment of may be applied to formula (IA-1a) in some embodiments.
[0245] In some embodiments, the compound of formula (IA-4a) below: TIFF2024541508000107.tif44170 (IA-4a), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In one embodiment, X in formula (IA-4a) 1 , X 2 , X 3 , X 4 , L and R t is as defined in formula (I-AB). In one embodiment, X in formula (IA-4a) 1 , X 2 , X 3 , X 4 , L, and R t is as defined in formula (AB). In one embodiment, X in formula (IA-4a) 1 , X 2 , X 3 , X 4 , L, and R t is as defined in formula (A). In one embodiment, X in formula (IA-4a) 1 , X 2 , X 3 , X 4 , L, and R t is as defined in formula (A'). X described for formula (I-AB), (AB), (A), or (A') 1 , X 2 , X 3 , X 4 , L, and R t It is understood that the embodiments of may be applied to formula (IA-4a) in some embodiments, where applicable.
[0246] In some embodiments, the compound of formula (IA-5) below: TIFF2024541508000108.tif38170 (IA-5), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In one embodiment, R of formula (IA-5) s , R a , R b , L, B, and R c is as defined in formula (I-AB). In one embodiment, R in formula (IA-5) s , R a , R b , L, B, and R c is as defined in formula (AB). In one embodiment, R in formula (IA-5) s , R a , R b , L, B, and R c is as defined in formula (AB'). In one embodiment, R in formula (IA-5) s , R a , R b , L, B, and R c is as defined in formula (A). In one embodiment, R in formula (IA-5) s , R a , R b , L, B, and R c is as defined in formula (A'). R as described for formula (I-AB), (AB), (AB'), (A), or (A') s , R a , R b , L, B, and R c It is understood that the embodiments of may be applied to formula (IA-5) in some embodiments, where applicable.
[0247] In some embodiments, the compound of formula (IA-6) below: TIFF2024541508000109.tif38170 (IA-6), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In one embodiment, R of formula (IA-6) a , R b , L, B, and R cis as defined in formula (I-AB). In one embodiment, R in formula (IA-6) a , R b , L, B, and R c is as defined in formula (AB). In one embodiment, R in formula (IA-6) a , R b , L, B, and R c is as defined in formula (A). In one embodiment, R in formula (IA-6) a , R b , L, B, and R c is as defined in formula (A'). R described for formula (I-AB), (AB), (A), or (A') a , R b , L, B, and R c It is understood that the embodiments of may be applied to formula (IA-6) in some embodiments, where applicable.
[0248] In some embodiments, the compound of formula (IA-7) below: TIFF2024541508000110.tif40170 (IA-7), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In one embodiment, R of formula (IA-7) a , R b , L, B, and R c is as defined in formula (I-AB). In one embodiment, R in formula (IA-7) a , R b , L, B, and R c is as defined in formula (AB). In one embodiment, R in formula (IA-7) a , R b , L, B, and R c is as defined in formula (A). In one embodiment, R in formula (IA-7) a , R b , L, B, and R c is as defined in formula (A'). R described for formula (I-AB), (AB), (A), or (A') a , Rb , L, B, and R c It is understood that the embodiments of may be applied to formula (IA-7) in some embodiments, where applicable.
[0249] In some embodiments, the compound of formula (IA-8) below: TIFF2024541508000111.tif35170 (IA-8), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In one embodiment, L and B of formula (IAB) are as defined in formula (I-AB). In one embodiment, L and B of formula (IAB) are as defined in formula (AB). In one embodiment, L and B of formula (IAB) are as defined in formula (A). In one embodiment, L and B of formula (IAB) are as defined in formula (A'). It is understood that the embodiments of L and B described for formula (I-AB), (AB), (A) or (A') may be applied to formula (IA-8) in some embodiments, where applicable.
[0250] In some embodiments, the compound of formula (IA-9) is TIFF2024541508000112.tif37170 (IA-9), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In one embodiment, R of formula (IA-9) s , R a , R b , L, B, and R c is as defined in formula (I-AB). In one embodiment, R in formula (IA-9) s , R a , R b , L, B, and R c is as defined in formula (AB). In one embodiment, R in formula (IA-9) s , R a , R b , L, B, and R cis as defined in formula (AB'). In one embodiment, R in formula (IA-9) s , R a , R b , L, B, and R c is as defined in formula (A). In one embodiment, R in formula (IA-9) s , R a , R b , L, B, and R c is as defined in formula (A'). R as described for formula (I-AB), (AB), (AB'), (A) or (A') s , R a , R b , L, B, and R c It is understood that the embodiments of may be applied to formula (IA-9) in some embodiments, where applicable.
[0251] In some embodiments, the compound of formula (IA-10) below: TIFF2024541508000113.tif39170 (IA-10), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In one embodiment, X in formula (IA-10) 1 , X 2 , X 3 , X 4 , and R t is as defined in formula (I-AB). In one embodiment, X in formula (IA-10) 1 , X 2 , X 3 , X 4 , and R t is as defined in formula (AB). In one embodiment, X in formula (IA-10) 1 , X 2 , X 3 , X 4 , and R t is as defined in formula (A). In one embodiment, X in formula (IA-10) 1 , X 2 , X 3 , X 4 , and R tis as defined in formula (A'). X described for formula (I-AB), (AB), (A) or (A') 1 , X 2 , X 3 , X 4 , and R t It is understood that the embodiments of may be applied to formula (IA-10) in some embodiments, where applicable.
[0252] In some embodiments, the compound of formula (IA-11) below: TIFF2024541508000114.tif41170 (IA-11), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In one embodiment, X in formula (IA-11) 1 , X 2 , X 3 , X 4 , and R t is as defined in formula (I-AB). In one embodiment, X in formula (IA-11) 1 , X 2 , X 3 , X 4 , and R t is as defined in formula (AB). In one embodiment, X in formula (IA-11) 1 , X 2 , X 3 , X 4 , and R t is as defined in formula (A). In one embodiment, X in formula (IA-11) 1 , X 2 , X 3 , X 4 , and R t is as defined in formula (A'). X described for formula (I-AB), (AB), (A) or (A') 1 , X 2 , X 3 , X 4 , and R t It is understood that the above embodiments may be applied to formula (IA-11) in some embodiments, where applicable.
[0253] In some embodiments, the following formula (I-A'-11): TIFF2024541508000115.tif40170 (I-A'-11), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In one embodiment, X of formula (IA-11) or (I-A'-11) 1 , X 2 , X 3 , X 4 , and R t is as defined in formula (I-AB). In one embodiment, X in formula (IA-11) or (I-A'-11) 1 , X 2 , X 3 , X 4 , and R t is as defined in formula (AB). In one embodiment, X in formula (IA-11) or (I-A'-11) 1 , X 2 , X 3 , X 4 , and R t is as defined in formula (A). In one embodiment, X in formula (IA-11) or (I-A'-11) 1 , X 2 , X 3 , X 4 , and R t is as defined in formula (A'). X described for formula (I-AB), (AB), (A) or (A') 1 , X 2 , X 3 , X 4 , and R t It is understood that the embodiment of may be applied to formula (IA-11) or (I-A'-11) in some embodiments, where applicable.
[0254] In some embodiments, the compound of formula (IA-10a) is TIFF2024541508000116.tif43170 (IA-10a), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In one embodiment, X of formula (IA-10a) 1 , X 2 , X 3 , X 4 , and R t is as defined in formula (I-AB). In one embodiment, X in formula (IA-10a) 1 , X 2 , X 3 , X 4 , and R t is as defined in formula (AB). In one embodiment, X in formula (IA-10a) 1 , X 2 , X 3 , X 4 , and R t is as defined in formula (A). In one embodiment, X in formula (IA-10a) 1 , X 2 , X 3 , X 4 , and R t is as defined in formula (A'). X described for formula (I-AB), (AB), (A) or (A') 1 , X 2 , X 3 , X 4 , and R t It is understood that the embodiments of may be applied to formula (IA-10a) in some embodiments, where applicable.
[0255] In some embodiments, the compound of formula (IA-11a) below: TIFF2024541508000117.tif40170 (IA-11a), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In one embodiment, X of formula (IA-11a) 1 , X 2 , X 3 , X 4 , and R t is as defined in formula (I-AB). In one embodiment, X in formula (IA-11a) 1 , X 2 , X 3 , X 4 , and Rt is as defined in formula (AB). In one embodiment, X in formula (IA-11a) 1 , X 2 , X 3 , X 4 , and R t is as defined in formula (A). In one embodiment, X in formula (IA-11a) 1 , X 2 , X 3 , X 4 , and R t is as defined in formula (A'). X described for formula (I-AB), (AB), (A) or (A') 1 , X 2 , X 3 , X 4 , and R t It is understood that the embodiments of may be applied to formula (IA-11a) in some embodiments, where applicable.
[0256] In some embodiments, the compound of formula (IA-11a) below: TIFF2024541508000118.tif49170 (I-A'-11a), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In one embodiment, X of formula (IA-11a) or (I-A'-11a) 1 , X 2 , X 3 , X 4 , and R t is as defined in formula (I-AB). In one embodiment, X in formula (IA-11a) or (I-A'-11a) 1 , X 2 , X 3 , X 4 , and R t is as defined in formula (AB). In one embodiment, X in formula (IA-11a) or (I-A'-11a) 1 , X 2 , X 3 , X 4 , and R tis as defined in formula (A). In one embodiment, X in formula (IA-11a) or (I-A'-11a) 1 , X 2 , X 3 , X 4 , and R t is as defined in formula (A'). X described for formula (I-AB), (AB), (A) or (A') 1 , X 2 , X 3 , X 4 , and R t It is understood that the embodiment of may be applied to formula (IA-11a) or (I-A'-11a) in some embodiments, where applicable.
[0257] In some embodiments, the compound of formula (IA-12) below: TIFF2024541508000119.tif38170 (IA-12), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In one embodiment, R of formula (IA-12) s , R a , R b , L, and R c is as defined in formula (I-AB). In one embodiment, R in formula (IA-12) s , R a , R b , L, and R c is as defined in formula (AB). In one embodiment, R in formula (IA-12) s , R a , R b , L, and R c is as defined in formula (AB'). In one embodiment, R in formula (IA-12) s , R a , R b , L, and R c is as defined in formula (A). In one embodiment, R in formula (IA-12) s , R a , R b , L, and R cis as defined in formula (A'). R as described for formula (I-AB), (AB), (AB'), (A) or (A') s , R a , R b , L, and R c It is understood that the embodiments of may be applied to formula (IA-12) in some embodiments, where applicable.
[0258] In some embodiments, the compound of formula (IA-13) below: TIFF2024541508000120.tif38170 (IA-13), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In one embodiment, R of formula (IA-13) s , R t , R a , R b , and R c is as defined in formula (I-AB). In one embodiment, R in formula (IA-13) s , R t , R a , R b , and R c is as defined in formula (AB). In one embodiment, R in formula (IA-13) s , R t , R a , R b , and R c is as defined in formula (AB'). In one embodiment, R in formula (IA-13) s , R t , R a , R b , and R c is as defined in formula (A). In one embodiment, R in formula (IA-13) s , R t , R a , R b , and R c is as defined in formula (A'). R as described for formula (I-AB), (AB), (AB'), (A) or (A') s , R t , Ra , R b , and R c It is understood that the embodiments of may be applied to formula (IA-13) in some embodiments, where applicable.
[0259] In some embodiments, the compound of formula (IA-14) below: TIFF2024541508000121.tif35170 (IA-14), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In one embodiment, X in formula (IA-14) 1 , X 2 , X 3 , X 4 , Z, L and R 1 is as defined in formula (I-AB). In one embodiment, X in formula (IA-14) 1 , X 2 , X 3 , X 4 , Z, L, and R 1 is as defined in formula (AB). In one embodiment, X in formula (IA-14) 1 , X 2 , X 3 , X 4 , Z, L, and R 1 is as defined in formula (A). In one embodiment, X in formula (IA-14) 1 , X 2 , X 3 , X 4 , Z, L, and R 1 is as defined in formula (A'). X described for formula (I-AB), (AB), (A) or (A') 1 , X 2 , X 3 , X 4 , Z, L, and R 1 It is understood that the embodiments of may be applied to formula (IA-14) in some embodiments, where applicable.
[0260] In some embodiments, the compound of formula (IA-15) below: TIFF2024541508000122.tif34170 (IA-15), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In one embodiment, R of formula (IA-15) s , Z, L, and R 1 is as defined in formula (I-AB). In one embodiment, R in formula (IA-15) s , Z, L, and R 1 is as defined in formula (AB). In one embodiment, R in formula (IA-15) s , Z, L, and R 1 is as defined in formula (AB'). In one embodiment, R in formula (IA-15) s , Z, L, and R 1 is as defined in formula (A). In one embodiment, R in formula (IA-15) s , Z, L, and R 1 is as defined in formula (A'). R as described for formula (I-AB), (AB), (AB'), (A), or (A') s , Z, L, and R 1 It is understood that the embodiments of may be applied to formula (IA-15) in some embodiments, where applicable.
[0261] In some embodiments, the compound of formula (IA-16) below: TIFF2024541508000123.tif35170 (IA-16), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In one embodiment, R of formula (IA-16) s , R a , R b , and R c is as defined in formula (I-AB). In one embodiment, R in formula (IA-16) s , R a , R b , and R c is as defined in formula (AB). In one embodiment, R in formula (IA-16) s , Ra , R b , and R c is as defined in formula (AB'). In one embodiment, R in formula (IA-16) s , R a , R b , and R c is as defined in formula (A). In one embodiment, R in formula (IA-16) s , R a , R b , and R c is as defined in formula (A'). R as described for formula (I-AB), (AB), (AB'), (A) or (A') s , R a , R b , and R c It is understood that the embodiments of may be applied to formula (IA-16) in some embodiments, where applicable.
[0262] In some embodiments, the compound of formula (IA-17) below: TIFF2024541508000124.tif42170 (IA-17), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In one embodiment, R of formula (IA-17) s , Z, L, B, and R 1 is as defined in formula (I-AB). In one embodiment, R in formula (IA-17) s , Z, L, B, and R 1 is as defined in formula (AB). In one embodiment, R in formula (IA-17) s , Z, L, B, and R 1 is as defined in formula (AB'). In one embodiment, R in formula (IA-17) s , Z, L, B, and R 1 is as defined in formula (A). In one embodiment, R in formula (IA-17) s , Z, L, B, and R 1is as defined in formula (A'). R as described for formula (I-AB), (AB), (AB'), (A), or (A') s , Z, L, B, and R 1 It is understood that the embodiments of may be applied to formula (IA-17) in some embodiments, where applicable.
[0263] In some embodiments, the compound of formula (IA-18) is TIFF2024541508000125.tif42170 (IA-18), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In one embodiment, Z, L, B, and R of formula (IA-18) 1 are as defined in formula (I-AB). In one embodiment, Z, L, B, and R of formula (IA-18) 1 are as defined in formula (AB). In one embodiment, Z, L, B, and R of formula (IA-18) 1 are as defined in formula (A). In one embodiment, Z, L, B, and R of formula (IA-18) 1 are as defined in formula (A'). Z, L, B and R as described for formula (I-AB), (AB), (A) or (A') 1 It is understood that the embodiments of may be applied to formula (IA-18) in some embodiments, where applicable.
[0264] In some embodiments, the compound of formula (IA-19) is TIFF2024541508000126.tif47170 (IA-19), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In one embodiment, Z, L, B, and R of formula (IA-19) 1 are as defined in formula (I-AB). In one embodiment, Z, L, B, and R of formula (IA-19) 1 are as defined in formula (AB). In one embodiment, Z, L, B, and R of formula (IA-19)1 are as defined in formula (A). In one embodiment, Z, L, B, and R of formula (IA-19) 1 are as defined in formula (A'). Z, L, B and R as described for formula (I-AB), (AB), (A) or (A') 1 It is understood that the above embodiments may be applied to formula (IA-19) in some embodiments, where applicable.
[0265] In some embodiments, the compound of formula (IA-20) is TIFF2024541508000127.tif47170 (IA-20), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In one embodiment, Z, L, B, R of formula (IA-20) d , R e , and R 1 are as defined in formula (I-AB). In one embodiment, Z, L, B, R of formula (IA-20) d , R e , and R 1 are as defined in formula (AB). In one embodiment, Z, L, B, R of formula (IA-20) d , R e , and R 1 are as defined in formula (A). In one embodiment, Z, L, B, R of formula (IA-20) d , R e , and R 1 are as defined in formula (A'). Z, L, B, R as defined in formula (I-AB), (AB), (A) or (A') d , R e , and R 1 It is understood that the embodiments of may be applied to formula (IA-20) in some embodiments, where applicable.
[0266] In some embodiments, the compound of formula (IA-21) is TIFF2024541508000128.tif45170 (IA-21), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In one embodiment, Z, L, B, and R of formula (IA-21) 1 are as defined in formula (I-AB). In one embodiment, Z, L, B, and R of formula (IA-21) 1 are as defined in formula (AB). In one embodiment, Z, L, B, and R of formula (IA-21) 1 are as defined in formula (A). In one embodiment, Z, L, B, and R of formula (IA-21) 1 are as defined in formula (A'). Z, L, B and R as described for formula (I-AB), (AB), (A) or (A') 1 It is understood that the above embodiments may be applied to formula (IA-21) in some embodiments, where applicable.
[0267] In some embodiments, the compound of formula (IB-1) below: TIFF2024541508000129.tif40170 (IB-1), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In one embodiment, X in formula (IB-1) 1 , X 2 , X 3 , X 4 , R t , R a , R b , R c , n, m and R t is as defined in formula (I-AB). In one embodiment, X in formula (IB-1) 1 , X 2 , X 3 , X 4 , R t , R a , R b , R c , n, m, and R t is as defined in formula (AB). In one embodiment, X in formula (IB-1) 1, X 2 , X 3 , X 4 , R t , R a , R b , R c , n, m and R t is as defined in formula (B). In one embodiment, X in formula (IB-1) 1 , X 2 , X 3 , X 4 , R t , R a , R b , R c , n, m and R t is as defined in formula (B'). X described for formula (I-AB), (AB), (B) or (B') 1 , X 2 , X 3 , X 4 , R t , R a , R b , R c , n, m, and R t It is understood that the embodiments of may be applied to formula (IB-1) in some embodiments, where applicable.
[0268] In some embodiments, the following formula (IB-2): TIFF2024541508000130.tif44170 (IB-2), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In one embodiment, X in formula (IB-2) 1 , X 2 , X 3 , X 4 , R t , R a , R b , R c , n, m and R t is as defined in formula (I-AB). In one embodiment, X in formula (IB-2) 1 , X 2 , X 3 , X 4 , R t , R a, R b , R c , n, m, and R t is as defined in formula (AB). In one embodiment, X in formula (IB-2) 1 , X 2 , X 3 , X 4 , R t , R a , R b , R c , n, m, and R t is as defined in formula (B). In one embodiment, X in formula (IB-2) 1 , X 2 , X 3 , X 4 , R t , R a , R b , R c , n, m, and R t is as defined in formula (B'). X described for formula (I-AB), (AB), (B) or (B') 1 , X 2 , X 3 , X 4 , R t , R a , R b , R c , n, m, and R t It is understood that the embodiments of may be applied to formula (IB-2) in some embodiments, where applicable.
[0269] In some embodiments, the following formula (IB-2): TIFF2024541508000131.tif38170 (IB-3), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In one embodiment, X in formula (IB-3) 1 , X 2 , X 3 , X 4 , n, m, and B are as defined in formula (I-AB). In one embodiment, X in formula (IB-3) 1 , X 2 , X 3 , X 4, n, m and B are as defined in formula (AB). In one embodiment, X in formula (IB-3) 1 , X 2 , X 3 , X 4 , n, m and B are as defined in formula (B). In one embodiment, X in formula (IB-3) 1 , X 2 , X 3 , X 4 , n, m, and B are as defined in formula (B'). X described for formula (I-AB), (AB), (B) or (B') 1 ,X 2 ,X 3 ,X 4 It is understood that the embodiments of n, m and B may be applied to formula (IB-3) in some embodiments, where applicable.
[0270] In some embodiments, the following formula (IB-4): TIFF2024541508000132.tif40170 (IB-4), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In one embodiment, X in formula (IB-4) 1 , X 2 , X 3 , X 4 , R t , R a , R b , R c , n, m and R t is as defined in formula (I-AB). In one embodiment, X in formula (IB-4) 1 , X 2 , X 3 , X 4 , R t , R a , R b , R c , n, m, and R t is as defined in formula (AB). In one embodiment, X in formula (IB-4) 1 , X 2 , X 3 , X 4 , R t, R a , R b , R c , n, m, and R t is as defined in formula (B). In one embodiment, X in formula (IB-4) 1 , X 2 , X 3 , X 4 , R t , R a , R b , R c , n, m, and R t is as defined in (B'). X described for formula (I-AB), (AB), (B) or (B') 1 , X 2 , X 3 , X 4 , R t , R a , R b , R c , n, m, and R t It is understood that the embodiments of may be applied to formula (IB-4) in some embodiments, where applicable.
[0271] In some embodiments, the following formula (IB-5): TIFF2024541508000133.tif40170 (IB-5), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In one embodiment, R of formula (IB-5) s , R a , R b , R c , n, m and B are as defined in formula (I-AB). In one embodiment, R s , R a , R b , R c , n, m and B are as defined in formula (AB). In one embodiment, R s , R a , R b , R c , n, m, and B are as defined in formula (AB'). In one embodiment, R of formula (IB-5) s, R a , R b , R c , n, m and B are as defined in formula (B). In one embodiment, R s , R a , R b , R c , n, m, and B are as defined in formula (B'). R described for formula (I-AB), (AB), (AB'), (B) or (B') s , R a , R b , R c It is understood that the embodiments of n, m and B may be applied to formula (IB-5) in some embodiments, where applicable.
[0272] In some embodiments, the following formula (IB-6): TIFF2024541508000134.tif41170 (IB-6), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In one embodiment, R of formula (IB-6) a , R b , R c , n, m and B are as defined in formula (I-AB). In one embodiment, R a , R b , R c , n, m and B are as defined in formula (AB). In one embodiment, R a , R b , R c , n, m and B are as defined in formula (B). In one embodiment, R a , R b , R c , n, m, and B are as defined in formula (B'). R described for formula (I-AB), (AB), (B) or (B') a , R b , R c It is understood that the embodiments of n, m and B may be applied to formula (IB-6) in some embodiments, where applicable.
[0273] In some embodiments, the compound of formula (IB-7): TIFF2024541508000135.tif43170 (IB-7), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In one embodiment, R of formula (IB-7) a , R b , R c , n, m and B are as defined in formula (I-AB). In one embodiment, R a , R b , R c , n, m and B are as defined in formula (AB). In one embodiment, R a , R b , R c , n, m and B are as defined in formula (B). In one embodiment, R a , R b , R c , n, m, and B are as defined in formula (B'). R described for formula (I-AB), (AB), (B) or (B') a , R b , R c It is understood that the embodiments of n, m and B may be applied to formula (IB-7) in some embodiments, where applicable.
[0274] In some embodiments, the compound of formula (IB-8) below: TIFF2024541508000136.tif38170 (IB-8), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In one aspect, n, m, and B of formula (IB-8) are as defined in formula (I-AB). In one aspect, n, m, and B of formula (IB-8) are as defined in formula (AB). In one aspect, n, m, and B of formula (IB-8) are as defined in formula (B). In one aspect, n, m, and B of formula (IB-8) are as defined in formula (B'). It is understood that embodiments of n, m, and B described for formula (I-AB), (AB), (B), or (B') may be applied to formula (IB-8) in some embodiments, where applicable.
[0275] In some embodiments, the compound of formula (IB-9) below: TIFF2024541508000137.tif37170 (IB-9), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In one embodiment, R of formula (IB-9) s , R a , R b , R c , n, m and B are as defined in formula (I-AB). In one embodiment, R s , R a , R b , R c , n, m and B are as defined in formula (AB). In one embodiment, R s , R a , R b , R c , n, m and B are as defined in formula (AB'). In one embodiment, R s , R a , R b , R c , n, m and B are as defined in formula (B). In one embodiment, R s , R a , R b , R c, n, m and B are as defined in formula (B'). R described for formula (I-AB), (AB), (AB'), (B) or (B') s , R a , R b , R c It is understood that the embodiments of n, m and B may be applied to formula (IB-9) in some embodiments, where applicable.
[0276] In some embodiments, the compound of formula (IB-10) below: TIFF2024541508000138.tif38170 (IB-10), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In one embodiment, R of formula (IB-10) s , R a , R b , R c , n, m and R t is as defined in formula (I-AB). In one embodiment, R in formula (IB-10) s , R a , R b , R c , n, m and R t is as defined in formula (AB). In one embodiment, R in formula (IB-10) s , R a , R b , R c , n, m and R t is as defined in formula (AB'). In one embodiment, R in formula (IB-10) s , R a , R b , R c , n, m and R t is as defined in formula (B). In one embodiment, R in formula (IB-10) s , R a , R b , R c , n, m and R t is as defined in formula (B'). R described for formula (I-AB), (AB), (AB'), (B) or (B') s , Ra , R b , R c , n, m, and R t It is understood that the embodiments of may be applied to formula (IB-10) in some embodiments, where applicable.
[0277] In some embodiments, the compound of formula (IB-11) below: TIFF2024541508000139.tif38170 (IB-11), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In one embodiment, R of formula (IB-11) s , R a , R b , R c , and R t is as defined in formula (I-AB). In one embodiment, R in formula (IB-11) s , R a , R b , R c , and R t is as defined in formula (AB). In one embodiment, R in formula (IB-11) s , R a , R b , R c , and R t is as defined in formula (AB'). In one embodiment, R in formula (IB-11) s , R a , R b , R c , and R t is as defined in formula (B). In one embodiment, R in formula (IB-11) s , R a , R b , R c , and R t is as defined in formula (B'). R described for formula (I-AB), (AB), (AB'), (B) or (B') s , R a , R b , R c , and R tIt is understood that the embodiments of may be applied to formula (IB-11) in some embodiments, where applicable.
[0278] In some embodiments, the compound of formula (IB-12) below: TIFF2024541508000140.tif34170 (IB-12), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In one embodiment, X of formula (IB-12) 1 , X 2 , X 3 , X 4 , n, m, and Z are as defined in formula (I-AB). In one embodiment, X in formula (IB-12) 1 , X 2 , X 3 , X 4 , n, m, and Z are as defined in formula (AB). In one embodiment, X in formula (IB-12) 1 , X 2 , X 3 , X 4 , n, m, and Z are as defined in formula (B). In one embodiment, X in formula (IB-12) 1 , X 2 , X 3 , X 4 , n, m, and Z are as defined in formula (B'). X described for formula (I-AB), (AB), (B), or (B') 1 , X 2 , X 3 , X 4 It is understood that the embodiments of n, m, and Z may be applied to formula (IB-12) in some embodiments, where applicable.
[0279] In some embodiments, the compound of formula (IB-13) below: TIFF2024541508000141.tif33170 (IB-13), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In one embodiment, R of formula (IB-13)s , n, m and Z are as defined in formula (I-AB). In one embodiment, R s , n, m and Z are as defined in formula (AB). In one embodiment, R s , n, m and Z are as defined in formula (AB'). In one embodiment, R s , n, m and Z are as defined in formula (B). In one embodiment, R s , n, m, and Z are as defined in formula (B'). R described for formula (I-AB), (AB), (AB'), (B), or (B') s It is understood that the embodiments of n, m, and Z may be applied to formula (IB-13) in some embodiments, where applicable.
[0280] In some embodiments, the compound of formula (IB-14): TIFF2024541508000142.tif43170 (IB-14), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In one embodiment, R of formula (IB-14) s , R a , R b , and R c is as defined in formula (I-AB). In one embodiment, R in formula (IB-14) s , R a , R b , and R c is as defined in formula (AB). In one embodiment, R in formula (IB-14) s , R a , R b , and R c is as defined in formula (AB'). In one embodiment, R in formula (IB-14) s , R a , R b , and R c is as defined in formula (B). In one embodiment, R in formula (IB-14) s, R a , R b , and R c is as defined in formula (B'). R described for formula (I-AB), (AB), (AB'), (B) or (B') s , R a , R b , and R c It is understood that the embodiments of may be applied to formula (IB-14) in some embodiments, where applicable.
[0281] In some embodiments, the compound of formula (IB-15) below: TIFF2024541508000143.tif39170 (IB-15), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In one embodiment, R of formula (IB-15) s , n, m, B, and Z are as defined in formula (I-AB). In one embodiment, R s , n, m, B, and Z are as defined in formula (AB). In one embodiment, R s , n, m, B, and Z are as defined in formula (AB'). In one embodiment, R of formula (IB-15) s , n, m, B, and Z are as defined in formula (B). In one embodiment, R of formula (IB-15) s , n, m, B, and Z are as defined in formula (B'). R described for formula (I-AB), (AB), (AB'), (B), or (B') s It is understood that the embodiments of n, m, B, and Z may be applied to formula (IB-15) in some embodiments, where applicable.
[0282] In some embodiments, the compound of formula (IB-16): TIFF2024541508000144.tif43170 (IB-16), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In one aspect, B, n, m, and Z of formula (IB-16) are as defined in formula (I-AB). In one aspect, B, n, m, and Z of formula (IB-16) are as defined in formula (AB). In one aspect, B, n, m, and Z of formula (IB-16) are as defined in formula (B). In one aspect, B, n, m, and Z of formula (IB-16) are as defined in formula (B'). It is understood that embodiments of B, n, m, and Z described for formula (I-AB), (AB), (B), or (B') may be applied to formula (IB-16) in some embodiments, where applicable.
[0283] In some embodiments, the compound of formula (IB-17): TIFF2024541508000145.tif44170 (IB-17), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In one aspect, B, n, m, and Z of formula (IB-17) are as defined in formula (I-AB). In one aspect, B, n, m, and Z of formula (IB-17) are as defined in formula (AB). In one aspect, B, n, m, and Z of formula (IB-17) are as defined in formula (B). In one aspect, B, n, m, and Z of formula (IB-17) are as defined in formula (B'). It is understood that embodiments of B, n, m, and Z described for formula (I-AB), (AB), (B), or (B') may be applied to formula (IB-17) in some embodiments, where applicable.
[0284] In some embodiments, the compound of formula (IB-18) below: TIFF2024541508000146.tif44170 (IB-18), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In one embodiment, B, n, m, R of formula (IB-18) d , R eand Z are as defined in formula (I-AB). In one embodiment, B, n, m, R of formula (IB-18) d , R e and Z are as defined in formula (AB). In one embodiment, B, n, m, R of formula (IB-18) d , R e and Z are as defined in formula (B). In one embodiment, B, n, m, R of formula (IB-18) d , R e , and Z are as defined in formula (B'). B, n, m, R as described for formula (I-AB), (AB), (B), or (B') d , R e It is understood that the embodiments of, and Z, may be applied to formula (IB-18) in some embodiments, where applicable.
[0285] In some embodiments, the compound of formula (IB-19) below: TIFF2024541508000147.tif42170 (IB-19), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In one embodiment, B, n, m, and Z of formula (IB-19) are as defined in formula (I-AB). In one embodiment, B, n, m, and Z of formula (IB-19) are as defined in formula (AB). In one embodiment, B, n, m, and Z of formula (IB-19) are as defined in formula (B). In one embodiment, B, n, m, and Z of formula (IB-19) are as defined in formula (B'). B, n, m, R as described for formula (I-AB), (AB), (B), or (B') may be used. d , R e It is understood that the embodiments of, and Z, may be applied to formula (IB-19) in some embodiments, where applicable.
[0286] Certain TEAD inhibitors described herein inhibit cardiac sodium channels (e.g., NaV 1.5In some embodiments, the antibody may exhibit reduced off-target inhibition, such as inhibition of NaV 1.5 Inhibition is measured by the assays described herein, for example, the assays described in one or more of the Examples.
[0287] In some aspects, the compound of formula (I-AB), (AB), (AB'), (A), (B), (A'), (B'), (IA) or (IB) or any variation or embodiment thereof is selected from the compounds listed in Table 1 below, including racemic mixtures and resolved isomers, as appropriate. [Table 1] TIFF2024541508000149.tif230170TIFF2024541508000150.tif213170TIFF2024541508000151.tif231170TIFF2024541508000152.tif236170TIFF2024541508000153.tif238170TIFF2024541508000154.tif217170TIFF2024541508000155.tif235170TIFF2024541508000156.tif243170TIFF2024541508000157.tif255170TIFF2024541508000158.tif243170TIFF2024541508000159.tif241170TIFF2024541508000160.tif233170TIFF2024541508000161.tif241170TIFF2024541508000162.tif250170TIFF2024541508000163.tif230170TIFF2024541508000164.tif236170TIFF2024541508000165.tif239170TIFF2024541508000166.tif232170TIFF2024541508000167.tif233170TIFF2024541508000168.tif242170TIFF2024541508000169.tif244170TIFF2024541508000170.tif235170TIFF2024541508000171.tif235170TIFF2024541508000172.tif229170TIFF2024541508000173.tif226170TIFF2024541508000174.tif246170TIFF2024541508000175.tif223170TIFF2024541508000176.tif246170TIFF2024541508000177.tif196170TIFF2024541508000178.tif248170TIFF2024541508000179.tif199170TIFF2024541508000180.tif202170TIFF2024541508000181.tif248170TIFF2024541508000182.tif232170TIFF2024541508000183.tif218170TIFF2024541 508000184.tif229170TIFF2024541508000185.tif208170TIFF2024541508000186.tif187170.
[0288] As used herein: N-((1-(4-(trifluoromethoxy)phenyl)-1H-indazol-3-yl)methyl)acrylamide, 2-chloro-N-((1-(4-(trifluoromethoxy)phenyl)-1H-indazol-3-yl)methyl)acetamide, N-((1-(4-(pentafluoro-λ6-sulfanyl)phenyl)-1H-indazol-3-yl)methyl)acrylamide, N-((4-(hydroxymethyl)-1-(4-(trifluoromethoxy)phenyl)-1H-indazol-3-yl)methyl)acrylamide, N-((4-(hydroxymethyl)-1-(4-(pentafluoro-λ6-sulfanyl)phenyl)-1H-indazol-3-yl)methyl)acrylamide, N-((4-(1,2-dihydroxyethyl)-1-(4-(trifluoromethoxy)phenyl)-1H-indazol-3-yl)methyl)acrylamide, (R)—N-((4-(1,2-dihydroxyethyl)-1-(4-(trifluoromethoxy)phenyl)-1H-indazol-3-yl)methyl)acrylamide, (S)—N-((4-(1,2-dihydroxyethyl)-1-(4-(trifluoromethoxy)phenyl)-1H-indazol-3-yl)methyl)acrylamide, N-((4-(1,2-dihydroxyethyl)-1-(4-(pentafluoro-λ6-sulfanyl)phenyl)-1H-indazol-3-yl)methyl)acrylamide, (R)—N-((4-(1,2-dihydroxyethyl)-1-(4-(pentafluoro-λ6-sulfanyl)phenyl)-1H-indazol-3-yl)methyl)acrylamide, (S)—N-((4-(1,2-dihydroxyethyl)-1-(4-(pentafluoro-λ6-sulfanyl)phenyl)-1H-indazol-3-yl)methyl)acrylamide, N-((1-(4-(pentafluoro-λ6-sulfanyl)phenyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)methyl)acrylamide, N-((1-(4-(pentafluoro-λ6-sulfanyl)phenyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)methyl)acrylamide, N-((4-cyano-1-(4-(pentafluoro-λ6-sulfanyl)phenyl)-1H-indazol-3-yl)methyl)acrylamide, N-[[4-(1,2-dihydroxyethyl)-1-(4-(trifluoromethoxy)phenyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]methyl]acrylamide, (R)—N-[[4-(1,2-dihydroxyethyl)-1-(4-(trifluoromethoxy)phenyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]methyl]acrylamide, (S)—N-[[4-(1,2-dihydroxyethyl)-1-(4-(trifluoromethoxy)phenyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]methyl]acrylamide, N-methyl-N-((1-(4-(trifluoromethoxy)phenyl)-1H-indazol-3-yl)methyl)acrylamide, and 2-chloro-N-methyl-N-((1-(4-(trifluoromethoxy)phenyl)-1H-indazol-3-yl)methyl)acetamide, or a pharmaceutically acceptable salt thereof. Also provided herein are any and all stereoisomers of the compounds presented herein, including, where applicable, their geometric isomers (e.g., cis / trans or E / Z isomers), enantiomers, diastereomers, tautomers, or mixtures in any ratio, including racemic mixtures.
[0289] As used herein: N-((1-(4-(trifluoromethoxy)phenyl)-1H-indazol-3-yl)methyl)acrylamide; 2-chloro-N-((1-(4-(trifluoromethoxy)phenyl)-1H-indazol-3-yl)methyl)acetamide; N-((1-(4-(pentafluoro-λ6-sulfanyl)phenyl)-1H-indazol-3-yl)methyl)acrylamide; N-((4-(hydroxymethyl)-1-(4-(trifluoromethoxy)phenyl)-1H-indazol-3-yl)methyl)acrylamide; N-((4-(hydroxymethyl)-1-(4-(pentafluoro-λ6-sulfanyl)phenyl)-1H-indazol-3-yl)methyl)acrylamide; N-((4-(1,2-dihydroxyethyl)-1-(4-(trifluoromethoxy)phenyl)-1H-indazol-3-yl)methyl)acrylamide; (R)-N-((4-(1,2-dihydroxyethyl)-1-(4-(trifluoromethoxy)phenyl)-1H-indazol-3-yl)methyl)acrylamide; (S)—N-((4-(1,2-dihydroxyethyl)-1-(4-(trifluoromethoxy)phenyl)-1H-indazol-3-yl)methyl)acrylamide; N-((4-(1,2-dihydroxyethyl)-1-(4-(pentafluoro-λ6-sulfanyl)phenyl)-1H-indazol-3-yl)methyl)acrylamide; (R)-N-((4-(1,2-dihydroxyethyl)-1-(4-(pentafluoro-λ6-sulfanyl)phenyl)-1H-indazol-3-yl)methyl)acrylamide; (S)—N-((4-(1,2-dihydroxyethyl)-1-(4-(pentafluoro-λ6-sulfanyl)phenyl)-1H-indazol-3-yl)methyl)acrylamide; N-((1-(4-(pentafluoro-λ6-sulfanyl)phenyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)methyl)acrylamide; N-((1-(4-(pentafluoro-λ6-sulfanyl)phenyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)methyl)acrylamide; N-((4-cyano-1-(4-(pentafluoro-λ6-sulfanyl)phenyl)-1H-indazol-3-yl)methyl)acrylamide; N-[[4-(1,2-dihydroxyethyl)-1-(4-(trifluoromethoxy)phenyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]methyl]acrylamide; (R)-N-[[4-(1,2-dihydroxyethyl)-1-(4-(trifluoromethoxy)phenyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]methyl]acrylamide; (S)-N-[[4-(1,2-dihydroxyethyl)-1-(4-(trifluoromethoxy)phenyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]methyl]acrylamide; N-methyl-N-((1-(4-(trifluoromethoxy)phenyl)-1H-indazol-3-yl)methyl)acrylamide; 2-chloro-N-methyl-N-((1-(4-(trifluoromethoxy)phenyl)-1H-indazol-3-yl)methyl)acetamide; 2-Fluoro-1-[3-[4-(hydroxymethyl)-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]azetidin-1-yl]prop-2-en-1-one; 1-[3-[4-[(1R)-1,2-dihydroxyethyl]-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]azetidin-1-yl]-2-fluoro-prop-2-en-1-one; 1-[3-[4-(hydroxymethyl)-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]azetidin-1-yl]-2-methyl-prop-2-en-1-one; N-[[1-[4-(pentafluoro-lambda-6-sulfanyl)phenyl]-4-[rac-(1S)-1,2-dihydroxyethyl]pyrazolo[3,4-b]pyridin-3-yl]methyl]prop-2-enamide; N-[[4-[(2-hydroxyacetyl)amino]-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]methyl]prop-2-enamide; N-(2-hydroxyethyl)-3-[(prop-2-enoylamino)methyl]-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridine-4-carboxamide; (Z)-3-chloro-N-[[4-[(1R)-1,2-dihydroxyethyl]-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]methyl]prop-2-enamide; N-[[1-[4-(pentafluoro-lambda 6-sulfanyl)phenyl]-4-[rac-(1R)-1,2-dihydroxyethyl]pyrazolo[3,4-b]pyridin-3-yl]methyl]prop-2-enamide; 2-Fluoro-1-[3-[4-[1-(2-hydroxyethyl)pyrazol-4-yl]-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]azetidin-1-yl]prop-2-en-1-one; 2-Fluoro-1-[3-[4-(1,2,4-triazol-4-yl)-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]azetidin-1-yl]prop-2-en-1-one; N-methyl-3-[(prop-2-enoylamino)methyl]-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridine-4-carboxamide; 1-[3-[4-[(1S)-1,2-dihydroxyethyl]-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]azetidin-1-yl]-2-fluoro-prop-2-en-1-one; N-[[4-(hydroxymethyl)-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]methyl]prop-2-enamide; N-[[4-[(3S)-3-hydroxy-1-piperidyl]-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]methyl]prop-2-enamide; N-[[4-(3-hydroxycyclobutoxy)-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]methyl]prop-2-enamide; N-[[4-[1-(2-hydroxyethyl)pyrazol-4-yl]-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]methyl]prop-2-enamide; N-[[4-(2-hydroxyethylamino)-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]methyl]prop-2-enamide; (E)-3-chloro-N-[[4-(hydroxymethyl)-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]methyl]prop-2-enamide; N-[[4-(3-hydroxycyclobutyl)-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]methyl]prop-2-enamide; 2-Fluoro-1-[3-[4-[3-fluoro-3-(hydroxymethyl)azetidin-1-yl]-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]azetidin-1-yl]prop-2-en-1-one; (E)-1-[3-[4-(hydroxymethyl)-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]azetidin-1-yl]-4-methoxy-but-2-en-1-one; 1-[3-[4-(2,6-diazaspiro[3.3]heptan-2-yl)-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]azetidin-1-yl]-2-fluoro-prop-2-en-1-one; N-[3-[1-(2-fluoroprop-2-enoyl)azetidin-3-yl]-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-4-yl]-2-hydroxy-acetamide; N-[[4-[3-(hydroxymethyl)azetidin-1-yl]-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]methyl]prop-2-enamide; N-[[4-(1H-1,2,4-triazol-3-yl)-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]methyl]prop-2-enamide; 1-[3-[4-[1-[2-(dimethylamino)ethyl]pyrazol-4-yl]-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]azetidin-1-yl]-2-fluoro-prop-2-en-1-one; N-[[4-[(3S)-3-hydroxypyrrolidin-1-yl]-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]methyl]prop-2-enamide; N-[[4-[(3R)-3-hydroxypyrrolidin-1-yl]-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]methyl]prop-2-enamide; 1-[3-[4-ethynyl-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]azetidin-1-yl]prop-2-en-1-one; 2-chloro-N-[[4-(hydroxymethyl)-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]methyl]prop-2-enamide; (E)-4-hydroxy-1-[3-[4-(1H-pyrazol-4-yl)-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]azetidin-1-yl]but-2-en-1-one; N-[[4-(1H-triazol-4-yl)-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]methyl]prop-2-enamide; N-[[4-(3-cyanoazetidin-1-yl)-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]methyl]prop-2-enamide; (Z)-3-chloro-N-[[4-[(1S)-1,2-dihydroxyethyl]-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]methyl]prop-2-enamide; N-[[4-[(3-hydroxyazetidin-1-yl)methyl]-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]methyl]prop-2-enamide; N-[[4-(hydroxymethyl)-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]methyl]-N-methyl-prop-2-enamide; N-[[4-(3-hydroxycyclobutyl)-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]methyl]prop-2-enamide; 3-Fluoro-1-[3-[1-(2-fluoroprop-2-enoyl)azetidin-3-yl]-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-4-yl]azetidine-3-carboxamide; 1-[3-[4-[3-[(1R)-1,2-dihydroxyethyl]azetidin-1-yl]-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]azetidin-1-yl]-2-fluoro-prop-2-en-1-one; 1-[3-[4-[(1S)-1,2-dihydroxyethyl]-1-[4-(pentafluoro-lambda 6-sulfanyl)phenyl]pyrazolo[3,4-b]pyridin-3-yl]azetidin-1-yl]-2-fluoro-prop-2-en-1-one; 1-[3-[4-[(1R)-1,2-dihydroxyethyl]-1-[4-(pentafluoro-lambda 6-sulfanyl)phenyl]pyrazolo[3,4-b]pyridin-3-yl]azetidin-1-yl]-2-fluoro-prop-2-en-1-one; (E)-N-[[4-(hydroxymethyl)-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]methyl]but-2-enamide; N-[[4-[(1R)-1-hydroxyethyl]-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]methyl]prop-2-enamide; N-[[4-[(1S)-1-hydroxyethyl]-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]methyl]prop-2-enamide; 2-Fluoro-1-[3-[4-imidazol-1-yl-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]azetidin-1-yl]prop-2-en-1-one; N-[[4-[(3R)-3-hydroxy-1-piperidyl]-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]methyl]prop-2-enamide; (E,4R)-4-hydroxy-1-[3-[4-(hydroxymethyl)-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]azetidin-1-yl]pent-2-en-1-one; N-[[4-(3-hydroxycyclobutoxy)-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]methyl]prop-2-enamide; 2-Fluoro-N-[[4-(hydroxymethyl)-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]methyl]prop-2-enamide; (E)-4,4-difluoro-N-[[4-(hydroxymethyl)-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]methyl]but-2-enamide; (E)-4-hydroxy-1-[3-[4-(3-hydroxyazetidin-1-yl)-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]azetidin-1-yl]but-2-en-1-one; 1-[3-[4-[(1R)-1,2-dihydroxyethyl]-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]azetidin-1-yl]but-2-yn-1-one; Cyclobuten-1-yl-[3-[4-[(1S)-1,2-dihydroxyethyl]-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]azetidin-1-yl]methanone; N-[[4-[rac-(1S)-1,2-dihydroxyethyl]-1-[3-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]methyl]prop-2-enamide; N-[[4-(3-hydroxy-3-methyl-azetidin-1-yl)-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]methyl]prop-2-enamide; 2-Fluoro-1-[3-[4-[3-hydroxy-3-(hydroxymethyl)azetidin-1-yl]-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]azetidin-1-yl]prop-2-en-1-one; N-[[4-(6-hydroxy-2-azaspiro[3.3]heptan-2-yl)-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]methyl]prop-2-enamide; N-[[4-morpholino-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]methyl]prop-2-enamide; 2-Fluoro-1-[3-[4-(3-hydroxyazetidin-1-yl)-1-[4-(trifluoromethoxy)phenyl]pyrazolo[4,3-c]pyridin-3-yl]azetidin-1-yl]prop-2-en-1-one; 3-[1-[(E)-4-hydroxybut-2-enoyl]azetidin-3-yl]-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridine-4-carbonitrile; 3-[1-(2-fluoroprop-2-enoyl)azetidin-3-yl]-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridine-4-carbonitrile; 2-Fluoro-1-[3-[4-(3-hydroxyazetidin-1-yl)-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]azetidin-1-yl]prop-2-en-1-one; (3S)-1-[3-[1-(2-fluoroprop-2-enoyl)azetidin-3-yl]-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-4-yl]-3-hydroxy-pyrrolidin-2-one; N-[[4-(1H-pyrazol-3-yl)-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]methyl]prop-2-enamide N-[[4-(3-fluoroazetidin-1-yl)-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]methyl]prop-2-enamide; N-[[4-[(3-hydroxycyclobutyl)amino]-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]methyl]prop-2-enamide; N-[[4-(hydroxymethyl)-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]methyl]prop-2-ynamide; N-[[4-(hydroxymethyl)-1-[4-(pentafluoro-lambda 6-sulfanyl)phenyl]pyrazolo[3,4-b]pyridin-3-yl]methyl]prop-2-enamide; N-[[4-[rac-(1R)-1,2-dihydroxyethyl]-1-[4-(trifluoromethyl)phenyl]pyrazolo[3,4-b]pyridin-3-yl]methyl]prop-2-enamide; Cyclobuten-1-yl-[3-[4-(hydroxymethyl)-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]azetidin-1-yl]methanone; N-[[4-[(3-hydroxycyclobutyl)-methyl-amino]-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]methyl]prop-2-enamide; N-[[4-(4-hydroxy-1-piperidyl)-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]methyl]prop-2-enamide; N-[[4-(3-aminoazetidin-1-yl)-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]methyl]prop-2-enamide; N-[[4-[(1R)-1,2-dihydroxyethyl]-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]methyl]-N-methyl-prop-2-enamide; (E)-4-hydroxy-1-[3-[4-(hydroxymethyl)-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]azetidin-1-yl]but-2-en-1-one; (E)-1-[3-[4-[(1R)-1,2-dihydroxyethyl]-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]azetidin-1-yl]-4-hydroxy-but-2-en-1-one; (E)-4-hydroxy-1-[3-[4-methyl-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]azetidin-1-yl]but-2-en-1-one; (E,4S)-4-hydroxy-1-[3-[4-(hydroxymethyl)-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]azetidin-1-yl]pent-2-en-1-one; N-[[4-(hydroxymethyl)-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]methyl]but-2-ynamide; (Z)-3-chloro-N-[[4-(hydroxymethyl)-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]methyl]prop-2-enamide; N-[[4-[rac-(1S)-1,2-dihydroxyethyl]-1-[4-(trifluoromethyl)phenyl]pyrazolo[3,4-b]pyridin-3-yl]methyl]prop-2-enamide; N-[[4-[2-hydroxyethyl(methyl)amino]-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]methyl]prop-2-enamide; (E)-3-chloro-1-[3-[4-(hydroxymethyl)-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]azetidin-1-yl]prop-2-en-1-one; (E)-4-hydroxy-1-[3-[4-(3-hydroxyazetidin-1-yl)-1-[4-(trifluoromethoxy)phenyl]pyrazolo[4,3-c]pyridin-3-yl]azetidin-1-yl]but-2-en-1-one; 3-[(prop-2-enoylamino)methyl]-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridine-4-carboxamide; N-[[4-[(dimethylamino)methyl]-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]methyl]prop-2-enamide; N-[[4-(3-hydroxyazetidin-1-yl)-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]methyl]prop-2-enamide; N-[[4-[3-(dimethylamino)azetidin-1-yl]-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]methyl]prop-2-enamide; (E)-1-[3-[4-[(1S)-1,2-dihydroxyethyl]-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]azetidin-1-yl]-4-hydroxy-but-2-en-1-one; 2-chloro-1-[3-[4-[(1S)-1,2-dihydroxyethyl]-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]azetidin-1-yl]prop-2-en-1-one; 2-chloro-1-[3-[4-[(1R)-1,2-dihydroxyethyl]-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]azetidin-1-yl]prop-2-en-1-one; 2,3,3-trideuterio-N-[[4-(hydroxymethyl)-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]methyl]prop-2-enamide; 1-[3-[4-(hydroxymethyl)-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]azetidin-1-yl]prop-2-en-1-one; 1-[3-[4-[(1S)-1,2-dihydroxyethyl]-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]azetidin-1-yl]prop-2-en-1-one; 1-[3-[4-[(1R)-1,2-dihydroxyethyl]-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]azetidin-1-yl]prop-2-en-1-one; Cyclobuten-1-yl-[3-[4-[(1R)-1,2-dihydroxyethyl]-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]azetidin-1-yl]methanone; N-[[4-(3-acetamidoazetidin-1-yl)-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]methyl]prop-2-enamide; N-[[4-[(3-hydroxycyclobutyl)-methyl-amino]-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]methyl]prop-2-enamide; N-[[4-(3-methoxyazetidin-1-yl)-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]methyl]prop-2-enamide; N-[[4-(1H-imidazol-4-yl)-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]methyl]prop-2-enamide; (E)-1-[3-[4-(hydroxymethyl)-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]azetidin-1-yl]but-2-en-1-one; (E)-4-fluoro-N-[[4-(hydroxymethyl)-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]methyl]but-2-enamide; N-[[4-[3-(methylamino)azetidin-1-yl]-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]methyl]prop-2-enamide; N-[[4-[3-[(1R)-1-hydroxyethyl]azetidin-1-yl]-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]methyl]prop-2-enamide; N-[[4-[3-hydroxy-3-(hydroxymethyl)azetidin-1-yl]-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]methyl]prop-2-enamide; (3R)-1-[3-[1-(2-fluoroprop-2-enoyl)azetidin-3-yl]-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-4-yl]-3-hydroxy-pyrrolidin-2-one; N-[[4-(2-hydroxyethoxy)-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]methyl]prop-2-enamide; (E)-1-[3-[4-chloro-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]azetidin-1-yl]-4-hydroxy-but-2-en-1-one; 4-Hydroxy-N-[[4-(hydroxymethyl)-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]methyl]but-2-ynamide; 1-[3-[4-[(1S)-1,2-dihydroxyethyl]-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]azetidin-1-yl]but-2-yn-1-one; 2-Fluoro-1-[3-[4-(1H-imidazol-4-yl)-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]azetidin-1-yl]prop-2-en-1-one; N-[[4-[rac-(1R)-1,2-dihydroxyethyl]-1-[3-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]methyl]prop-2-enamide; (E)-4,4,4-trifluoro-N-[[4-(hydroxymethyl)-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]methyl]but-2-enamide; 1-[3-[4-(azetidin-3-yl)-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]azetidin-1-yl]-2-fluoro-prop-2-en-1-one; N-[[4-(1H-pyrazol-4-yl)-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]methyl]prop-2-enamide; N-[[4-(1-hydroxy-1-methyl-ethyl)-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]methyl]prop-2-enamide; N-[[4-[3-(1-hydroxy-1-methyl-ethyl)azetidin-1-yl]-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]methyl]prop-2-enamide; (E)-4-Fluoro-1-[3-[4-(3-hydroxyazetidin-1-yl)-1-[4-(trifluoromethoxy)phenyl]pyrazolo[4,3-c]pyridin-3-yl]azetidin-1-yl]but-2-en-1-one; N-[[4-[3-[(1S)-1-hydroxyethyl]azetidin-1-yl]-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]methyl]prop-2-enamide; N-[[4-[(1S)-1,2-dihydroxyethyl]-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]methyl]-N-methyl-prop-2-enamide; N-[[1-[4-(difluoromethoxy)phenyl]-4-(hydroxymethyl)pyrazolo[3,4-b]pyridin-3-yl]methyl]prop-2-enamide; 1-[3-[4-[3-[(1S)-1,2-dihydroxyethyl]azetidin-1-yl]-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]azetidin-1-yl]-2-fluoro-prop-2-en-1-one; 1-[3-[4-[3,3-bis(hydroxymethyl)azetidin-1-yl]-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]azetidin-1-yl]-2-fluoro-prop-2-en-1-one; N-[[4-[(3-hydroxycyclobutyl)amino]-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]methyl]prop-2-enamide; (S)—N-((4-(2-oxo-1,3-dioxolan-4-yl)-1-(4-(trifluoromethoxy)phenyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)methyl)acrylamide; (S)-2-(3-(acrylamidomethyl)-1-(4-(trifluoromethoxy)phenyl)-1H-pyrazolo[3,4-b]pyridin-4-yl)-2-hydroxyethyl 2-aminoacetate formate; (S)-2-(3-(acrylamidomethyl)-1-(4-(trifluoromethoxy)phenyl)-1H-pyrazolo[3,4-b]pyridin-4-yl)-2-hydroxyethyl acetate; (S)-2-(3-(acrylamidomethyl)-1-(4-(trifluoromethoxy)phenyl)-1H-pyrazolo[3,4-b]pyridin-4-yl)-2-hydroxyethyl dihydrogen phosphate; N-((4-(hydroxymethyl)-1-(4-(trifluoromethoxy)phenyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)methyl)cyclobut-1-enecarboxamide; N-((4-(hydroxymethyl)-1-(4-(trifluoromethoxy)phenyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)methyl)-2,5-dihydrofuran-3-carboxamide; Cyclopent-1-en-1-yl(3-(4-(hydroxymethyl)-1-(4-(trifluoromethoxy)phenyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)azetidin-1-yl)methanone; (E)-1-(3-(4-(hydroxymethyl)-1-(4-(trifluoromethoxy)phenyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)azetidin-1-yl)-2-methylbut-2-en-1-one; (2,5-Dihydrofuran-3-yl)(3-(4-(hydroxymethyl)-1-(4-(trifluoromethoxy)phenyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)azetidin-1-yl)methanone; Bicyclo[1.1.0]butan-1-yl(3-(4-(hydroxymethyl)-1-(4-(trifluoromethoxy)phenyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)azetidin-1-yl)methanone; (S)—N-((4-(1,2-dihydroxyethyl)-1-(4-(trifluoromethoxy)phenyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)methyl)acrylamide-2,3,3-d3; (S)—N-((4-(1,2-dihydroxyethyl)-1-(4-(trifluoromethoxy)phenyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)methyl)-2-fluoroacrylamide; (S)—N-((4-(1,2-dihydroxyethyl)-1-(4-(trifluoromethoxy)phenyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)methyl)cyclobut-1-enecarboxamide; (R)-Cyclobut-1-en-1-yl(3-(4-(1,2-dihydroxyethyl)-1-(4-(trifluoromethoxy)phenyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)azetidin-1-yl)methanone; 2-fluoro-1-(3-(4-(1-methyl-1H-pyrazol-4-yl)-1-(4-(trifluoromethoxy)phenyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)azetidin-1-yl)prop-2-en-1-one; (S)-1-(3-(1-(prop-1-en-2-ylsulfonyl)azetidin-3-yl)-1-(4-(trifluoromethoxy)phenyl)-1H-pyrazolo[3,4-b]pyridin-4-yl)ethane-1,2-diol; (R)-1-(3-(1-(prop-1-en-2-ylsulfonyl)azetidin-3-yl)-1-(4-(trifluoromethoxy)phenyl)-1H-pyrazolo[3,4-b]pyridin-4-yl)ethane-1,2-diol; (S,E)-1-(3-(1-(prop-1-en-1-ylsulfonyl)azetidin-3-yl)-1-(4-(trifluoromethoxy)phenyl)-1H-pyrazolo[3,4-b]pyridin-4-yl)ethane-1,2-diol; (R,E)-1-(3-(1-(prop-1-en-1-ylsulfonyl)azetidin-3-yl)-1-(4-(trifluoromethoxy)phenyl)-1H-pyrazolo[3,4-b]pyridin-4-yl)ethane-1,2-diol; Cyclobut-1-en-1-yl(3-(1-(4-(trifluoromethoxy)phenyl)-1H-pyrazolo[3,4-b]pyrazin-3-yl)azetidin-1-yl)methanone; N-((4-(1-methyl-1H-pyrazol-4-yl)-1-(4-(trifluoromethoxy)phenyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)methyl)acrylamide; N-((4-(1-(2-amino-2-oxoethyl)-1H-pyrazol-4-yl)-1-(4-(trifluoromethoxy)phenyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)methyl)acrylamide; N-((4-(1-(2-(dimethylamino)-2-oxoethyl)-1H-pyrazol-4-yl)-1-(4-(trifluoromethoxy)phenyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)methyl)acrylamide; N-((4-(1-(2-methoxyethyl)-1H-pyrazol-4-yl)-1-(4-(trifluoromethoxy)phenyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)methyl)acrylamide; N-((4-(1-(2-(methylsulfonyl)ethyl)-1H-pyrazol-4-yl)-1-(4-(trifluoromethoxy)phenyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)methyl)acrylamide; N-((4-(1-(difluoromethyl)-1H-pyrazol-4-yl)-1-(4-(trifluoromethoxy)phenyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)methyl)acrylamide; N-((4-(1-isopropyl-1H-pyrazol-4-yl)-1-(4-(trifluoromethoxy)phenyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)methyl)acrylamide; N-((4-(1-(oxetan-3-yl)-1H-pyrazol-4-yl)-1-(4-(trifluoromethoxy)phenyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)methyl)acrylamide; N-((4-(1-(2-(dimethylamino)ethyl)-1H-pyrazol-4-yl)-1-(4-(trifluoromethoxy)phenyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)methyl)acrylamide; N-((4-(1-cyclopropyl-1H-pyrazol-4-yl)-1-(4-(trifluoromethoxy)phenyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)methyl)acrylamide; 1-(3-(4-(1-(difluoromethyl)-1H-pyrazol-4-yl)-1-(4-(trifluoromethoxy)phenyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)azetidin-1-yl)-2-fluoroprop-2-en-1-one; 2-fluoro-1-(3-(4-(1-(oxetan-3-yl)-1H-pyrazol-4-yl)-1-(4-(trifluoromethoxy)phenyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)azetidin-1-yl)prop-2-en-1-one; 2-fluoro-1-(3-(4-(1-(2-methoxyethyl)-1H-pyrazol-4-yl)-1-(4-(trifluoromethoxy)phenyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)azetidin-1-yl)prop-2-en-1-one; 1-(3-(4-(1-cyclopropyl-1H-pyrazol-4-yl)-1-(4-(trifluoromethoxy)phenyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)azetidin-1-yl)-2-fluoroprop-2-en-1-one; 2-fluoro-1-(3-(4-(1-isopropyl-1H-pyrazol-4-yl)-1-(4-(trifluoromethoxy)phenyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)azetidin-1-yl)prop-2-en-1-one; 2-fluoro-1-(3-(4-(1-(2-(methylsulfonyl)ethyl)-1H-pyrazol-4-yl)-1-(4-(trifluoromethoxy)phenyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)azetidin-1-yl)prop-2-en-1-one; 2-(4-(3-(1-(2-fluoroacryloyl)azetidin-3-yl)-1-(4-(trifluoromethoxy)phenyl)-1H-pyrazolo[3,4-b]pyridin-4-yl)-1H-pyrazol-1-yl)-N,N-dimethylacetamide; 2-(4-(3-(1-(2-fluoroacryloyl)azetidin-3-yl)-1-(4-(trifluoromethoxy)phenyl)-1H-pyrazolo[3,4-b]pyridin-4-yl)-1H-pyrazol-1-yl)acetamide; 1-(3-(4-(1H-pyrazol-4-yl)-1-(4-(trifluoromethoxy)phenyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)azetidin-1-yl)-2-fluoroprop-2-en-1-one; 1-(3-(1-(2-chloro-4-(trifluoromethoxy)phenyl)-4-(hydroxymethyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)azetidin-1-yl)-2-fluoroprop-2-en-1-one; 2-fluoro-1-(3-(4-(hydroxymethyl)-1-(2-methyl-4-(trifluoromethoxy)phenyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)azetidin-1-yl)prop-2-en-1-one; 2-fluoro-1-(3-(1-(2-fluoro-4-(trifluoromethoxy)phenyl)-4-(hydroxymethyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)azetidin-1-yl)prop-2-en-1-one; N-((4-cyano-1-(4-(trifluoromethoxy)phenyl)-1H-indazol-3-yl)methyl)acrylamide; N-((1-(4-(trifluoromethoxy)phenyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)methyl)acrylamide; and N-((1-(4-(trifluoromethoxy)phenyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)methyl)acrylamide or a pharmaceutically acceptable salt thereof. Also provided herein are any and all stereoisomers of the compounds presented herein, including, where applicable, their geometric isomers (e.g., cis / trans or E / Z isomers), enantiomers, diastereomers, tautomers, or mixtures in any ratio, including racemic mixtures.
[0290] In one aspect, provided herein is any one of the compounds listed in Table 1, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof.
[0291] In one aspect, provided herein is a compound selected from the group consisting of: TIFF2024541508000187.tif240170
[0292] In some embodiments, provided herein are compounds of Formula (A) or (A'), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is N and X 4 is CH and R 1 is H and R t is S(R y )5 and R x is ethenyl and R y is fluoro.
[0293] In some embodiments, provided herein are compounds of Formula (A) or (A'), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is CH and X 4 is N and R 1 is H and R t is S(R y )5 and R x is ethenyl and R y is fluoro.
[0294] In some embodiments, provided herein are compounds of Formula (A) or (A'), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is CR s and X 4 is N and R 1 is H and R s is CN and R t is S(R y )5 and R x is ethenyl and R y is fluoro.
[0295] In some embodiments, provided herein are compounds of Formula (A) or (A'), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is CR s and X 4 is N and R 1 is H and R s is ethyl substituted with two -OH, and R t is methoxy substituted with three fluoro groups, and R x is ethenyl.
[0296] In some embodiments, provided herein are compounds of Formula (A) or (A'), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is CH and X 4 is CH and R 1 is H and R t is methoxy substituted with three fluoro groups, and R x is ethenyl.
[0297] In some embodiments, provided herein are compounds of Formula (A) or (A'), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is CH and X 4 is CH and R 1 is H and R t is methoxy substituted with three fluoro groups, and R x is ethanyl substituted with one chloro.
[0298] In some embodiments, provided herein are compounds of Formula (A) or (A'), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is CH and X 4 is CH and R 1 is H and R t is S(R y )5 and R x is ethenyl and R y is fluoro.
[0299] In some embodiments, provided herein are compounds of Formula (A) or (A'), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is CR s and X 4 is CH and R 1 is H and R s is methyl substituted with one -OH, and R t is methoxy substituted with three fluoro groups, and R x is ethenyl.
[0300] In some embodiments, provided herein are compounds of Formula (A) or (A'), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is CR s and X 4 is CH and R 1 is H and R s is methyl substituted with one -OH, and R t is S(R y )5 and R x is ethenyl and R y is fluoro.
[0301] In some embodiments, provided herein are compounds of Formula (A) or (A'), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is CR s and X 4 is CH and R 1 is H and R s is ethyl substituted by two -OH, and R t is methoxy substituted with three fluoro groups, and R x is ethenyl.
[0302] In some embodiments, provided herein are compounds of Formula (A) or (A'), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is CRs and X 4 is CH and R 1 is H and R s is ethyl substituted with two -OH, and R t is S(R y )5 and R x is ethenyl and R y is fluoro.
[0303] In some embodiments, provided herein are compounds of Formula (A) or (A'), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is CH and X 4 is CH and R t is methoxy substituted with three fluoro groups, and R x is ethenyl and R 1 is methyl.
[0304] In some embodiments, provided herein are compounds of Formula (A) or (A'), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is CH and X 4 is CH and R t is methoxy substituted with three fluoro groups, and R x is ethanyl substituted with one chloro, and R 1 is methyl.
[0305] In some embodiments, provided herein are compounds of formula (AB), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is N and X 4 is CH and R 1 is H and R t is S(R y )5 and R x is ethenyl and R y is fluoro.
[0306] In some embodiments, provided herein are compounds of formula (AB), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is N and X 4 is CH and R 1 is H and R t is S(R y )5 and R x is ethenyl and R y is fluoro.
[0307] In some embodiments, provided herein are compounds of formula (AB), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is CR s and X 4 is N and R 1 is H and R s is CN and R t is S(R y )5 and R x is ethenyl and R y is fluoro.
[0308] In some embodiments, provided herein are compounds of formula (AB), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is CR s and X 4 is N and R 1 is H and R s is ethyl substituted with two -OH, and R t is methoxy substituted with three fluoro groups, and R x is ethenyl.
[0309] In some embodiments, provided herein are compounds of formula (AB), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is CH and X 4 is CH and R 1 is H and R t is methoxy substituted with three fluoro groups, and R xis ethenyl.
[0310] In some embodiments, provided herein are compounds of formula (AB), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is CH and X 4 is CH and R 1 is H and R t is methoxy substituted with three fluoro groups, and R x is ethanyl substituted with one chloro.
[0311] In some embodiments, R x is methyl substituted with one chloro.
[0312] In some embodiments, provided herein are compounds of formula (AB), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is CH and X 4 is CH and R 1 is H and R t is S(R y )5 and R x is ethenyl and R y is fluoro.
[0313] In some embodiments, provided herein are compounds of formula (AB), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is CR s and X 4 is CH and R 1 is H and R s is methyl substituted with one -OH, and R t is methoxy substituted with three fluoro groups, and R x is ethenyl.
[0314] In some embodiments, provided herein are compounds of formula (AB), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is CRs and X 4 is CH and R 1 is H and R s is methyl substituted with one -OH, and R t is S(R y )5 and R x is ethenyl and R y is fluoro.
[0315] In some embodiments, provided herein are compounds of formula (AB), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is CR s and X 4 is CH and R 1 is H and R s is ethyl substituted with two -OH groups, and R t is methoxy substituted with three fluoro groups, and R x is ethenyl.
[0316] In some embodiments, provided herein are compounds of formula (AB), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is CR s and X 4 is CH and R 1 is H and R s is ethyl substituted with two -OH groups, and R t is S(R y )5 and R x is ethenyl and R y is fluoro.
[0317] In some embodiments, provided herein are compounds of formula (AB), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is CH and X 4 is CH and R t is methoxy substituted with three fluoro groups, and R x is ethenyl and R 1 is methyl.
[0318] In some embodiments, provided herein are compounds of formula (AB), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is CH and X 4 is CH and R t is methoxy substituted with three fluoro groups, and R x is ethanyl substituted with one chloro, and R 1 is methyl.
[0319] In some embodiments, provided herein are compounds of formula (I-AB), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is N and X 4 is CH and R 1 is H and R t is S(R y )5 and R x is ethenyl and R y is fluoro.
[0320] In some embodiments, provided herein are compounds of formula (I-AB), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is N and X 4 is CH and R 1 is H and R t is S(R y )5 and R x is ethenyl and R y is fluoro.
[0321] In some embodiments, provided herein are compounds of formula (I-AB), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is CR s and X 4 is N and R 1 is H and R s is CN and R t is S(R y )5 and R xis ethenyl and R y is fluoro.
[0322] In some embodiments, provided herein are compounds of formula (I-AB), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is CR s and X 4 is N and R 1 is H and R s is ethyl substituted with two -OH, and R t is methoxy substituted with three fluoro groups, and R x is ethenyl.
[0323] In some embodiments, provided herein are compounds of formula (I-AB), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is CH and X 4 is CH and R 1 is H and R t is methoxy substituted with three fluoro groups, and R x is ethenyl.
[0324] In some embodiments, provided herein are compounds of formula (I-AB), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is CH and X 4 is CH and R 1 is H and R t is methoxy substituted with three fluoro groups, and R x is a methyl substituted with one chloro.
[0325] In some embodiments, provided herein are compounds of formula (I-AB), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is CH and X 4 is CH and R 1 is H and R t is S(R y )5 and Rx is ethenyl and R y is fluoro.
[0326] In some embodiments, provided herein are compounds of formula (I-AB), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is CR s and X 4 is CH and R 1 is H and R s is methyl substituted with one -OH, and R t is methoxy substituted with three fluoro groups, and R x is ethenyl.
[0327] In some embodiments, provided herein are compounds of formula (I-AB), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is CR s and X 4 is CH and R 1 is H and R s is methyl substituted with one -OH, and R t is S(R y )5 and R x is ethenyl and R y is fluoro.
[0328] In some embodiments, provided herein are compounds of formula (I-AB), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is CR s and X 4 is CH and R 1 is H and R s is ethyl substituted with two -OH groups, and R t is methoxy substituted with three fluoro groups, and R x is ethenyl.
[0329] In some embodiments, provided herein are compounds of formula (I-AB), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is CR s and X 4 is CH and R 1 is H and R s is ethyl substituted with two -OH groups, and R t is S(R y )5 and R x is ethenyl and R y is fluoro.
[0330] In some embodiments, provided herein are compounds of formula (I-AB), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is CH and X 4 is CH and R t is methoxy substituted with three fluoro groups, and R x is ethenyl and R 1 is methyl.
[0331] In some embodiments, provided herein are compounds of formula (I-AB), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is CH and X 4 is CH and R t is methoxy substituted with three fluoro groups, and R x is ethanyl substituted with one chloro, and R 1 is methyl.
[0332] In some embodiments, compounds of the present disclosure are isotopically labeled by having one or more atoms therein replaced by an atom having a different atomic mass or mass number. Such isotopically labeled (i.e., radiolabeled) compounds of formula (A), (B), (A'), (B'), (IA), or (IB) are considered to be within the scope of the present disclosure. Examples of isotopes that can be incorporated into compounds of formula (A), (B), (A'), (B'), (IA), or (IB) include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine, and iodine, respectively, e.g., 2 H, 3 H, 11 C. 13 C. 14 C. 13 N, 15 N, 15 O. 17 O. 18 O. 31 P, 32 P, 35 S, 18 F, 36 Cl, 123 I, and 125 I. These isotopically labeled compounds may be useful, for example, to characterize the site or mode of action, or binding affinity, for TEAD, thereby aiding in the determination or measurement of compound efficacy. Certain isotopically labeled compounds of formula (A), (B), (A'), (B'), (IA), or (IB), for example, those incorporating a radioactive isotope, are useful in drug and / or substrate tissue distribution studies. The radioactive isotope tritium, i.e., 3 H and carbon-14, i.e., 14 C are particularly useful for this purpose given their ease of incorporation and ready means of detection. For example, compounds of formula (A), (B), (A'), (B'), (IA), or (IB) can be enriched with 1, 2, 5, 10, 25, 50, 75, 90, 95, or 99% of a given isotope.
[0333] In some embodiments, any of the methods by which a compound of Formula (A) or Formula (B) may be isotopically labeled, and any of the methods by which an isotopically labeled compound of Formula (A) or Formula (B) may be used (e.g., as described in the previous paragraph), also apply to a compound of Formula (AB).
[0334] In some embodiments, any of the methods by which a compound of Formula (A) or Formula (B) may be isotopically labeled, and any of the methods by which an isotopically labeled compound of Formula (A) or Formula (B) may be used (e.g., as described in the previous paragraph), also apply to a compound of Formula (I-AB).
[0335] Heavier isotopes, such as deuterium, i.e. 2 Substitutions such as H may result in greater metabolic stability and may confer certain therapeutic advantages, for example, by increasing in vivo half-life or requiring lower dosages.
[0336] 11 C. 18 F, 15 O and 13 Substitution with positron emitting isotopes, such as N, can be useful in positron emission tomography (PET) studies for examining substrate receptor occupancy. Isotopically labeled compounds of formula (A), (B), (A'), (B'), (IA), or (IB) can generally be prepared by conventional techniques known to those skilled in the art, or by methods analogous to those described in the Examples set forth below, substituting the appropriate isotopically labeled reagent for the previously employed non-isotopically labeled reagent.
[0337] In some embodiments, any of the methods by which a compound of Formula (A) or Formula (B) can be isotopically labeled and any of the methods by which an isotopically labeled compound of Formula (A) or Formula (B) can be used (e.g., as described in the previous paragraph) also apply to a compound of Formula (AB).
[0338] In some embodiments, any of the methods by which a compound of Formula (A) or Formula (B) may be isotopically labeled, and any of the methods by which an isotopically labeled compound of Formula (A) or Formula (B) may be used (e.g., as described in the previous paragraph), also apply to a compound of Formula (I-AB).
[0339] Also provided herein are pharmaceutically acceptable salts or esters of any of the compounds provided herein, as well as stereoisomers, geometric isomers, tautomers, solvates, metabolites, isotopes, or prodrugs of such compounds, or pharmaceutically acceptable salts of such compounds.
[0340] Preparation method In one aspect, the present disclosure relates to methods of preparing one or more of the TEAD inhibitors described herein. In some embodiments, the methods of preparing the TEAD inhibitors are described herein in one or more Examples.
[0341] In one embodiment, a compound of formula (I-AB): Provided herein is a method for preparing a compound of formula (S1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt thereof, the method comprising: The compound of formula (S2) TIFF2024541508000190.tif27170 to form a compound of formula (S3) providing a compound of formula TIFF2024541508000191.tif38170, wherein: L' is * -N(R 1 )-L- ** and TIFF2024541508000192.tif16170; * indicates the point of attachment to Z, ** teeth, This shows the connection point with TIFF2024541508000193.tif33170. R 1 is H or C 1~6 is alkyl, X 1 is N or CR s and R s H, deuterium, -CN, halo, C 1~15 Alkyl, C 1~6 Alkynyl, C 6~20 Aryl, 5-15 membered heteroaryl, C 3~20 Cycloalkyl, 3- to 15-membered heterocyclyl, -OH, -OR f , C 1~15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , and -NR d R e is selected from R d , R e and R f each independently represents H, C 1~6 Alkyl or C 3~20 is cycloalkyl, C 1~6 Alkyl and C 3~20 each cycloalkyl independently may be optionally substituted with one or more halo, oxo, —OH, or —CN; R s C 1~15 Alkyl and C 1~15 Each alkoxy is independently one or more R t1 and R t1 -O-, -OH-, -OR ... f1 , -CN, -NR d R e and 3- to 15-membered heterocyclyl optionally substituted with one or more —OH; R f1 is -C(O)CHNR d R e , -C(O)C 1~6alkyl, -P(O)(OH)2, and R d and R e are each independently H or C 1~6 alkyl, and R d or R e C 1~6 the alkyl is optionally substituted with one or more halo, oxo, —OH, or —CN; R s C 6~20 Aryl, 5-15 membered heteroaryl, C 3~20 Cycloalkyl and 3- to 15-membered heterocyclyl each independently represent one or more R t2 and R t2 represents, at each occurrence, halo, oxo, -OH, -CN, C(O)NH2, -C(O)NR d R e , -NR d R e , C 1~6 Alkoxyl, 3-6 membered heterocyclyl, C 3~6 Cycloalkyl, and C 1~6 alkyl; R t2 C 1~6 Alkyl is a group consisting of one or more -OH, C 1~6 Alkoxyl, halo, oxo, -S(O)2CH3, or -NR d R e and R d and R e are each independently H, -C(O)CH3, or -C(O)C 1~6 Alkyl or C 1~6 is alkyl, X 2 and X 3 are CH, respectively, X 4 are independently N, CH, or CD, provided that 1) X 1 , X 2 , X 3 , and X 4 1) Only one of the two is N, or 2) X 1 is N and X 2 is CH and X 3 is CH and X4 is N or 3) X 1 is CR s and X 2 , X 3 , and X 4 are each independently CH or CD; B is TIFF2024541508000194.tif23170, R t Ha, Halo, C 1~15 Alkyl, C 1~6 Alkoxy and S(R y )5 independently selected from y is the halo and R t C 1~15 Alkyl or C 1~6 The alkoxy may be optionally substituted with one or more halo; Z is -C(O)R x and R x is C 1~6 Alkyl, Deuterium, -OH, C 1~6 C optionally substituted with one or more substituents selected from alkoxyl and halo 2~6 alkenyl, or R x C optionally substituted with one or more halo 1~6 alkyl or R x C optionally substituted with -OH 1~6 alkynyl or R x is cyclobutenyl, dihydrofuranyl, bicyclobutanyl or cyclopentenyl, or Z is S(O)2R x1 and R x1 is C 2~6 is alkenyl, L is one or more C 1~6 methylene optionally substituted with alkyl; n and m are each 1 or n and m are each 2; X A is N or CR L and Each R Lis independently selected from halo.
[0342] In one embodiment, a compound of formula (I-AB): Provided herein is a method for preparing a compound of formula (S4): The compound of formula (S5) was reacted with the compound of formula (TIFF2024541508000196.tif47170. providing a compound of formula TIFF2024541508000197.tif44170, wherein: L' is * -N(R 1 )-L- ** and * indicates the point of attachment to Z, ** teeth, This shows the connection point with TIFF2024541508000198.tif33170. R 1 is H, X 1 is CR s and R s teeth, TIFF2024541508000199.tif17170, X 2 and X 3 are CH, respectively, X 4 are independently N, CH, or CD, provided that 1) X 1 , X 2 , X 3 , and X 4 1) Only one of the two is N, or 2) X 1 is N and X 2 is CH and X 3 is CH and X 4 is N or 3) X 1 is CR s and X 2 , X 3 , and X 4 are each independently CH or CD; B is phenyl or 5- to 6-membered heteroaryl, and each phenyl or 5- to 6-membered heteroaryl of B is independently one or more R t and R t At each occurrence, halo, C 1~15 Alkyl, C 1~6 Alkoxy, and S(R y )5 independently selected from y is the halo and R t C 1~15 Alkyl or C 1~6 The alkoxy may be optionally substituted with one or more halo; TIFF2024541508000200.tif15170L is methylene.
[0343] In one embodiment, a compound of formula (I-AB): Provided herein is a method for preparing a compound of formula (S6), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt thereof, the method comprising: The compound of formula (S7) TIFF2024541508000203.tif18170 to form the compound of formula (S8) TIFF2024541508000204.tif64170, wherein L' is TIFF2024541508000205.tif16170, * indicates the point of attachment to Z, ** teeth, This shows the connection point with TIFF2024541508000206.tif33170. R 1 is H or C 1~6 is alkyl, X 1 is CR s and R s H, deuterium, -CN, halo, C 1~15 Alkyl, C 1~6Alkynyl, C 6~20 Aryl, 5-15 membered heteroaryl, C 3~20 Cycloalkyl, 3- to 15-membered heterocyclyl, -OH, -OR f , C 1~15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , and -NR d R e is selected from R d , R e and R f each independently represents H, C 1~6 Alkyl or C 3~20 is cycloalkyl, C 1~6 Alkyl and C 3~20 each cycloalkyl independently may be optionally substituted with one or more halo, oxo, —OH, or —CN; R s C 1~15 Alkyl and C 1~15 Each alkoxy is independently one or more R t1 and R t1 -O-, -OH-, -OR ... f1 , -CN, -NR d R e and 3- to 15-membered heterocyclyl optionally substituted with one or more —OH; R f1 is -C(O)CHNR d R e , -C(O)C 1~6 alkyl, -P(O)(OH)2, and R d and R e are each independently H or C 1~6 alkyl, and R d or R e C 1~6the alkyl is optionally substituted with one or more halo, oxo, —OH, or —CN; R s C 6~20 Aryl, 5-15 membered heteroaryl, C 3~20 Cycloalkyl and 3- to 15-membered heterocyclyl each independently represent one or more R t2 and R t2 represents, at each occurrence, halo, oxo, -OH, -CN, C(O)NH2, -C(O)NR d R e , -NR d R e , C 1~6 Alkoxyl, 3-6 membered heterocyclyl, C 3~6 Cycloalkyl, and C 1~6 alkyl; R t2 C 1~6 Alkyl is a group consisting of one or more -OH, C 1~6 Alkoxyl, halo, oxo, -S(O)2CH3, or -NR d R e and R d and R e are each independently H, -C(O)CH3, or -C(O)C 1~6 Alkyl or C 1~6 is alkyl, X 3 is CH, X 2 and X 4 are each independently N, CH, or CD, provided that: 1) X 1 , X 2 , X 3 , and X 4 1) Only one of the two is N, or 2) X 1 is N and X 2 is CH and X 3 is CH and X 4 is N or 3) X 1 is CR s and X 2 , X 3 , and X 4 are each independently CH or CD; TIFF2024541508000207.tif49170n and m are 1, R b and R c are H and C, respectively. 1~6 Alkyl, Deuterium, -OH, C 1~6 are independently selected from the group consisting of alkoxyl, and halo.
[0344] In one embodiment, a compound of formula (I-AB): Provided herein is a method for preparing a compound of formula (S9), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt thereof, the method comprising: The compound of formula (S10) was reacted with the compound of formula (TIFF2024541508000209.tif53170. TIFF2024541508000210.tif49170, wherein L' is * -N(R 1 )-L- ** and * indicates the point of attachment to Z, ** teeth, This shows the connection point with TIFF2024541508000211.tif33170. R 1 is H, X 1 is N or CR s and R s H, deuterium, -CN, halo, C 1~15 Alkyl, C 1~6 Alkynyl, C 6~20 Aryl, 5-15 membered heteroaryl, C 3~20 Cycloalkyl, 3- to 15-membered heterocyclyl, -OH, -OR f , C 1~15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d Re , -NR d SO2R e , and -NR d R e is selected from R d , R e and R f each independently represents H, C 1~6 Alkyl or C 3~20 is cycloalkyl, C 1~6 Alkyl and C 3~20 each cycloalkyl independently may be optionally substituted with one or more halo, oxo, —OH, or —CN; R s C 1~15 Alkyl and C 1~15 Each alkoxy is independently one or more R t1 and R t1 -O-, -OH-, -OR ... f1 , -CN, -NR d R e and 3- to 15-membered heterocyclyl optionally substituted with one or more —OH; R f1 is -C(O)CHNR d R e , -C(O)C 1~6 alkyl, -P(O)(OH)2, and R d and R e are each independently H or C 1~6 alkyl, and R d or R e C 1~6 the alkyl is optionally substituted with one or more halo, oxo, —OH, or —CN; R s C 6~20 Aryl, 5-15 membered heteroaryl, C 3~20 Cycloalkyl and 3- to 15-membered heterocyclyl each independently represent one or more R t2 and R t2 represents, at each occurrence, halo, oxo, -OH, -CN, C(O)NH2, -C(O)NR d R e, -NR d R e , C 1~6 Alkoxyl, 3-6 membered heterocyclyl, C 3~6 Cycloalkyl, and C 1~6 alkyl; R t2 C 1~6 Alkyl is a group consisting of one or more -OH, C 1~6 Alkoxyl, halo, oxo, -S(O)2CH3, or -NR d R e and R d and R e are each independently H, -C(O)CH3, or -C(O)C 1~6 Alkyl or C 1~6 is alkyl, X 2 and X 3 are CH, respectively, X 4 are independently N, CH, or CD, provided that 1) X 1 , X 2 , X 3 , and X 4 1) Only one of the two is N, or 2) X 1 is N and X 2 is CH and X 3 is CH and X 4 is N or 3) X 1 is CR s and X 2 , X 3 , and X 4 are each independently CH or CD; TIFF2024541508000212.tif44170L is methylene.
[0345] Pharmaceutical Compositions and Administration In addition to one or more of the compounds provided above (including stereoisomers, geometric isomers, tautomers, solvates, metabolites, isotopes, pharmaceutically acceptable salts, or prodrugs thereof), the present invention provides compositions and pharmaceutical preparations comprising a compound of this disclosure and embodiments or aspects thereof and at least one pharmaceutically acceptable carrier. The compositions of this disclosure can be used to selectively inhibit TEAD in patients (e.g., humans).
[0346] In one aspect, the invention provides pharmaceutical compositions or medicaments comprising a compound of the present disclosure (or embodiments or aspects thereof, including stereoisomers, geometric isomers, tautomers, solvates, metabolites, isotopes, pharmaceutically acceptable salts, and prodrugs) and a pharmaceutically acceptable carrier, diluent, or excipient. In another aspect, the invention provides the preparation of a composition (or medicament) comprising a compound of the present disclosure. In another aspect, the invention provides the administration of a compound of the present disclosure, or a composition comprising a compound of the present disclosure, to a patient (e.g., a human patient) in need thereof.
[0347] The carrier can be selected from various oils, including those of petroleum, animal, vegetable, or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil, and the like.Water, saline, aqueous dextrose, and glycols are preferred liquid carriers, especially for liquid injections (when isotonic with blood).For example, a formulation for intravenous administration includes a sterile aqueous solution of the compound of the present disclosure, which is prepared by dissolving the solid compound of the present disclosure in water to produce an aqueous solution and sterilizing the solution.Suitable pharmaceutical additives include starch, cellulose, talc, glucose, lactose, talc, gelatin, malt, rice, flour, chalk, silica, magnesium stearate, sodium stearate, glycerol monostearate, sodium chloride, dried skim milk, glycerol, propylene glycol, water, ethanol, and the like. The compositions may be provided with conventional pharmaceutical additives such as preservatives, stabilizers, wetting or emulsifying agents, salts for adjusting osmotic pressure, buffers, and the like. Suitable pharmaceutical carriers and their formulations are described in Remington's Pharmaceutical Sciences by E.W. Martin. Such compositions will, in any event, contain an effective amount of the compounds of the present disclosure, together with a suitable carrier, so as to prepare a suitable dosage form for proper administration to the recipient individual.
[0348] The composition is formulated, dosed, and administered in a manner consistent with good medical practice. Factors to consider in this context include the specific disorder being treated, the specific mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the drug delivery site, the administration method, the administration schedule, and other factors known to medical professionals. The effective amount of the compound to be administered is governed by such considerations and is the minimum amount necessary to inhibit TEAD activity, which is required to prevent or treat an undesired disease or disorder, such as pain. For example, such an amount may be below the amount that is toxic to normal cells or the mammal as a whole.
[0349] In one example, the therapeutically effective amount of a compound of the present disclosure administered parenterally per dose ranges from about 0.01 to 100 mg / kg, alternatively, for example, from about 0.1 to 20 mg / kg of patient body weight per day, with a typical initial range of the compound used being 0.3 to 15 mg / kg / day. In certain embodiments, the daily dose is given as a single daily dose, in divided doses two to six times daily, or in sustained-release form. For a 70 kg adult, the total daily dose will generally be about 7 mg to about 1,400 mg. This dosing regimen may be adjusted to provide the optimal therapeutic response. The compound may be administered one to four times daily, preferably once or twice daily.
[0350] A therapeutically effective amount of a compound of the present invention or a pharmaceutically acceptable salt thereof may be administered in any convenient dosage form, such as a tablet, powder, capsule, solution, dispersion, suspension, syrup, spray, suppository, gel, emulsion, patch, etc. Such compositions may contain conventional components of pharmaceutical preparations, such as diluents, carriers, pH adjusters, sweeteners, fillers and additional active agents.
[0351] Compositions comprising the disclosed compounds (or embodiments or aspects thereof, including stereoisomers, geometric isomers, tautomers, solvates, metabolites, isotopes, pharmaceutically acceptable salts thereof, and prodrugs) are typically formulated in accordance with standard pharmaceutical practice as pharmaceutical compositions. A typical formulation is prepared by mixing a compound of the disclosure with a diluent, carrier, or excipient. Suitable diluents, carriers, and additives are well known to those skilled in the art and are described in detail, for example, in Ansel, Howard C., et al., Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems. Philadelphia: Lippincott, Williams & Wilkins, 2004; Gennaro, Alfonso R., et al., Remington: The Science and Practice of Pharmacy. Philadelphia: Lippincott, Williams & Wilkins, 2000; and Rowe, Raymond C., Handbook of Pharmaceutical Excipients. Chicago, Pharmaceutical Press, 2005. The formulation may also include one or more buffers, stabilizers, surfactants, wetting agents, lubricants, emulsifiers, suspending agents, preservatives, antioxidants, opaquing agents, glidants, processing aids, colorants, sweeteners, fragrances, flavorings, diluents, and other known additives to provide proper presentation of the drug (i.e., a compound of the present disclosure or a pharmaceutical composition thereof) or to aid in the manufacture of a pharmaceutical product (i.e., a medicament).Suitable carriers, diluents, and additives are well known to those skilled in the art and include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride; benzethonium chloride; phenol, butyl, or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; serum albumin, gelatin, or immunoglobulins. These include proteins such as globulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose, or sorbitol; salt-forming counterions such as sodium; metal complexes (e.g., Zn-protein complexes); and / or non-ionic surfactants such as TWEEN™, PLURONICS™, or polyethylene glycol (PEG). The active pharmaceutical ingredients of the present disclosure (e.g., compounds of Formula (I) or embodiments or aspects thereof) can also be encapsulated in colloidal drug delivery systems (e.g., liposomes, albumin microspheres, microemulsions, nanoparticles, and nanocapsules), or in macroemulsions, for example, by microcapsules prepared by coacervation techniques or interfacial polymerization, such as hydroxymethylcellulose or gelatin-microcapsules and poly-(methyl methacrylate) microcapsules, respectively. Such techniques are described in Remington: The Science and Practice of Pharmacy: Remington: The Science and Practice of Pharmacy (2005) 21. stEdition, Lippincott Williams & Wilkins, Philadelphia, PA. The specific carrier, diluent, or additive used depends on the means and purpose for which the compounds of the present disclosure are applied. Solvents are generally selected based on solvents recognized by those skilled in the art as safe (GRAS) for mammalian administration. Generally, safe solvents are non-toxic aqueous solvents, such as water and other non-toxic solvents that are soluble or miscible in water. Suitable aqueous solvents include water, ethanol, propylene glycol, polyethylene glycol (e.g., PEG400, PEG300), etc., and mixtures thereof.
[0352] Sustained-release preparations of compounds of the present disclosure (e.g., compounds of Formula (A), (B), (A'), (B'), (IA) or (IB), or embodiments or aspects thereof) may also be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing a compound of Formula (A), (B), (A'), (B'), (IA) or (IB), or an embodiment or aspect thereof, which matrices are in the form of shaped articles, e.g., films or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels (e.g., poly(2-hydroxyethyl-methacrylate) or poly(vinyl alcohol)), polylactides (U.S. Pat. No. 3,773,919), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (Sidman et al., Biopolymers 22:547, 1983), non-degradable ethylene-vinyl acetate (Langer et al., J. Biomed. Mater. Res. 15:167, 1981), degradable lactic acid-glycolic acid copolymers such as LUPRON DEPOT™ (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid (European Patent Application Publication No. 133,988). Sustained-release compositions also include liposomally entrapped compounds, which can be prepared by known methods (Epstein et al., Proc. Natl. Acad. Sci. USA 82:3688, 1985; Hwang et al., Proc. Natl. Acad. Sci. USA 77:4030, 1980; U.S. Patent Nos. 4,485,045 and 4,544,545; and European Patent Application Publication No. 102,324). Typically, liposomes are small (about 200-800 angstroms), unilamellar, with a lipid content of greater than about 30 mol% cholesterol, the selected ratio being adjusted for optimal therapy.
[0353] Controlled release preparations of compounds of formula (AB) can be prepared in the same manner as controlled release preparations of compounds of formula (A) or formula (B) (eg, as described in the previous paragraph).
[0354] Sustained-release preparations of compounds of formula (I-AB) can be prepared in the same manner as sustained-release preparations of compounds of formula (A) or formula (B) (e.g., as described in the previous paragraph).
[0355] In one example, a compound of the present disclosure, or an embodiment or aspect thereof, can be formulated into a galenic dosage form by mixing it at ambient temperature, at an appropriate pH, and to the desired degree of purity with a physiologically acceptable carrier, i.e., a carrier that is nontoxic to recipients at the dosage amounts and concentrations used. The pH of the formulation will depend primarily on the particular application and concentration of the compound, but preferably ranges from about 3 to about 8. In one example, a compound of the present disclosure (or an embodiment or aspect thereof) is formulated in acetate buffer at pH 5. In another aspect, a compound of the present disclosure, or an embodiment thereof, is sterile. The compound can be stored, for example, as a solid or amorphous composition, as a lyophilized formulation, or as an aqueous solution.
[0356] Formulations of the compounds of the disclosure suitable for oral administration may be prepared as discrete units such as pills, capsules, cachets or tablets, each containing a predetermined amount of the compound of the disclosure.
[0357] Compressed tablets can be prepared by compressing in a suitable machine a compound of the present disclosure in free-flowing form as a powder or granules, optionally mixed with binders, lubricants, inert diluents, preservatives, surface-active agents, or dispersing agents, etc. Molded tablets can be made by molding in a suitable machine a moistened mixture of a powdered compound of the present disclosure with an inert liquid diluent. The tablets can optionally be coated or slotted, and optionally formulated to provide a slow or controlled release of the compound of the present disclosure therefrom.
[0358] Tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, such as gelatin capsules, syrups, or elixirs can be prepared for oral use.The preparation of the compound of the present disclosure intended for oral use can be prepared according to any method known in the art of preparing pharmaceutical compositions, and such compositions can contain one or more agents, including sweeteners, flavorings, colorings, and preservatives, to provide a palatable preparation.Tablets containing the compound of the present disclosure mixed with non-toxic pharmaceutically acceptable additives suitable for tablet manufacture are acceptable.These additives can be, for example, inert diluents such as calcium carbonate or sodium carbonate, lactose, calcium phosphate or sodium phosphate, granulating agents and disintegrating agents such as corn starch or alginic acid, binders such as starch, gelatin, or acacia, and lubricants such as magnesium stearate, stearic acid, or talc. Tablets may be uncoated or may be coated by known techniques including microencapsulation to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period, for example, a time delay material such as glyceryl monostearate or glyceryl distearate alone or with a wax may be employed.
[0359] An example of a suitable oral dosage form is a tablet containing a compound of the present disclosure (or an embodiment or aspect thereof) formulated with about 0.1 mg, about 1 mg, about 5 mg, about 10 mg, about 25 mg, about 30 mg, about 50 mg, about 80 mg, about 100 mg, about 150 mg, about 250 mg, about 300 mg, and about 500 mg of a filler (e.g., lactose, such as about 90-30 mg anhydrous lactose), a disintegrant (e.g., croscarmellose, e.g., about 5-40 mg croscarmellose sodium), a polymer (e.g., polyvinylpyrrolidone (PVP), a cellulose (e.g., hydroxypropylmethylcellulose (HPMC)), and / or copovidone, e.g., about 5-30 mg PVP, HPMC, or copovidone), and a lubricant (e.g., magnesium stearate, such as about 1-10 mg). Wet granulation, dry granulation, or dry blending can be used. In one wet granulation embodiment, powdered ingredients are first mixed together and then mixed with a solution or suspension of a polymer (e.g., PVP). The resulting composition can be dried, granulated, mixed with a lubricant, and compressed into tablet form using conventional equipment. An example aerosol formulation can be prepared by dissolving, for example, 5-400 mg of a compound of the present disclosure in a suitable buffer solution, such as phosphate buffer, and, if desired, adding an isotonicity agent, such as a salt such as sodium chloride. The solution may be filtered, for example, using a 0.2 micron filter, to remove impurities and contaminants.
[0360] For treatment of the eye or other external tissues, e.g., the mouth and skin, the formulation is preferably applied as a topical ointment or cream containing a compound of the present disclosure in an amount of 0.075-20% w / w. When formulated in an ointment, the compound of the present disclosure can be used with either a paraffinic or water-miscible ointment base. Alternatively, the compound of the present disclosure can be formulated into a cream with an oil-in-water cream base. If desired, the aqueous phase of the cream base can contain a polyhydric alcohol, i.e., an alcohol having two or more hydroxyl groups, such as propylene glycol, butane-1,3-diol, mannitol, sorbitol, glycerol, polyethylene glycol (including PEG 400), and mixtures thereof. Topical formulations can optionally contain a compound that enhances absorption or penetration of the compound of the present disclosure through the skin or other affected areas. Examples of such skin penetration enhancers include dimethyl sulfoxide and related analogs.
[0361] For topical formulations, it is desirable to apply an effective amount of a pharmaceutical composition according to the present disclosure to a target area adjacent to the peripheral neuron being treated, such as the skin surface, mucosa, etc. This amount generally ranges from about 0.0001 mg to about 1 g of a compound of the present disclosure (or an embodiment or aspect thereof) per application, depending on the area to be treated, the severity of the symptoms, and the nature of the topical vehicle used, whether for diagnostic, prophylactic, or therapeutic use. A preferred topical preparation is an ointment, with about 0.001 to about 50 mg of a compound of the present disclosure used per cc of ointment base. Pharmaceutical compositions may also be formulated as transdermal compositions or transdermal delivery devices ("patches"). Such compositions include, for example, a backing, a reservoir of a compound of the present disclosure, a control membrane, a liner, and a contact adhesive. Such transdermal patches can be used to provide continuous pulsatile or on-demand delivery of a compound of the present disclosure, as desired.
[0362] The formulations may be packaged in unit-dose or multi-dose containers, for example, sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition, requiring only the addition of a sterile liquid carrier, for example, water, for injection immediately prior to use. Extemporaneous injection solutions and suspensions are prepared from sterile powders, granules, and tablets of the type described above. Preferred unit dosage formulations contain the daily dose or daily unit sub-dose of the compound of the present disclosure, as hereinbefore described, or an appropriate fraction thereof.
[0363] When the binding target is located in the brain, certain aspects of the present disclosure provide the compound of the present disclosure (or its embodiment or aspect) for crossing the blood-brain barrier.Since certain neurodegenerative diseases are associated with increased permeability of the blood-brain barrier, the compound of the present disclosure (or its embodiment or aspect) can be easily introduced into the brain.When the blood-brain barrier remains intact, there are several methods known in the art for transporting molecules across the blood-brain barrier, including but not limited to physical methods, lipid-based methods, and receptor and channel-based methods.
[0364] Physical methods of transporting a compound of the present disclosure (or an embodiment or aspect thereof) across the blood-brain barrier include, but are not limited to, bypassing the blood-brain barrier entirely or creating an opening in the blood-brain barrier.
[0365] Methods of circumvention include, but are not limited to, direct injection into the brain (see, e.g., Papanastassiou et al., Gene Therapy 9:398-406, 2002), interstitial injection / convection-enhanced delivery (see, e.g., Bobo et al., Proc. Natl. Acad. Sci. USA 91:2076-2080, 1994), and implanting a delivery device into the brain (see, e.g., Gill et al., Nature Med. 9:589-595, 2003; and Gliadel Wafers™, Guildford Pharmaceutical).
[0366] Methods for creating openings in the barrier include, but are not limited to, ultrasound (see, e.g., U.S. Patent Application Publication No. 2002 / 0038086), osmotic pressure (e.g., by administration of hypertonic mannitol (Neuwelt, E.A., Implications of the Blood-Brain Barrier and Its Manipulation, Volumes 1 and 2, Plenum Press, NY, 1989)), and permeabilization with, for example, bradykinin or permeabilizing agent A-7 (see, e.g., U.S. Patent Nos. 5,112,596, 5,268,164, 5,506,206, and 5,686,416).
[0367] Lipid-based methods of transporting a compound of the present disclosure (or an embodiment or aspect thereof) across the blood-brain barrier include, but are not limited to, encapsulating a compound of the present disclosure (or an embodiment or aspect thereof) within a liposome linked to an antibody binding fragment that binds to a receptor on the vascular endothelium of the blood-brain barrier (see, e.g., U.S. Patent Application Publication No. 2002 / 0025313), and coating a compound of the present disclosure (or an embodiment or aspect thereof) onto low-density lipoprotein particles (see, e.g., U.S. Patent Application Publication No. 2004 / 0204354) or apolipoprotein E (see, e.g., U.S. Patent Application Publication No. 2004 / 0131692).
[0368] Receptor and channel-based methods of transporting the disclosed compounds (or embodiments or aspects thereof) across the blood-brain barrier include, but are not limited to, using glucocorticoid blockers to increase the permeability of the blood-brain barrier (see, e.g., U.S. Patent Application Publication Nos. 2002 / 0065259, 2003 / 0162695, and 2005 / 0124533), activating potassium channels (see, e.g., U.S. Patent Application Publication No. 2005 / 0089473), inhibiting ABC drug transporters (see, e.g., U.S. Patent Application Publication No. 2003 / 0073713), coating the disclosed compounds (or embodiments or aspects thereof) with transferrin and modulating the activity of one or more transferrin receptors (see, e.g., U.S. Patent Application Publication No. 2003 / 0129186), and cationizing antibodies (see, e.g., U.S. Patent No. 5,004,697).
[0369] For intracerebral use, in certain embodiments, the compound can be continuously administered into the fluid reservoir of the CNS by infusion, although bolus injection is also acceptable.The inhibitor can be administered into the ventricles of the brain or otherwise introduced into the CNS or cerebrospinal fluid.Administration can be carried out by using continuous administration means such as an indwelling catheter and a pump, or can be administered by implantation, for example, intracerebral implantation of a sustained-release vehicle.More specifically, the inhibitor can be injected through a long-term implanted cannula or can be infused long-term with the help of an osmotic minipump.Subcutaneous pumps that deliver proteins to the ventricles through small tubes are also available.Highly sophisticated pumps can be loaded through the skin, and their delivery rate can be set without surgical intervention. Examples of suitable administration protocols and delivery systems involving continuous intraventricular infusion through a subcutaneous pump device or a completely implanted drug delivery system, used to administer dopamine, dopaminergic agents, and cholinergic agents to patients with Alzheimer's disease and animal models of Parkinson's disease, are described in Harbaugh, J. Neural Transm. Suppl. 24:271, 1987; and DeYebenes et al., Mov. Disord. 2:143, 1987.
[0370] Indications and Treatment Methods Representative compounds of the present disclosure have been shown to modulate TEAD activity.
[0371] In some embodiments, the compound that modulates TEAD activity has formula (A): TIFF2024541508000213.tif37170, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein: R 1 is H or C 1~6 is alkyl, X 1 is N or CR s and R s H, -CN, halo, C 1~15 Alkyl, C 6~20 Aryl, 5-15 membered heteroaryl, C3~20 Cycloalkyl, 3- to 15-mem...
Claims
1. Formula (I-AB): or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof, wherein L' is * -N(R 1 ) -L- ** and is selected from the group consisting of * indicates the point of attachment to Z, ** teeth, indicates the point of attachment to R 1 is H or C 1~6 is alkyl, X 1 is N or CR s and R s is H, deuterium, -CN, halo, C 1~15 Alkyl, C 1~6 Alkynyl, C 6~20 Aryl, 5-15 membered heteroaryl, C 3~20 Cycloalkyl, 3- to 15-membered heterocyclyl, -OH, -OR f , C 1~15 Alkoxy, -NR d C.O.R. e , -CONR d R e , -SO 2 R d , -SO 2 N.R. d R e , -NR d SO 2 R e and -NR d R e is selected from R d , R e and R f each independently represents H, C 1~6 Alkyl, or C 3~20 cycloalkyl, C 1~6 Alkyl and C 3~20 each cycloalkyl may be independently optionally substituted with one or more halo, oxo, -OH or -CN; R sThe above C 1~15 Alkyl and the C 1~15 Each alkoxy is independently one or more R t1 and R t1 is, at each occurrence, halo, oxo, -OH, -OR f1 , -CN, -NR d R e and 3- to 15-membered heterocyclyl optionally substituted with one or more —OH; R f1 is -C(O)CH 2 N.R. d R e , -C(O)C 1~6 Alkyl, -P(O)(OH) 2 and R d and R e are each independently H or C 1~6 alkyl, R d Or R e The above C 1~6 The alkyl may be optionally substituted with one or more halo, oxo, -OH, or -CN; R s The above C 6~20 aryl, the 5- to 15-membered heteroaryl, the C 3~20 Cycloalkyl and the 3- to 15-membered heterocyclyl each independently represent one or more R t2 and R t2 is, at each occurrence, halo, oxo, -OH, -CN, C(O)NH 2 , -C(O)NR d R e , -NR d R e , C 1~6 Alkoxyl, 3-6 membered heterocyclyl, C 3~6 Cycloalkyl, and C 1~6 alkyl; R t2 The above C 1~6 Alkyl is one or more -OH, C 1~6 Alkoxyl, halo, oxo, -S(O) 2 CH 3 or -NR d R eand R d and R e are each independently H, -C(O)CH 3 , -C(O)C 1~6 Alkyl, or C 1~6 is alkyl, X 2 , X 3 , and X 4 are each independently N, CH, or CD, provided that 1) X 1 , X 2 , X 3 , and X 4 or 2) X 1 is N and X 2 is CH, and X 3 is CH and X 4 is N, or 3) X 1 is CR s And X 2 , X 3 , and X 4 are each independently CH or CD; B is phenyl or 5- to 6-membered heteroaryl, and each of the phenyl or 5- to 6-membered heteroaryl of B is independently one or more R t and R t At each occurrence, halo, C 1~15 Alkyl, C 1~6 Alkoxy, and S(R y ) 5 and each R y is halo, R t The above C 1~15 Alkyl or the C 1~6 The alkoxy may be optionally substituted with one or more halo; Z is -C(O)R x and R x is C 1~6 Alkyl, Deuterium, -OH, C 1~6 C optionally substituted with one or more substituents selected from alkoxy and halo 2~6 alkenyl or R xC optionally substituted with one or more halo 1~6 alkyl or R x is C optionally substituted with —OH 1~6 alkynyl or R x is cyclobutenyl, dihydrofuranyl, bicyclobutanyl or cyclopentenyl, or Z is S(O) 2 R x1 and R x1 is C 2~6 alkenyl, L is one or more C 1~6 methylene optionally substituted with alkyl; n and m are each 1, or n and m are each 2; A compound of formula (I-AB), or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof.
2. Formula (A):
2. The compound of claim 1, which is a compound of the formula:
3. Formula (IA): or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof, wherein R a , R b , and R c are each independently H, deuterium, —OH, C 1~6 Alkoxyl, halo, or C 1~5 3. The compound of claim 1 or 2, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof, wherein R is an alkyl group.
4. Formula (A-1):
3. The compound of claim 1 or 2, which is a compound of the formula:
5. Formula (IA-1): or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof, wherein R a , R b , and R c are each independently H, halo, deuterium, —OH, C 1~6 Alkoxyl, or C 1~5 is alkyl, R t Ha, Haro, C 1~15 Alkyl, C 1~6 Alkoxy, and S(R y ) 5 Each R y is halo, R t The above C 1~15 Alkyl or the C 1~6 5. The compound according to any one of claims 1 to 4, wherein alkoxy is optionally substituted with one or more halo, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof.
6. Formula (I-A-5): or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof.
4. The compound according to any one of claims 1 to 3, which is a compound of the formula:
7. Formula (I-A-12): or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof.
10. The compound according to claim 1, wherein the compound is
8. Formula (I-A-13): or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof.
8. The compound according to any one of claims 1 to 7, which is a compound of the formula:
9. Formula (B):
2. The compound of claim 1, which is a compound of the formula:
10. Formula (IB): or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof, wherein R a , R b , and R c are each independently H, deuterium, —OH, C 1~6 Alkoxyl, halo, or C 1~5 10. The compound of claim 1 or 9, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof, wherein R is an alkyl group.
11. Formula (B-1):
10. The compound of claim 1 or 9, which is a compound of the formula: or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof.
12. Formula (IB-1): or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof, wherein R a , R b , and R c are each independently H, halo, deuterium, —OH, C 1~6 Alkoxyl, or C 1~5 is alkyl, R t Ha, Haro, C 1~15 Alkyl, C 1~6 Alkoxy, and S(R y ) 5 Each R y is halo, R t The above C 1~15 Alkyl or the C 1~6 12. The compound of any one of claims 1 or 9-11, wherein alkoxy is optionally substituted with one or more halo, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof.
13. Formula (IB-5): or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof.
11. The compound of claim 1, or any one of claims 10 to 11, wherein the compound is
14. Formula (X-B): or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof.
15. Formula (IB-11):
15. The compound of claim 14, which is a compound of the formula: or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof.
16. B's R t But -SF 5 , -O-CHF 2、 Or -O-CF 3 16. The compound according to any one of claims 1 to 15, wherein:
17. Z is -C(O)R x and R x But, C 1~6 Alkyl, Deuterium, -OH, C 1~6C optionally substituted with one or more substituents selected from alkoxy and halo 2~6 alkenyl, or R x C optionally substituted with one or more halo 1~6 12. The compound of any one of claims 1 to 2, 4, 9, or 11, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof, wherein:
18. R x is methyl optionally substituted with one or more Cl, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof.
19. R a , R b , and R c or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof.
20. R a , R b , and R c is H, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof.
21. X 1 is CR s And X 2 , X 3 , and X 4 is CH, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof.
22. X 1 is CR s And X 2 is N and X 3 and X 4is CH, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof.
23. X 1 is CR s And X 3 is N and X 2 and X 4 is CH, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof.
24. X 1 is CR s And X 2 and X 3 is CH, and X 4 is N, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof.
25. X 1 is N and X 2 , X 3 , and X 4 13. The compound of any one of claims 1 to 5 or 9 to 12, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof, wherein each is CH.
26. R s The compound of any one of claims 1 to 25, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof, wherein is H, halo, or -CN.
27. R s Ga-OR f and R f C optionally substituted with one or more —OH 3~20 26. The compound of any one of claims 1 to 25, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof, which is cycloalkyl.
28. R sBut, C 1~15 Alkyl or C 1~15 Alkoxy, R s The above C 1~15 Alkyl or C 1~15 Each alkoxy is independently one or more R t1 and R t1 each occurrence of halo, oxo, -OH, -OR f1 , -CN, -NR d R e and 3- to 15-membered heterocyclyl optionally substituted with one or more —OH; R f1 is -C(O)CH 2 N.R. d R e , -C(O)C 1~6 Alkyl, -P(O)(OH) 2 and R d and R e are each independently H or C 1~6 alkyl, R d Or R e The above C 1~6 26. The compound of any one of claims 1 to 25, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof, wherein alkyl is optionally substituted with one or more halo, oxo, -OH, or -CN.
29. R s But -NR d R e and R d and R e are H and C, respectively. 1~6 Alkyl, C 3~20 Cycloalkyl, —C(O)R t R is independently selected from the group consisting of t But, C 1~6 alkyl, C 1~6 Alkyl, C 3~20 26. The compound of any one of claims 1 to 25, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof, wherein each cycloalkyl is optionally substituted with one or more -OH.
30. R s is -C(O)NR d R e and R d and R e are H and C, respectively. 1~6 alkyl, C 1~6 26. The compound of any one of claims 1 to 25, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof, wherein alkyl is optionally substituted with one or more -OH.
31. R s C optionally substituted with one or more —OH 1~6 26. The compound of any one of claims 1 to 25, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof, wherein R is an alkyl group.
32. R s is substituted with one or more -OH 1~2 26. The compound of any one of claims 1 to 25, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof, wherein R is an alkyl group.
33. R s but, 26. The compound according to any one of claims 1 to 25, selected from the group consisting of:
34. A compound selected from any one of the compounds in Table 1, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof. [Table 1]
35. 35. A pharmaceutical composition comprising: (i) a compound according to any one of claims 1 to 34, or a stereoisomer, tautomer, or pharma- ceutically acceptable salt thereof; and (ii) a pharma- ceutically acceptable carrier, diluent, or excipient.
36. 35. A compound according to any one of claims 1 to 34, or a stereoisomer, tautomer or pharma- ceutically acceptable salt thereof, for use in medical therapy.
37. Acoustic neuroma, acute leukemia, acute lymphocytic leukemia, acute myeloid leukemia (monocytic, myeloblastic, adenocarcinoma, angiosarcoma, astrocytoma, myelomonocytic and promyelocytic), acute T-cell leukemia, basal cell carcinoma, bile duct cancer, bladder cancer, brain cancer, breast cancer, bronchogenic carcinoma, cervical cancer, chondrosarcoma, chordoma, choriocarcinoma, chronic leukemia, chronic lymphocytic leukemia, chronic myelocytic (granulocytic) leukemia, chronic myeloid leukemia, colon cancer, colorectal cancer, craniopharyngioma, cystadenocarcinoma, diffuse large B-cell lymphoma, proliferative disorders Alterations (dysplasia and metaplasia), embryonal carcinoma, endometrial carcinoma, endothelial sarcoma, ependymoma, epithelial carcinoma, erythroleukemia, esophageal carcinoma, estrogen receptor positive breast cancer, essential thrombocythemia, Ewing's sarcoma, fibrosarcoma, follicular lymphoma, testicular germ cell carcinoma, glioma, glioblastoma, gliosarcoma, heavy chain disease, hemangioblastoma, hepatocellular carcinoma, hormone insensitive prostate cancer, leiomyosarcoma, leukemia, liposarcoma, lung cancer, lymphangioendothelial sarcoma, lymphangiosarcoma, lymphoblastic leukemia, lymphoma (Hodgkin and non-Hodgkin), bladder , malignant tumors and hyperproliferative disorders of the breast, colon, lung, ovary, pancreas, prostate, skin and uterus, lymphoid malignancies of T-cell or B-cell origin, medullary carcinoma, medulloblastoma, melanoma, meningioma, mesothelioma, multiple myeloma, myeloid leukemia, myeloma, myxosarcoma, neuroblastoma, NUT midline carcinoma (NMC), non-small cell lung cancer, oligodendroglioma, oral cancer, osteogenic sarcoma, ovarian cancer, pancreatic cancer, papillary adenocarcinoma, papillary carcinoma, pinealoma, polycythemia vera, prostate cancer, rectal cancer, renal cell carcinoma, retinoblastoma, rhabdomyosarcoma, sarcoma, lipoma 35. The compound of any one of claims 1 to 34, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, for use in the treatment and / or prevention of a disease or condition mediated by TEAD activity selected from the group consisting of adenocarcinoma, seminoma, skin cancer, small cell lung cancer, solid tumors (carcinoma and sarcoma), small cell lung cancer, gastric cancer, squamous cell carcinoma, synovium, sweat gland carcinoma, thyroid cancer, Waldenstrom's macroglobulinemia, testicular tumor, uterine cancer and Wilms' tumor.
38. 35. The compound of any one of claims 1 to 34, or a stereoisomer, tautomer, or pharma- ceutically acceptable salt thereof, for use in modulating TEAD activity.
39. 35. The compound of any one of claims 1 to 34, or a stereoisomer, tautomer or pharma- ceutically acceptable salt thereof, for use in the treatment and / or prevention of a disease or condition mediated by TEAD activity.
40. 40. The compound for use according to claim 39, wherein the disease or condition mediated by TEAD activity is cancer.
41. 35. Use of a compound according to any one of claims 1 to 34, or a stereoisomer, tautomer or pharma- ceutically acceptable salt thereof, for the preparation of a medicament for the prevention or treatment of a disease or condition mediated by TEAD activity.
42. 42. The use of claim 41 , wherein the disease or condition mediated by TEAD activity is cancer.
43. 35. A method for treating cancer in a mammal, comprising administering to said mammal a therapeutically effective amount of a compound of any one of claims 1 to 34, or a stereoisomer, tautomer, or pharma- ceutically acceptable salt thereof.
44. 35. A method for modulating TEAD activity, comprising contacting a TEAD with a therapeutically effective amount of a compound of any one of claims 1 to 34, or a stereoisomer, tautomer, or pharma- ceutically acceptable salt thereof.
45. 35. A method for treating a disease or condition mediated by TEAD activity in a mammal, comprising administering to the mammal a therapeutically effective amount of a compound of any one of claims 1 to 34, or a pharma- ceutically acceptable salt thereof.
46. 35. Use of a compound according to any one of claims 1 to 34, or a stereoisomer, tautomer or pharma- ceutically acceptable salt thereof, for modulating TEAD activity.
47. 35. Use of a compound according to any one of claims 1 to 34, or a stereoisomer, tautomer or pharma- ceutically acceptable salt thereof, for the treatment and / or prevention of a disease or condition mediated by TEAD activity.
48. 48. The use of claim 47, wherein the disease or condition mediated by TEAD activity is cancer.
49. A composition comprising: (i) one or more TEAD inhibitors, or pharma- ceutically acceptable salts thereof; and (ii) one or more KRAS inhibitors, or pharma- ceutically acceptable salts thereof; 35. A composition, wherein the one or more TEAD inhibitors is any one of the compounds according to any one of claims 1 to 34.
50. 50. The composition of claim 49, wherein the one or more KRAS inhibitors comprises a G12C KRAS inhibitor.
51. 1. A method of treating cancer in a subject in need thereof, comprising administering to the subject an effective amount of a combination comprising: i) one or more TEAD inhibitors, or pharma- ceutically acceptable salts thereof; and (ii) one or more KRAS inhibitors, or pharma- ceutically acceptable salts thereof; The method, wherein the one or more TEAD inhibitors comprise a compound according to any one of claims 1 to 34.
52. 52. The method of claim 51, wherein the one or more KRAS inhibitors comprises a G12C KRAS inhibitor.
53. A kit comprising: (i) one or more TEAD inhibitors, or pharma- ceutically acceptable salts thereof; (ii) one or more KRAS inhibitors, or pharma- ceutically acceptable salts thereof; and (iii) instructions for administering the combination to treat cancer in a subject in need thereof; 35. A kit, wherein the one or more TEAD inhibitors comprise a compound according to any one of claims 1 to 34.
54. 54. The kit of claim 53, wherein the one or more KRAS inhibitors comprises a G12C KRAS inhibitor.
55. 35. Use of a compound according to any one of claims 1 to 34, or a stereoisomer, tautomer or pharma- ceutically acceptable salt thereof, for the preparation of a medicament for the prevention or treatment of a disease or condition mediated by KRAS activity.
56. 56. The use of claim 55, wherein the disease or condition mediated by KRAS activity is cancer.
57. 35. Use of a compound according to any one of claims 1 to 34, or a stereoisomer, tautomer or pharma- ceutically acceptable salt thereof, for modulating KRAS activity.
58. 35. Use of a compound according to any one of claims 1 to 34, or a stereoisomer, tautomer or pharma- ceutically acceptable salt thereof, for the treatment and / or prevention of a disease or condition mediated by KRAS activity.
59. 59. The use of claim 58, wherein the disease or condition mediated by KRAS activity is cancer.
60. 1. A method of reducing a subject's resistance to a treatment comprising a KRAS inhibitor, the method comprising administering a therapeutically effective amount of a TEAD inhibitor, or a pharma- ceutically acceptable salt thereof.
61. Formula (I-AB): or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof, said method comprising the step of: The compound of formula (S2) to react with a compound of formula (S3) providing a compound of formula: L' is * -N(R 1 ) -L- ** and is selected from the group consisting of * indicates the point of attachment to Z, ** teeth, indicates the point of attachment to R 1 is H or C 1~6 is alkyl, X 1 is N or CR s and R s is H, deuterium, -CN, halo, C 1~15 Alkyl, C 1~6 Alkynyl, C 6~20 Aryl, 5-15 membered heteroaryl, C 3~20 Cycloalkyl, 3- to 15-membered heterocyclyl, -OH, -OR f , C 1~15 Alkoxy, -NR d C.O.R. e , -CONR d R e , -SO 2 R d , -SO 2 N.R. d R e , -NR d SO 2 R e and -NR d R e is selected from R d , R e and R f each independently represents H, C 1~6 Alkyl or C 3~20 cycloalkyl, C 1~6 Alkyl and C 3~20each cycloalkyl may be independently optionally substituted with one or more halo, oxo, -OH or -CN; R s The above C 1~15 Alkyl and the C 1~15 Each alkoxy is independently one or more R t1 and R t1 is, at each occurrence, halo, oxo, -OH, -OR f1 , -CN, -NR d R e and 3- to 15-membered heterocyclyl optionally substituted with one or more —OH; R f1 is -C(O)CH 2 N.R. d R e , -C(O)C 1~6 Alkyl, -P(O)(OH) 2 and R d and R e are each independently H or C 1~6 alkyl, R d Or R e The above C 1~6 The alkyl may be optionally substituted with one or more halo, oxo, -OH or -CN; R s The above C 6~20 aryl, the 5- to 15-membered heteroaryl, the C 3~20 Cycloalkyl and the 3- to 15-membered heterocyclyl each independently represent one or more R t2 and R t2 is, at each occurrence, halo, oxo, -OH, -CN, C(O)NH 2 , -C(O)NR d R e , -NR d R e , C 1~6 Alkoxyl, 3-6 membered heterocyclyl, C 3~6 Cycloalkyl, and C 1~6 alkyl; R t2 The above C 1~6 Alkyl is one or more -OH, C 1~6Alkoxyl, halo, oxo, -S(O) 2 CH 3 or -NR d R e and R d and R e are each independently H, -C(O)CH 3 , -C(O)C 1~6 Alkyl or C 1~6 is alkyl, X 2 and X 3 are CH, X 4 are independently N, CH, or CD, with the proviso that 1) X 1 , X 2 , X 3 , and X 4 or 2) X 1 is N and X 2 is CH, and X 3 is CH and X 4 is N, or 3) X 1 is CR s And X 2 , X 3 , and X 4 are each independently CH or CD; B is, and R t Ha, Haro, C 1~15 Alkyl, C 1~6 Alkoxy and S(R y ) 5 and each R y is halo, R t The above C 1~15 Alkyl or the C 1~6 The alkoxy may be optionally substituted with one or more halo; Z is -C(O)R x and R x is C 1~6 Alkyl, Deuterium, -OH, C 1~6 C optionally substituted with one or more substituents selected from alkoxy and halo 2~6alkenyl or R x C optionally substituted with one or more halo 1~6 alkyl or R x is C optionally substituted with —OH 1~6 alkynyl or R x is cyclobutenyl, dihydrofuranyl, bicyclobutanyl or cyclopentenyl, or Z is S(O) 2 R x1 and R x1 is C 2~6 alkenyl, L is one or more C 1~6 methylene optionally substituted with alkyl; n and m are each 1 or n and m are each 2; X A is N or CR L and Each R L is independently selected from halo.
62. Formula (I-AB): or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof, said method comprising the step of: to react a compound of formula (S5) providing a compound of formula: L' is * -N(R 1 ) -L- ** and * indicates the point of attachment to Z, ** teeth, indicates the point of attachment to R 1 is H, X 1 is CR s and R s teeth, and X 2 and X 3 are CH, X 4 are independently N, CH, or CD, with the proviso that 1) X 1 , X 2 , X 3 , and X 4 or 2) X 1 is N and X 2 is CH, and X 3 is CH and X 4 is N, or 3) X 1 is CR s And X 2 , X 3 , and X 4 are each independently CH or CD; B is phenyl or 5- to 6-membered heteroaryl, and the phenyl or the 5- to 6-membered heteroaryl of B each independently represents one or more R t and R t At each occurrence, halo, C 1~15 Alkyl, C 1~6 Alkoxy, and S(R y ) 5 and each R y is halo, R t The above C 1~15 Alkyl or the C 1~6 The alkoxy may be optionally substituted with one or more halo; The method wherein L is methylene.
63. Formula (I-AB): or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof, said method comprising the step of: The compound of formula (S7) to react with a compound of formula (S8) providing a compound of formula L' is and * indicates the point of attachment to Z, ** teeth, indicates the point of attachment to R 1 is H or C 1~6 is alkyl, X 1 is CR s and R s is H, deuterium, -CN, halo, C 1~15 Alkyl, C 1~6 Alkynyl, C 6~20 Aryl, 5-15 membered heteroaryl, C 3~20 Cycloalkyl, 3- to 15-membered heterocyclyl, -OH, -OR f , C 1~15 Alkoxy, -NR d C.O.R. e , -CONR d R e , -SO 2 R d , -SO 2 N.R. d R e , -NR d SO 2 R e and -NR d R e is selected from R d , R e and R f each independently represents H, C 1~6 Alkyl or C 3~20 cycloalkyl, C 1~6 Alkyl and C 3~20 each cycloalkyl may be independently optionally substituted with one or more halo, oxo, -OH or -CN; R s The above C 1~15 Alkyl and the C 1~15 Each alkoxy is independently one or more R t1 and R t1 is, at each occurrence, halo, oxo, -OH, -OR f1 , -CN, -NR d R e and 3- to 15-membered heterocyclyl optionally substituted with one or more —OH; R f1 is -C(O)CH 2 N.R. dR e , -C(O)C 1~6 Alkyl, -P(O)(OH) 2 and R d and R e are each independently H or C 1~6 alkyl, R d Or R e The above C 1~6 The alkyl may be optionally substituted with one or more halo, oxo, -OH or -CN; R s The above C 6~20 aryl, the 5- to 15-membered heteroaryl, the C 3~20 Cycloalkyl and the 3- to 15-membered heterocyclyl each independently represent one or more R t2 and R t2 is, at each occurrence, halo, oxo, -OH, -CN, C(O)NH 2 , -C(O)NR d R e , -NR d R e , C 1~6 Alkoxyl, 3-6 membered heterocyclyl, C 3~6 Cycloalkyl, and C 1~6 alkyl; R t2 The above C 1~6 Alkyl is one or more -OH, C 1~6 Alkoxyl, halo, oxo, -S(O) 2 CH 3 or -NR d R e and R d and R e are each independently H, -C(O)CH 3 , -C(O)C 1~6 Alkyl or C 1~6 is alkyl, X 3 is CH, X 2 and X 4 are each independently N, CH, or CD, provided that 1) X 1 , X 2 , X 3 , and X 4 or 2) X 1 is N and X 2 is CH, and X 3 is CH and X 4 is N, or 3) X 1 is CR s And X 2 , X 3 , and X 4 are each independently CH or CD; n and m are each 1; R b and R c are H and C, respectively. 1~6 Alkyl, deuterium, -OH, C 1~6 alkoxyl, and halo.
64. Formula (I-AB): or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof, said method comprising the step of: to react a compound of formula (S10) providing a compound of formula: L' is * -N(R 1 ) -L- ** and * indicates the point of attachment to Z, ** teeth, indicates the point of attachment to R 1 is H, X 1 is N or CR s and R s is H, deuterium, -CN, halo, C 1~15 Alkyl, C 1~6 Alkynyl, C 6~20 Aryl, 5-15 membered heteroaryl, C 3~20 Cycloalkyl, 3- to 15-membered heterocyclyl, -OH, -OR f , C 1~15 Alkoxy, -NR d C.O.R. e , -CONR d R e , -SO 2 R d , -SO 2 N.R. d R e , -NR d SO 2 R e and -NR d R e is selected from R d , R e and R f each independently represents H, C 1~6 Alkyl or C 3~20 cycloalkyl, C 1~6 Alkyl and C 3~20 each cycloalkyl may be independently optionally substituted with one or more halo, oxo, -OH or -CN; R s The above C 1~15 Alkyl and the C 1~15 Each alkoxy is independently one or more R t1 and R t1 is, at each occurrence, halo, oxo, -OH, -OR f1 , -CN, -NR d R e and 3- to 15-membered heterocyclyl optionally substituted with one or more —OH; R f1 is -C(O)CH 2 N.R. d R e , -C(O)C 1~6 Alkyl, -P(O)(OH) 2 and R d and R e are each independently H or C 1~6 alkyl, R d Or R e The above C 1~6 the alkyl is optionally substituted with one or more halo, oxo, -OH or -CN; R s The above C 6~20aryl, the 5- to 15-membered heteroaryl, the C 3~20 Cycloalkyl and the 3- to 15-membered heterocyclyl each independently represent one or more R t2 and R t2 is, at each occurrence, halo, oxo, -OH, -CN, C(O)NH 2 , -C(O)NR d R e , -NR d R e , C 1~6 Alkoxyl, 3-6 membered heterocyclyl, C 3~6 Cycloalkyl, and C 1~6 alkyl; R t2 The above C 1~6 Alkyl is one or more -OH, C 1~6 Alkoxyl, halo, oxo, -S(O) 2 CH 3 or -NR d R e and R d and R e are each independently H, -C(O)CH 3 , -C(O)C 1~6 Alkyl or C 1~6 is alkyl, X 2 and X 3 are CH, X 4 are independently N, CH, or CD, with the proviso that 1) X 1 , X 2 , X 3 , and X 4 or 2) X 1 is N and X 2 is CH, and X 3 is CH and X 4 is N, or 3) X 1 is CR s And X 2 , X 3 , and X 4 are each independently CH or CD; The method wherein L is methylene.
65. 13. The invention as described above.
Citation Information
Patent Citations
Antipsychotic 3-(piperidinyl)- and 3-(pyrrolidinyl)-1H-indazoles
US4670447A
Bicyclic compounds, compositions and use thereof
WO2022037568A1
